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A bstract
The purpose of the work described in this thesis was to develop and apply efficient 
methodologies based on MALDI-MSI for the direct analysis and targeting of protein 
tumour biomarkers within both frozen and formalin fixed paraffin embedded (FFPE) 
cancerous tissue sections.
Method development for protein analysis directly in tumour tissue sections were per­
formed using tumour xenograft models. This involved improvements in sample prepa­
ration, such as tissue washing protocols, and the development of data  pre-processing 
methods prior to statistical analysis using a freely available software package, which 
referred to as Spec Align.
The use of MALDI-MSI for studying proteome patterns directly from tum our tissue 
sections with no requirement for known targets is demonstrated. In addition, in situ 
identification of proteins within tum our tissue sections was achieved and correlated with 
their localisation. The method demonstrated here involved the use of octyl glucoside, 
a non-ionic detergent, which aims to improve the solubilisation and detection of low 
abundance and membrane-associated proteins within tumour tissue section after on- 
tissue digestion. The coupling of MALDI-MSI with ion mobility separation (IMS) has 
been found to improve the specificity and selectivity of the method.
Combining these two methodological approaches allowed the targeting and identi­
fication of known tumour biomarkers and potential protein markers in various tum our 
tissue samples including frozen AQ4N dosed colon tumour xenografts and F F P E  hum an 
adenocarcinoma tissue sections. The localisation and identification of proteins corre­
lated to tumour growth and aggressiveness were studied using IMS-Tag MALDI-MSI, 
a novel concept developed in this work.
In order to demonstrate its use as a potential biomarker discovery tool, MALDI-MSI 
was used for high throughput analysis of proteins within tissue micro arrays. Combining 
MALDI-MSI with statistical analysis allowed the design of a novel tumour classification 
model based on proteomic imaging information after on-tissue digestion.
Another challenge for the MALDI-MSI technology is to achieve more targeted quan­
titative approaches for in situ analysis of proteins. A proof-of-concept based on multiple 
reaction monitoring (MRM) analysis with MALDI-MSI is described using a high repe­
tition rate solid state laser. This aimed to improve the sensitivity and specificity of the 
methodology for the investigation of peptides/proteins directly within tum our tissue 
sections.
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1.1 M olecular Insights into Cancer
1.1.1 M olecular origins o f  cancer
Cancer remains a major public health issue despite progression in detection and 
therapy. It refers to a group of more than 100 different diseases and caused about 13 
% of death worldwide in 2004 [1]. It occurs when cells in a part of the body begin to 
grow out of control which leads to a tumour. Most cancers form a tumour which can be 
benign or malignant. Benign tumours are not cancerous, they can usually be treated or 
removed. Malignant tumours yield cancer cells.
Cancer diseases have different causes as well as molecular and biological origins. 
This has been reviewed by Croce [2] where it is described tha t normal cells transform 
into cancer cells following alterations of genes tha t regulate and control cell growth and 
differentiation. Genetic changes, usually somatic events including alteration of onco­
genes, tumour-suppressor genes and microRNA genes, can lead to cancer [3, 4].
Oncogenes encode proteins th a t regulate cell proliferation and/or programmed cell 
death such as apoptosis and can be grouped in six categories including transcription 
factors, chromatin remodelers, growth factors, growth factor receptors, signal transduc­
ers and apoptosis regulators. Oncogene activation and alteration have been shown to be 
closely associated with cancer initiation and progression [5]. It has been reported th a t 
most hematopoietic cancers, such as leukemia, and also soft tissue sarcoma are initiated 
by the activation of an oncogene followed by the alteration of tumour-suppressor genes 
and additional oncogenes [6 ]. The inhibition of a tumour-suppressor gene followed by 
alteration of oncogenes and other tumour-suppressor genes have been shown to initiate 
most carcinoma [7].
MicroRNAs consist of a single RNA strand comprising between 21 and 23 nucleotides 
and act as gene expression regulators. MicroRNAs have been found to be involved in 
cancer initiation and progression [8 ]. They can be highly expressed or down-regulated 
in cancer cells depending on their targets in the specific tissue. When up-regulated, 
microRNAs act as oncogenes by down-regulating tumour-suppressor genes [9].
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As originate from changes in cells, there are several types of cancers which are pri­
marily defined according to the microscopic characteristics of the tumour, i.e. based 
on type of cells from which the disease originates and histological patterns. Among 
them  are the following examples, including epithelial tumours or c a rc in o m a  which are 
tumours derived from epithelial cells. Adenocarcinoma types refer to cancers th a t orig­
inate in glandular tissues. S a rco m a  are types of tumours composed of mesenchymal 
cells while L y m p h o m a  and leu k em ia  are haemopoietica and Lymphoid tumours.
Tumour classifications are based on the grading, which describes the abnormality of 
the cells, and the staging which defines the extent of the disease are also used to  deter­
mine and help clinical prognosis as well as appropriate treatm ents [10, 11]. Edmondson 
and Steiner have reported a grading system of classification for primary carcinoma of 
the liver and identified up to 4 grades including grade I, II, III and IV. However, if cell 
differentiation has been of significance for prognosis for some tumour types, research is 
still undergoing to improve such way of tumour classification [1 0 , 1 1 ].
The stage of the tumour is also used for tum our classification in combination with 
the grading and is based on both clinical and pathological examinations [10, 12]. The 
tumour node metastasis (TNM) classification is the staging classification system used 
where T  provides information about the presence or absence of a prim ary tum our as 
well as its size. N  is used for assessing the presence of regional nodes and M  provides 
information on existing distant metastases.
The identification of oncogenes involved in tum our initiation and progression has 
led to the development of new therapeutic drugs th a t target oncogenic proteins [13-15]. 
Several molecular pathways, including those which involve oncogenic products as well 
as proteins th a t are known to participate in oncogenic pathways and processes, cellular 
stress and metastasis, are usually observed in solid tumours. Additional protein targets 
are required for the improvement and development of anticancer drugs. Furthermore 
tumour classifications may most likely be based on molecular information, i.e. genomic 
and proteomic data tha t provide insights into tumour progression, aggressiveness and 
resistance to therapy.
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1.1.2 T h e tu m our m icro-environm ent
The tumour micro-environment remains complex and is not yet fully understood. 
However, it is known to be a host of physiological stresses and where several molecular 
pathways occur, yielding abnormal cellular metabolism and cell proliferations. Here, 
some key molecular responses, including the unfolded protein response (UPR), hypoxia 
and tum our metastases, which are correlated with the tumour micro-environment are 
described.
1.1.2.1 The unfolded protein response (U PR ) in cancer
Proteins are fundamental to cell functioning and cell processes via metabolism, cell 
signaling and immune responses. After synthesis by the ribosomes, secretory and mem­
brane proteins, which account for about one third of the cell’s proteins, undergo a folding 
process within the endoplasmic reticulum (ER) [16]. Protein folding is a process which 
takes place in a calcium-rich, oxidised and energetic milieu and is assisted by molecular 
chaperones. Molecular chaperones are proteins which play a critical role in stabilising 
and facilitating nascent protein folding processes as well as ensuring that the desired 
conformation is obtained [17]. The ER resident, glucose-regulated protein 78 (Grp78) is 
a key molecular chaperone within the ER [18, 19] and provides the trigger for activation 
of the signal cascade known as the unfolded protein response (UPR) [20, 21].
In mammalian cells, the UPR is activated when misfolded or unfolded proteins are 
accumulated in the lumen of the ER [22]. The three key receptors are:
• the transmembrane kinases: inositol-requiring enzyme 1  (Irel) and pancreatic 
kinase like ER (PERK)
• the UPR-specific transcription factor activating transcription factor 6  (ATF6 ).
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In the absence of cellular stress, Grp78 binds to the ER transmembrane sensor 
proteins i.e. Ire l, PERK and ATF6  and maintains them in an inactive form. When 
unfolded proteins are accumulated in the ER lumen, Grp78 is recruited to ensure protein 
folding. The initial steps in the activation of the UPR consist of two main functions. 
Firstly, PERK is dimerised and activated leading to the phosphorylation of eIF-2o;, the 
a  subunit of the regulating initiator of the mRNA translation machinery. This results in 
a period of translation attenuation producing cell cycle arrest in the G1 phase [20, 2 1 ].
UPR activation also yields an increased production of proteins involved in the func­
tions of the UPR, i. e. an up-regulation of molecular chaperones of malfolding proteins 
including Grp78, in order to export misfolded proteins to the proteasome for degrada­
tion. This response is promoted by the migration of ATF6  and XBP1 (X-box binding 
protein 1) to the nucleus. The aim of these two preliminary responses is to remove 
the accumulated misfolded proteins from the ER lumen so tha t normal function of the 
ER can be restored. If the disruption is prolonged, apoptosis is initiated. Figure 1.1 
displays the currently understood mechanism of the UPR [20].
The UPR is poorly characterised in cancer, however it has been shown th a t the UPR 
could be seen as a key mechanism in perm itting tumour cell survival in an acidotic, 
hypoxic and glucose deprived environment and in altering chemosensitivity to a variety 
of established anticancer agents [23-26]. Targeting proteins tha t are involved in the UPR 
cascade directly within tumour tissue sections may result in an improved understanding 
of tumour behaviour and treatm ent response.
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Figure 1.1: D iag ram  o f th e  u n fo lded  p ro te in  resp o n se  in  h u m a n  cells [20].
A  Recruitment of Grp78 to chaperone or assist malfolded proteins which leads to dis­
sociation from its conformational binding state to the transmembrane receptors PERK, 
Irel and ATF6. B Activation of PERK leads to the phosphorylation of eIF-2a, the in­
hibition of translation and results in cell cycle arrest. C and D Migration of ATF6 and 
XBP1 to the nucleus, which promotes upregulation of molecular chaperones including 
Grp78 in order to ensure misfolded protein degradation. E  If disruption is prolonged, 
apoptosis is initiated.
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1.1.2.2 H ypoxia in solid tumours
To permit growth and expansion, solid tumours must develop their own vasculature 
system (called angiogenesis) which is also critical in enabling tumour cells to metastasise 
to distant organs [27, 28]. Due to their inadequate structure and function, these new 
tumour vessels have been found to create micro environmental stressors including hy­
poxia, acidosis, glucose deprivation and disturbance of calcium homeostasis [23, 29, 30].
Hypoxia is a characteristic feature in most rapidly growing solid tumours and their 
metastases. Tissue hypoxia results from an inadequate supply of oxygen (O2 ) tha t dis­
turbs the biological functions of the cells [31, 32], Studies have shown th a t up to 60% 
of solid tumours may contain hypoxic regions th a t are heterogeneously localised within 
the tum our [33]. Tumour hypoxia is strongly related to tumour propagation, malignant 
progression and resistance to chemotherapy as well as radiotherapy [34-37].
The hypoxia micro-environment induces adaptive changes to tumour cell m eta­
bolism and influences tumour cell biology [31, 38-40]. Cells exposed to hypoxia are 
usually stopped at the G i/S-phase boundary, thus resulting in several changes in the 
cellular proteome [41]. These hypoxia-induced proteome changes may promote tum our 
propagation as tumour cells may adapt to nutrient deprivation or escape this envi­
ronment [37]. Figure 1.2 [42] displays a schematic representation of tum our hypoxia. 
Several studies have reported th a t tumour hypoxia alters the molecular mechanisms of 
intracellular signal transduction, gene regulation angiogenesis and apoptosis [42, 43].
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Figure 1.2: T u m o u r h y p o x ia  in  h u m a n  cells (adapted from [42]).
When tumour cells develop their own vascular supply, tumour hypoxia arises in re­
gions with a lack of oxygen. As a consequence, hypoxic cells activate genes involved in 
angiogenesis (vascular endothelial growth factor (VEGF)), glucose transport (glucose 
transporter 1 (GLUT-1)) and cell migration (urokinase-type plasminogen activator re­
ceptor (u-PAR) and plasminogen activator inhibitor 1 (PAI-1)). Increased angiogenesis 
encourages tumour growth as well as tumour metastasis.
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The hypoxia-inducible factor la  (HIF-lcr) has been shown to be over-expressed in 
several malignant tumours including breast, head and neck, ovarian, gastric and prostate 
cancers [44-47]. Hypoxic cells encourage tumour growth as they activate target genes 
involved in angiogenesis (vascular endothelial growth factor (VEGF)), glucose trans­
port (glucose transporter 1 (GLUT-1)) and cell migration (urokinase-type plasminogen 
activator receptor (u-PAR) and plasminogen activator inhibitor 1 (PAI-1)) [37, 42]. 
Understanding these pathways and molecular mechanisms may improve chemotherapy 
development.
Several strategies are currently under investigation to target hypoxic cells within 
the tumour micro-environment. This involves the development of therapies tha t aim to 
increase the oxygen availability in the tumour micro-environment [48, 49]. Other ther­
apies consist of the use of bioreductive drugs th a t are selectively activated in hypoxic 
regions of the tumour [50-52]. Besides these therapies, research based on the develop­
ment of drugs tha t target proteins involved in hypoxic responses and angiogenesis have 
been reported [53, 54].
1.1.2.3 Tumour m etastasis
Metastasis is a complex process which is often observed in cancer. It involves a series 
of linked sequential steps favoring the spreading of a subpopulation of cells from the 
primary neoplasm to distant organs to initiate tumour growth [55-58]. A failure or limi­
tation at any stage of these steps can arrest the entire metastasis process. The formation 
of angiogenesis is essential for rapid primary tumour growth but also for m etastasis for­
mation [57, 59-62]. Synthesised and secreted angiogenic factors have been found to 
establish a capillary network from the surrounding normal tissues [63]. Metastasis be­
gins with the invasion of the host stroma by tumour cells [64]. These tum our cells are 
then released into the circulation through vasculature and lymph channels th a t offer 
less resistance to tum our cell penetration [58]. Tumour cells which survive during the 
circulation process can be trapped in the capillary beds of distant organs via capillary 
endothelial cells and further proliferate within these organs after extravasation from 
capillary beds [57, 60]. In order to survive and continue growing, these micro tumours 
must develop new angiogenesis and hence can continue to spread to other organs, there-
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fore creating additional metastasis. Figure 1.3 displays the main steps involved in the 
m etastatic cascade [55].
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Figure 1.3: T h e  m a in  s te p s  involved  in  th e  m e ta s ta t ic  cascade  [55]. 
Angiogenesis is a critical step for primary tumour growth as well as metastasis formation. 
Angiogenesis facilitates the invasion of the surrounding host stroma by tum our cells 
which are released into the circulation to further develop metastases in distant organs.
Understanding the neovasculature system at the molecular level is of great interest as 
it can allow the development of target agents tha t inhibit the function of ligands and /or 
receptors involved in the angiogenic process and therefore improve cancer metastasis 
targeting.
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1.2 P roteom ic A nalysis by M ass Spectrom etry
Research is currently being performed in many areas including biotechology, chem­
istry, bioinformatics and proteomics in order to improve the prevention and early de­
tection of cancer as well as to reduce mortality [65-67]. Proteomics refers to the study 
of the complete protein composition of a cell or a tissue sample [68-70]. Understand­
ing cancer requires the identification of diagnostic biomarkers, i.e. proteins and other 
biomolecules which are correlated to disease states or represent potential therapeutic 
targets. Mass spectrometry is one technique of choice for proteomics studies and has 
allowed the identification of several cancer biomarkers [67].
1.2.1 P rin cip les o f  m ass sp ectrom etry
Mass spectrometry (MS) is a powerful analytical technique tha t allows the separation 
and structural characterisation of compounds based on their molecular weights. The 
technique consists of the analysis of ions contained in a gas phase based on their mass-to- 
charge ratio (m/z). The data  generated are processed with a computer and appropriate 
software tools in order to produce a mass spectrum of the analysed sample where all 
the m /z values are displayed against their intensities.
A mass spectrometer consists of three fundamental parts (Figure 1.4):
•  the io n iz a tio n  so u rce
• the a n a ly se r
• and the d e te c to r .
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W ith the rapid advances and improvements in mass spectrometry, each of these 
elements are selected specifically depending on the desired experiment and compound 
being analysed. However, the principle of MS remains the same in all applications. 
Briefly, the sample is introduced into the ionization source of the instrument where gas- 
phase ions are generated. These ions are then extracted into the analyser and separated 
according to their mass (m) -to-charge (z) ratios (m/z). The separated ions are detected 
and the signals are sent to a data system where m /z ratios are stored together with their 
relative abundance, yielding a mass spectrum.
M a ss A n a ly serIon S o u rce D e te c to r
sa m p le
V acu u m
m a ss sp e c tr u m
u l
c o m p u te r
Figure 1.4: P r in c ip le s  o f a  m ass s p e c tro m e te r  in s tru m e n t.
Ions are generated in the ionisation source prior to being separated according to their 
mass-to-charge ratio (m/z). The detector registers the number of ions emerging from 
the analyser in order to provide an ion count. A mass spectrum is then generated, 
plotting the m /z values against their respective ion counts or intensities.
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1.2.1.1 Io n  sou rces
Several ionisation techniques are used with MS depending on the physicochemical
ionization (ESI) and matrix-assisted laser desorption ionisation (MALDI) are commonly 
used for the majority of biochemical analyses, including protein analysis, as they are soft 
ionisation techniques which produce ions from non-volatile large and complex species 
contained in solution into a vacuum.
1.2.1.1.1 E lectro  sp ray  io n isa tio n  (E S I)
Electrospray ionisation (ESI) occurs at atmospheric pressure and the resulting ions 
are transferred to the mass spectrometer. Under atmospheric pressure, an electrospray 
can be generated by applying a high electric field to a liquid going through a capillary 
tube [71]. Figure 1.5 displays a diagram of ESI process. Several applications have 
reported the use of ESI coupled to LC, HPLC and capillary electrophoresis (CE) for 
the analysis of proteins, polymers and also small polar molecules [71-73].
During electrospray ionisation, a flow of liquid-phase analytes is nebulised under atm o­
spheric pressure by applying a high voltage to the capillary. The ESI process generates 
vapor phase ions tha t can be analyzed for mass-to-charge ratio within the mass spec­
trometer.
properties of the samples to be analysed and the desired fragmentation. Electrospray
counter electrode
vacuum stage
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Figure 1.5: D ia g ra m  o f th e  p rin c ip le  o f e le c tro sp ra y  io n isa tio n  [71].
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1 .2 .1 .1.2 M a tr ix -a s s is te d  la ser  d e s o rp tio n /io n is a tio n  (M A L D I)
Matrix-assisted laser desorption/ionisation (MALDI) involves solid-state ionisation 
of compounds. The sample is first mixed with a matrix, which is usually a small organic 
molecule with a high absorption at the laser wavelength. The m atrix aims to crystalise 
with the analyte of interest in order to produce analyte ions once irradiated with the 
laser. Briefly, the ablation of the crystal (matrix-analyte) by the laser pulses induces 
the sublimation of the matrix which leads to a transfer of internal energy to the analyte, 
thus resulting in ionisation [74, 75]. However the full ionisation mechanism is not fully 
understood yet. The most accepted mechanism involves a proton-cation transfer along 
with photo-ionised matrix [76, 77]. Briefly, it consists of a two-step mechanism where, 
first, ion formation occurs after the matrix absorbs the laser energy in order to facilitate 
initial charge separation. Then, the excited states of the matrix act as buffers and 
transfer the energy to the ion plume through proton, photon or electron transfer. Figure 
1.6 shows a diagram of the principle of MALDI. MALDI is a soft ionisation technique; 
the sample destruction is minimised as the laser energy is absorbed by the matrix, hence 
increasing sensitivity.
Has®?
desorption desolvation
 > To mass analyser
Figure 1.6: D ia g ra m  o f th e  m a tr ix -a ss is te d  lase r d e so rp tio n  io n isa tio n  
MALDI involves the co-crystallisation of the m atrix and the analyte. The m atrix ab­
sorbs the laser energy, thus leading to a transfer of internal energy to the analyte and 
inducing the formation of ions.
Several applications have reported the use of MALDI-MS for the analysis of intact 
proteins as well as microorganisms [78, 79]. The choice and optimisation of the m atrix 
is critical for the analysis and is closely associated with the laser wavelength as well as 
the compound to be analysed. Im portant general properties of appropriate matrices for 
a given analysis include: their ability to strongly absorb the laser energy, their stability
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in a condensed phase under high-vacuum conditions and their ability to induce efficient 
ionisation of the analysed compounds [80]. A variety of matrices have been developed 
therefore and are used in many applications [81, 82].
Figure 1.7 displays the chemical structures and molecular weights of the commonly 
used UV-MALDI matrices, which are derivatives of benzoic acid.
Figure 1.7: M o lecu la r s tru c tu re s  o f com m on ly  u sed  U V -M A L D I m atr ic e s .
These matrices are derivatives of benzoic acid.
1 .2 .1.2 M ass an a ly se rs
Ions produced in the ion source are then separated in the mass analyser. There are 
several types of mass analyser, including quadrupole, quadrupole ion traps, time-of-flight 
(TOF), magnetic sectors and Fourier transform. These mass analysers present different 
features including the upper mass limit, the ion transmission and the resolution. Hence, 
the compatibility of the analyser with the ionisation method may vary.
1 .2 .1 .2.1 Q uadrupole m a ss  a n a lysers
Quadrupole mass analysers consist of four hyperbolic rods. In a quadrupole (Q) 
mass analyser, the separation of the ions according to their m /z is based on the stability 
of their trajectories in an oscillating electric field applied to the rods [80]. Figure 1.8 
displays a schematic description of a quadrupole mass analyser. The rod pairs are 
electrically connected together: a radio frequency (RF) voltage is applied to a rod pair 
while a direct current field is applied to the other rod pair. The stability of the ion 
trajectories within the rods is used for their separation. Quadrupole analysers usually 
show excellent selectivity, however they present a mass range limitation as well as low
COOH^  COOH x  COOH
a) ct-cyano-4-hydroxycInnamIc 
acid (a-CHCA)
0CH3
b) slnaplnlc acid (SA) c) 2,5-dihydroxybenzolc acid (DHB)
resolution.
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Q uadrupo le rods
IONS
source slit
Figure 1.8: S ch em atic  o f a  q u a d ru p o le  m ass an a ly se r  (adapted from [80]). 
Quadrupole analysers are made up of four hyperbolic rods. Ions oscillate in the electric 
field created by the rods. The stability of the ion trajectories within the rods is used 
for their separation.
1 .2 .1 .2 .2  T im e -o f- flig h t m a ss  a n a lyser
Time-of-flight (TOF) mass analysers are commonly used with MALDI because of 
the pulsed nature of the laser desorption ionisation and provide excellent m /z resolu­
tion, accurate mass capabilities and can operate at high repetition rates [80]. In TOF 
analysers, ions are separated in time, based on their velocity after being accelerated in 
a field-free tube between the source and the detector. TOF instruments can be used in 
a linear or reflector mode.
In linear mode, desorbed ions are accelerated into the TOF tube at a specific electric 
field and are allowed to fly a distance (d) which is fixed by the TOF tube length. Figure 
1.9 displays a schematic diagram of the principle of a linear TO F instrument.
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Figure 1.9: S chem atic  o f a  tim e-o f-fligh t m ass a n a ly se r  o p e ra tin g  in  lin e a r  
m o d e  (adapted from [80]).
Ions are separated in time, based on their velocities in a field free time-of-flight tube 
and are finally detected by an ion detector. The time each ion takes to travel through 
the mass spectrometer is measured precisely.
The kinetic energy of a given ion (E) is defined by the equation 1.1, where V is the 
accelerating potential and q the total charge of the ion.
E  =  - m v 2 = qV  =  zeH (1.1)
It is possible to correlate the m /z of a given ion to the time (t) needed to drift 
through a fixed distance (d) before reaching the detector, by the following equation:
=  ) (1 -2 )
The advantages of TOF analysers include the fast, sequential detection of all the ions 
with differing flight time and mass. Therefore, they provide high transmission of the 
generated ions and hence an improved sensitivity. High molecular weight compounds 
including proteins, monoclonal antibodies and polymers with a m /z above 300 kDa and 
present at low concentration have been detected using TOF mass analysers operating 
in linear mode [79, 83]. However, low mass resolution can usually be observed in linear 
mode. Low mass resolution can result from a variety of factors including the spread in 
the initial average velocity of ions produced in the ion source. It is common to improve 
the resolution by introducing a delayed pulse extraction. The delayed time extraction 
consists of introducing a short time delay between the ionisation and the ion extraction 
in order to compensate the spread in the distribution of the initial kinetic energy of the
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ions leaving the source. In the case of MALDI ion sources, this allows the ion plume 
to further expand before the extraction. Therefore, by adjusting the delay time and 
pulsed voltage, ions with the same m /z and different kinetic energy leaving the source 
will eventually reach the detector at the same time.
TOF analysers can also be used in reflector mode in order to improve the mass 
resolution. It involves the use of grids which are in a constant electric field and act 
as mirrors to compensate the kinetic energy spread between ions leaving the source by 
reflecting them back along the flight tube prior to detection. More energetic ions will 
penetrate deeper into the grid, while ions with the same m /z and less kinetic energy 
will have a shorter path back along the tube. As a result, both ions will eventually 
reach the detector at the same time. Figure 1.10 displays a schematic diagram of the 
principle of a reflector TOF mass analyser. Using a TOF analyser in reflector mode 
has been found to increase the mass resolution, however a loss of sensitivity as well as a 
mass limitation are observed [80, 84]. Peptides, lipids and small molecules are usually 
analysed in reflector mode.
positive ions
3000 V
Source
3000 V
-3000 V
Figure 1.10: S chem atic  o f a  tim e-o f-fligh t m ass a n a ly se r  o p e ra tin g  in  re f lec to r  
m ode  (adapted from [80]).
The energy dispersion of two isobaric ions leaving the source is corrected in the reflector. 
The ion with a higher kinetic energy will spend more time in the reflector compared 
to the one with a lower kinetic energy, so that both ions will reach the detector at the 
same time.
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1.2.1.2.3 Tandem m ass spectrom etry (M S /M S )
Tandem mass spectrometry (MS/MS) consists of selecting a particular ion of a com­
pound present in the sample to be analysed for fragmentation purposes in order to 
determine its structure or other properties. MS/MS can be achieved within field-free 
regions of the analyser with respect th a t the selected ion has sufficient energy to disso­
ciate [80, 84, 85]. Another way to perform MS/MS consists of applying collisions with 
neutral gas; this is often called collision-induced dissociation (CID). Two mass analysers 
can therefore be coupled together. The two analysers are separated with a collision cell, 
where an inert gas is used to  collide with the selected ions and produce fragmentation.
Quadrupole and TO F mass analysers are often coupled together, hence resulting in a 
QqTOF hybrid instrument, where q represents a radio frequency (RF)-only quadrupole 
and is used as a collision cell. Figure 1.11 displays a schematic diagram of a QqTOF hy­
brid instrument. In a QqTOF instrument, the m /z of a precursor ion may be specifically 
selected in the quadrupole analyser followed by collision-induced dissociation (CID) in 
the collision cell. The product ions are further analysed in the TO F which enhances the 
sensitivity and improves the S/N. QqTOF instruments have been reported to improve 
the resolution and the mass accuracy [85]. However a mass range limitation is often 
observed.
Peptides produced after enzymatic protein digestion are usually fragmented by 
MS/MS. The peptide sequence obtained by MS/MS can be used for protein identifi­
cation using database search [80].
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Figure 1.11: S ch em atic  d iag ra m  o f a n  A p p lied  B io sy stem s Q -S ta r®  P u ls a r  i 
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1 .2 .2  Io n  m o b il i ty  s e p a r a t io n  a n d  m a s s  s p e c t r o m e t r y
1 .2 .2 . 1  Ion  m o b ility  s e p a ra tio n /M A L D I-T O F  M S
Ion mobility separation (IMS) is a technique which permits gas-phase separations 
of ion packets based on their structural and conformational properties. In IMS, ions 
are separated according to their velocity based on their collision cross-section (fi), as 
they drift through an inert gas following application of a weak electric field [86, 87]. 
Gas-phase collision cross-section values can be obtained with the following equation 
[86]:
16A
2tt 0.5
j i k bT
where variables are as followed: N  represents the background gas number density, 
ze the ionic charge, ft is the reduced mass of the ion-neutral pair, kb is the Boltzm ann’s 
constant, T  the gas tem perature and Kq is the mobility corrected to 273.2 K and 760 
Torr.
Several improvements made in IMS technologies have been reported, including changes 
in geometries and devices, such as the use of an ion trap  for ion accumulation and ejec-
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tion into the drift tube as well as reducing the radial ion diffusion, in order to achieve 
a better combination of IMS with mass spectrometry [8 8 ]. This has been shown to 
allow fast detection and characterisation of structural and conformational properties of 
compounds contained in a complex mixture.
The use of MALDI-TOF MS, especially orthogonal MALDI-TOF MS (o-TOF MS) 
geometry, combined with IMS has been demonstrated for fast separation of compounds, 
including proteins, peptides, lipids and small molecules present in complex matrices, 
while maintaining good mass spectral data  quality as well as improved sensitivity [8 8 — 
90]. This is very beneficial as sample purification by means of LC/M S and 2 -DE sep­
aration techniques are not required. Small deviations observed in compound collision 
cross-sections generate differences in mobility drift time, hence specific separation and 
characterisation of the given analytes.
Recent improvements in IM S/o-TOF MS instrument designs have been shown to 
improve the signal transmission and separation power of IMS-MS [91]. This is discussed 
in detail below.
1.2.2.2 Travelling wave IM S/oa-TO F MS technology: M ALDI S Y N A P T ™  
HDM S system
The use of a travelling wave system incorporated into IMS combined with an or­
thogonal axial-TOF MS (oa-TOF MS) geometry has been described [91]. Here, the 
ion transmission and ion mobility separation power is increased using travelling wave 
technologies in the radio frequency (RF) ion guide chambers and the IMS cell. Figure 
1.12 displays a schematic diagram of the MALDI SY N A PT™  HDMS system, which 
has been used in the work described in this thesis (chapters 3, 4, 5 and 6 ).
In the travelling wave ion guide compartment (T-wave ion guide, see figure 1.12), 
ions are driven to the IMS cell by applying continuous sequence waves throughout the 
RF electrodes at regular time intervals. This aims to reduce the travel tim e of the 
ions to the IMS cell [92]. The travelling wave IMS (TWIMS) compartment consists of 
61 electrode pairs and is composed of 3 components, including a trap, an IMS and a 
transfer cell [91]. The IMS cell is placed between the trap and transfer compartments,
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Figure 1.12: S chem atic  d ia g ra m  of th e  M A L D I S Y N A P T rM H D M S  sy s te m
[91] (reproduced with permission from Elsevier publisher).
which are composed of 33 electrode pairs with RF applied and are 100 mm long. The 
last RF electrode of the trap cell acts as an ion gate operating at a modulated voltage, 
hence creating continuous ejection of ions into the IMS cell. Once in the IMS cell, 
ions are subjected to travelling waves at moderate pressures which allow mobility-based 
separation. That is, high mobility ions are transported at a faster speed than  low 
mobility ions throughout the waves. Travelling waves are still applied in the transfer 
cell in order to maintain the mobility separation of the ions.
The use of an oa-TOF MS geometry has been found to provide fast data acquisition 
since the MS is synchronised with the ejection of ions from the T-wave ion guide cell to 
the IMS cell [93]. Such an approach offers promise for the IMS-MS analyses of complex 
mixtures [94] and also the possibility of identifying proteins directly from such matrices 
with no requirement for sample purification. Different types of MS/MS experiments can 
be performed using such a technology. Ions can be collisionally dissociated in either or 
both the trap  and transfer chambers, while maintaining the mobility information of the 
parent and product ions [91].
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1.2 .3  P ro te in  an alysis by  m ass sp ectrom etry
Mass spectrometry is a technology of choice for proteomics studies [95, 96]. It allows 
the accurate determination of protein molecular weights as well as protein identifica­
tions via tandem  mass spectrometry (MS/MS) [97-99]. Even more desirable is the 
detection and identification of low abundance proteins present in a given sample. Mass 
spectrometry has been shown to allow the characterisation of proteins at concentrations 
in the low subpicomole range [100, 101]. Several separation techniques may be coupled 
with MS in order to perform purification steps prior to protein characterisation with 
MS. Among them, two-dimensional gel electrophoresis (2D-gel or 2D-PAGE) and liquid 
chromatography (LC) are the most commonly used.
1.2.3.1 Two-dimensional gel electrophoresis
Two-dimensional gel electrophoresis (2-DE) is a technique widely used for pro­
tein separation and purification prior to MS. It allows protein separation in a  two- 
dimensional gel. This is based on the isoelectric point of the proteins in one dimension 
and on their molecular weight in the other dimension. Studies have described the use 
of 2-DE for the evaluation of protein extracts from complex mixtures such as cells and 
tissue samples [102, 103]. Differences between samples can be evaluated and relative 
quantification of protein ratios between independent gels can be performed [103, 104].
Combining 2-DE with MALDI-TOF mass spectrometry has become popular as it 
allows the analysis and identification of small amounts of proteins isolated from the gel 
spots [101, 105, 106]. The strategy commonly used is described in figure 1.13 [80]. The 
method is based on the comparison of da ta  obtained by mass spectrometry analysis 
with those stored in a database. The sensitivity and mass accuracy of mass spectrom­
etry allow a rapid identification of numerous protein candidates contained in a given 
sample. Several studies have reported the identification of protein cancer biomarkers 
using 2-DE separation coupled to MALDI-TOFMS [107]. However, 2-DE methods have 
limited sensitivity and reproducibility compared to liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) approaches [108].
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Figure 1.13: S ch em atic  w orkflow  com m on ly  used  for th e  id e n tif ic a tio n  o f p ro ­
te in  using  2 -D E  com bined  w ith  m ass sp e c tro m e try , (adapted from [80])
This method allows the purification and separation of protein extracts from crude mix­
tures using 2-DE. Protein identification can be performed using the intact protein masses 
determined by mass spectrometry. However in most cases, in-gel tryptic digestion is per­
formed followed by peptide analysis with mass spectrometry. A peptide mass fingerprint 
database search is either achieved for protein identification or sequencing MS analyses 
are carried out in order to fully identify the protein of interest.
Proteomic Analysis by Mass Spectrometry 47
1.2.3.2 Liquid chromatography-tandem mass spectrom etry
Reversed phase liquid chromatography coupled to tandem mass spectrometry is 
another technique widely used to purify, concentrate, separate and identify peptides 
obtained after enzymatic digestion of proteins extracted from complex mixtures [109- 
1 1 2 ]. LC-MS/MS systems comprise conventional high performance liquid chromatog­
raphy (HPLC) columns and pumps coupled to a tandem  mass spectrometer. Briefly, 
peptide mixtures are separated by liquid chromatography prior to electrospray ionisa­
tion and MS/MS analysis. Rapid screening and identification of peptides present in a 
given sample can be achieved. Several studies have described the use of LC-MS/MS to 
enhance the separation and identification of proteins present in various types of samples, 
including cells, tissues and plasma [113, 114]. It can also be used to discriminate be­
tween healthy and cancerous tissue samples [115]. The use of LC-MS/MS has also been 
shown to improve the detection and identification of protein present a t low abundance 
in crude mixtures [1 0 1 ].
Both 2-DE and LC-MS/MS techniques are powerful methods to study the proteome 
of a given sample as they not only allow the separation and identification of proteins 
but also discrimination between diseased and healthy samples. However information 
regarding the spatial localisation of protein biomarkers within tissue samples is lost. 
The ability to detect, identify and study the distribution of protein biomarkers within 
tumour tissue sections in a single experiment is of significant interest to  improve the 
understanding of tumour biology and to help enhance clinical diagnostics and prognos­
tics.
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1.3 M ass Spectrom etry Im aging
Direct molecular analysis of biological tissues is a m ethod of choice for better un­
derstanding of tumour processes but it is extremely challenging. In vivo molecular 
imaging techniques, such as magnetic resonance imaging (MRI) and near-infra red or 
fluorescence imaging, are typically used to detect high level targeted analytes within 
the tissue, however these techniques are often time consuming and are limited when 
investigating unknown compounds. Immunohistochemistry (IHC) staining is a m ethod 
commonly used to study the spatial distribution and expression of proteins within tissue 
sections, however this technique is limited as it requires a specific known target, as well 
as a specific antibody.
Mass spectrometry imaging techniques are useful tools th a t can be used to map 
the distribution of several compound classes including proteins, lipids, drugs and small 
molecules directly in tissue sections with no requirement of pre-defined targets. This 
provides molecular information in many areas of biological research and creates new fun­
damental research opportunities in several fields. In this section, insights into mass spec­
trom etry imaging techniques, with an emphasis on MALDI-mass spectrometry imaging 
(MALDI-MSI) for the investigation of proteins within tumour tissue sections, will be 
given.
1.3.1 Secondary ion  m ass sp ectrom etry  im aging
Secondary ion mass spectrometry (SIMS) was one of the first techniques used for 
imaging mass spectrometry, yielding two-dimensional ion density images from thin bio­
logical tissue sections [116]. In SIMS, a pulsed ion beam up to  30 keV, usually C s+ or 
Ga+ , is used to bombard a sample, thus initiating the desorption process. The prim ary 
ion beam can be focused on a tissue sample surface to spot sizes as small as 1 0  nm in 
diameter, although they are usually operated with a spot size of 0.130 [im diameter, and 
ion images at specific m /z ratios are generated. Using the SIMS imaging technique, high 
resolution images of compound distribution at the cellular level within tissue samples 
can be generated [117].
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SIMS has been found to be suitable for the analysis of inorganic low molecular weight 
compounds such as metals and cations, but the technique has been found to be limited 
in terms of sensitivity for the investigation of organic molecules such as proteins [118]. 
However, biological tissue sections, including kidney tissue sections, have been analysed 
and imaged using SIMS technology [119].
Improvements in SIMS methodologies, including m atrix enhanced SIMS, have been 
found to increase the ionisation and sensitivity for the detection of low molecular weight 
peptides and proteins (typically m /z <  20000) [117, 120]. A further improvement con­
sisted of coating the tissue section surface with a thin layer of metal prior to analysis. 
This aims to enhance the signal intensity of several biomolecules such as lipids and fatty 
acids [121]. The resulting ion peaks are often observed as metal adducts and may be 
difficult to interpret in some cases, however improved image sensitivity was achieved.
1.3 .2  M A L D I-m ass sp ectrom etry  im aging
MALDI-mass spectrometry imaging (MALDI-MSI) is a technique which combines 
the high efficiency of MALDI-MS in providing structural information of compounds 
present in a biological tissue section while giving information related to their spatial 
localisation within the tissue section [122, 123]. Briefly, tissue sections obtained from 
frozen or archived samples are first uniformly coated with a MALDI m atrix which aims 
to crystallise with the surface compounds to be analysed. Then, multiple single mass 
spectra are acquired across the tissue section at a spatial resolution predefined by the 
operator and the instrument capacity by irradiating the coated tissue sections with very 
short laser pulses. These mass spectra are then processed together using imaging soft­
ware in order to generate ion density maps which represent the spatial distribution of 
a given analyte within the tissue section with its relative abundance or intensity. This 
provides a visualisation of the localisation of each specific analyte within the tissue sec­
tion in a two-dimensional (2-D) molecular intensity or heat map. The acquisition of 
series of 2-D molecular images using consecutive serial tissue sections can also be used 
to reconstruct 3-D volumetric localisation of the compounds of interest within the tissue 
sample being analysed [124-126].
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MALDI-MSI is rapidly becoming a powerful technology for studying the distribution 
and for the in situ identification of several classes of compounds including proteins, 
peptides, lipids, drugs and other small molecules directly within biological tissue sections 
[127]. It may hence provide and create new fundamental and translational research 
opportunities in various fields including cancer biomarker discovery as well as tumour 
classification systems.
1.3.2.1 Tissue sample preparation prior to m atrix application
MALDI-MS imaging of frozen and formalin fixed paraffin embedded (FFPE) tissue 
sections has been reported for the in situ investigation of proteins and peptides [128]. 
Depending on the type of tissue sample being analysed, appropriate tissue sample prepa­
ration is required. Various work has been performed in order to develop standard proto­
cols and methodologies for tissue preparation, including tissue sample collection, tissue 
sectioning, washing protocols and chemical pre-treatm ents, such as on-tissue digestion, 
prior to m atrix deposition [129, 130].
1.3.2.1.1 Tissue sam ple collection and handling
Tissue collection is an im portant step for MALDI-MSI experiments. Since protein 
and peptide profile patterns and localisation within the tissue sample reflect changes 
occurring during disease progression, degradation of tissue samples during collection 
may affect considerably the expression and distribution of proteins/peptides within the 
tissue section. Tissue samples must be carefully surgically removed in order to  main­
tain the native shape of the tissue as well as the integrity of the spatial arrangement of 
compounds present in the tissue sample and also avoid compound degradation [129].
Immediately after removal, fresh tissue samples may be snap-frozen in liquid nitrogen 
or fixed in formalin. Most studies report the use of frozen tissue sections for MALDI-MSI 
analysis. Tissue samples are frozen by first loosely wrapping the sample in aluminium 
foil (this may be optional, however the foil acts to stabilize more malleable tissues as 
well as to inhibit tissue adhesion to the sides of the liquid nitrogen dewar) and by then 
gently freezing in liquid nitrogen [129, 131]. Another method, which has been applied 
in the work reported in this thesis, consists of gently immersing the tissue in a beaker 
containing isopentane, which has been previously immersed in liquid nitrogen. The
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snap-frozen tissues may remain stored at -80° C for at least a year with no significant 
degradation [131].
Formalin fixation paraffin embedding is the most convenient method commonly used 
to conserve tissue samples for study by pathologists in clinical practice. The formalin 
fixative creates protein cross-linking via methylene bridges, hence formalin fixed paraffin 
embedded (FFPE) tissue samples can be stored over many years. This creates a huge 
sample bank for clinical use. The analysis of FFP E  tissue sections by MALDI-MSI 
is achieved after performing on-tissue enzymatic digestion, which will be discussed in 
another section (section 1.3.2.1.4).
1.3.2.1.2 Tissue sectioning
Thin tissue sections are cut at about -15 to -20°C using a cryostat (the optimum 
cutting tem perature depends on the tissue type being analysed) followed by mounting 
onto either a conductive MALDI target plate or histological glass slides. The tissue 
section thickness has been shown to affect the observed MS signal sensitivity [129]. 
For MALDI MS analysis of mammalian tissues, an optimum tissue section thickness is 
between 5 and 20 [im , depending on the tissue sample type as well as the analysis to 
be performed.
The tissue sample is maintained on the cryostat cutting block using a medium such 
as an optimum cutting tem perature polymer(OCT). However, one should avoid con­
tact between the OCT and the surface of the tissue to be sectioned. The presence of 
OCT inhibits ion formation in MALDI MS analysis. The use of carboxymethylcellulose 
(CMC) has also been reported for embedding tissue samples prior to  sectioning [132]. 
Here, no signal inhibition was observed in the MALDI-MSI analysis.
1.3.2.1.3 Tissue washing methods
Following tissue sectioning, washing steps are usually performed in order to  remove 
residual salts, small molecules and lipids present in the tissue sections, which can either 
interfere with proteins/peptides by forming adducts or inhibit or suppress protein sig­
nals in the obtained mass spectra. Several protocols have described the use of a series of 
ethanol solutions, typically from 70 to 95 %, for washing tissue sections [129, 133, 134]. 
This process aims to enhance the m atrix co-crystallisation process onto the tissue sec­
tion, hence resulting in improved direct MALDI-MS profiling and imaging data  quality
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[130].
The use of organic solvents such as chloroform and xylene has also been successfully 
reported as an efficient washing method for tissue sections [135]. Rinsing tissue sections 
with such solvents aims to decrease the lipid content present in the tissue sections and 
improve protein detection.
1.3.2.1.4 O n-tissue enzym atic digestion and specific M A L D I im aging
MALDI-MSI allows the detection and localisation of proteins from tissue sections, 
however the sensitivity for protein signal detection is usually limited to 30-40 kDa. On- 
tissue (in situ) enzymatic digestion is a sample pre-treatm ent which has been found to 
considerably increase the amount of protein information obtained by direct MALDI-MSI 
analysis [136-138]. It can be used to improve the detection of some proteins which are 
not detected by direct MALDI-MSI analysis due to  either their molecular weight or their 
low abundance in tissue samples. Using on-tissue digestion as a sample pre-treatm ent 
has been reported for the study of protein distribution and identification within FFPE  
tissue sections with MALDI-MSI [137, 139], and hence provides new methodologies for 
retrieving proteomic information directly from archived tissue sections. Another advan­
tage of such a methodology is tha t protein identification can be correlated with observed 
protein distribution within the tissue section. This is achieved by performing peptide 
MS/MS fragmentation directly within tissue sections, thus allowing the identification 
of proteins [140].
Specific MALDI-MS imaging has also been reported for more targeted approaches 
for biomarker identification within tissue sections [141, 142]. This sample pre-treatm ent 
methodology is referred to as Tag-Mass Specific MALDI-MSI. Briefly, it is based on 
indirect detection of a probe (such as oligonucleotide and antibody) via an indicator 
called Tag-Mass added to the probe. The Tag-Mass consists of a photocleavable linker, 
tha t has a specific absorption band close to th a t of MALDI lasers (i.e. 337-355 nm), 
and which is attached to a tag of known mass which can be detected by MALDI-MSI. 
Figure 1.14 displays a description of the Tag-Mass concept. This forms photocleavable 
linker tagged oligonucleotide or secondary antibody probes which are deposited onto the 
tissue section and followed by in situ hybridisation of the tag-Mass probe for specific 
MALDI-MSI of mRNA and proteins within the tissue sections. MALDI-MSI analysis is
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then performed, leading to the detection of the tags, which provides a localisation and 
relative abundance of mRNAs or proteins, thus yielding a specific unique signature for 
the probed molecules.
O ligonudeotid ic  
or protein s e q u e n c e
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Figure 1.14: S chem atic  o f th e  p h o to c leav ab le  l in k e r / ta g  sy s te m  o r  T ag-M ass 
for u sed  in d ire c t d e te c tio n  o f m R N A  a n d  p ro te in s  a fte r  p h o to -d isso c ia tio n  
u n d e r  th e  M A L D I U V  lase r w av e len g th  [141].
The Tag-Mass is a photocleavable linker tagged oligonucleotide or secondary antibody 
probe and can hybridises to its complementary mRNA sequences or attaches to the 
target proteins. Then, the linker is photocleaved after MALDI laser irradiation, thus 
inducing tag release and leading to the characteristic signal of the tag in the resulting 
mass spectrum.
1.3.2.2 M a tr ic e s  a n d  m a tr ix  d e p o s itio n
Sample pre-treatm ent methodologies, such as on-tissue digestion or Tag-Mass Spe­
cific MALDI-MSI, may enhance the signal detected as well as the observed sensitivity 
and specificity of the technique. However, the choice of the m atrix and the m atrix 
deposition method are of great importance in obtaining high-quality spectra directly 
from thin tissue sections as well as keeping intact the spatial integrity of compound 
distribution within the tissue surface.
1.3.2.2.1 M a tr ic e s  used  fo r  M A L D I - M S I
Several MALDI matrices are available, depending on the target analyte. Derivatives 
of benzoic acid, cinnamic acid and related aromatic compounds, have all been found 
to be good MALDI matrices for proteins and peptides. Sinapinic acid, 3,5-dimethoxy-
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4-hydroxycinnamic acid (SA), is routinely used for higher molecular weight proteins, 
whereas ct-cyano-4-hydroxycinnamic acid (cr-CHCA) is commonly used for low molecu­
lar weight peptides species [129]. The m atrix solution concentration used is also a factor 
to take into account for direct tissue analysis with MALDI-MSI, since it allows an op­
timal crystal coverage as well as an improved mass spectral signal quality. In addition, 
many matrix/solvent combinations can be used, thus allowing improved spectral signals 
in terms of protein profiling and imaging. 50:50 acetonitrile/water and ethanol/w ater 
have been found to be good solvent combinations, providing good results for a variety 
of tissues analysed by MALDI-MSI [131].
The use of solid ionic matrices has also been reported for direct analysis of tis­
sue sections with MALDI-MSI [135]. Ionic MALDI matrices are formed following an 
acid/base reaction, by coupling ionic liquids with UV-MALDI matrices, hence yield­
ing improved m atrix solutions as well as mass spectral quality and signal sensitivity
[143]. Coupling common UV-MALDI matrices, such as ck-CHCA and SA, with aniline 
or dimethylaniline derivatives has significantly improved signal intensities and enhanced 
the sensitivity for MALDI-MS profiling and imaging of proteins and peptides directly 
within tissue sections [135, 137].
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1.3.2.2.2 M atrix  deposition methods
M atrix deposition onto the tissue section also represents an im portant step of the 
sample preparation carried out prior to MALDI-MSI analysis as it affects the repro­
ducibility of the methodology as well as the spectral quality and spatial resolution that 
can be achieved. Several methods for m atrix deposition, including manual and robotic 
methods, have been described [136, 137, 144].
M atrix solutions can be spotted onto the tissue section using an autom atic pipette. 
This methodology is commonly used for direct MALDI-MS profiling experiments [131, 
145]. Robotic devices allow the deposition of microdroplets onto the tissue section, 
yielding accurate spot arrays of m atrix solutions and other reagents, such as enzyme, 
onto the tissue section. This has been found to improve the reproducibility as well as 
data  quality obtained with MALDI-MS imaging analyses [144, 146]. However the inter 
spot distance can be a limiting factor for MALDI-MS imaging spatial resolution.
Spraying methods are also commonly used to achieve good m atrix coverage onto tis­
sue sections using airbrush devices [147]. This allows an even m atrix coating onto tissue 
sections, however, compound delocalisation can be observed in some cases. Automatic 
spraying instruments are also commercially available, hence producing a homogenous 
thin layer of m atrix and/or proteases on the tissue sections [148].
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1.3.2.3 D a ta  a cq u is itio n
Two modes of data  acquisition are used in MALDI-MSI: p ro filing  and im aging . 
Figure 1.15 displays a schematic description of data acquisition modes.
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Figure 1.15: S chem atic  d e sc r ip tio n  o f M A L D I-M S  p rofiling  a n d  im ag in g  a n a l­
ysis [149].
The aim of the profiling experiment is to obtain a relatively quick characterisation 
of the biological compound content within a tissue section as well as comparing their 
patterns from a discrete number of spots. M atrix is applied as droplets (spots) on the 
tissue, by using either an automatic pipette (200 nL to 500 nL droplets) or an autom ated 
spotter. MS analysis is then performed on each individual m atrix droplet by summing 
200 or more consecutive laser shots taken across the droplet surface, thus generating a 
mass spectrum. However, because of the MALDI TO F mass spectrometer limitations 
in detecting higher molecular weight compounds, most of the detected signals are below 
m /z  40000 Da. Furthermore, most intense signals result from soluble and abundant 
compound species.
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In an imaging experiment, the laser can probe the tissue in a raster and thousands of 
spots can produce an array, with each spot corresponding to a full mass spectrum. An 
image is then constructed from a selected m /z value by integrating the corresponding 
signal intensity. Mass spectrometry images can be acquired either in microprobe or 
microscope mode. Each of these modes has its advantages and limitations.
1.3.2.3.1 M icroprobe mode
The microprobe mode is the most commonly used for MALDI-MS imaging data 
acquisition [150, 151]. It involves a correlation between mass spectra and the position 
on the sample where they are acquired. A focused laser spot allows acquisition of several 
mass spectra corresponding to the spatial coordinates of the region of the sample being 
analysed. Molecular ion images are generated by collecting mass spectra using a spot- 
to-spot laser raster across the tissue section and reconstructed from the obtained mass 
spectra once the imaging experiment is completed. Therefore, the spatial resolution 
achievable in microprobe mode is strongly related to the laser irradiation spot size, 
typically 25-150 pm  depending on the instrument.
1.3.2.3.2 M icroscope mode
Another way to acquire mass spectrometric images is by operating in microscope 
mode [152]. The microscope imaging mode involves the use of an ion-optical microscope. 
In this case, all information gained within the ionised sample region is projected onto a 
position-sensitive detector. The spatial resolution of the molecular images depends on 
the microscope magnification, the ion-optics and the resolution of the detector.
1.3.2.4 Instrum entation
MALDI-MSI allows the examination of several molecules, especially proteins and 
peptides, directly from tissue sections. This makes the technique a valuable and promis­
ing tool in biomedical and clinical research fields. Several improvements in MALDI-MSI 
instrumentation are currently being made in order to improve spatial resolution, mass 
resolution as well as data acquisition time. This includes development of new laser 
technologies and mass analysers.
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1.3.2.4.1 Lasers
The laser is a key factor in MALDI-MSI experiments [153], since it affects the amount 
of ions generated in the source, the spatial resolution as well as the data  acquisition time. 
The laser beam commonly used in MALDI-MSI analysis is between 100 and 150 /xm 
in diameter. Since MALDI-MS imaging analyses are usually acquired in microprobe 
mode, the spatial resolution in the observed images is limited by the laser beam spot 
size. However, methods aiming to improve MALDI-MS image spatial resolution have 
been developed and consist of either reducing the laser spot size [118, 154] or oversam­
pling methodologies [155], the latest consists of obtaining data  in such a way th a t the 
distance between points on the sample is smaller than  the size of the focused spot. Un­
fortunately, limitations associated with signal sensitivity and analysed mass range were 
also observed. The microscope imaging mode has also been used to improve the image 
spatial resolution, however less molecules are desorbed when the resolution is less than 
about 10 nm [152].
High resolution MALDI-MS images are also associated with long data  acquisition 
times. Common standard nitrogen (N2 ) lasers are being replaced by solid-state lasers, 
which present a high repetition rate, for MALDI-MS profiling and imaging experiments. 
High-repetition rate solid-state lasers have been found to enhance mass spectral quality 
and signal sensitivity [156]. The use of 1 kHz repetition rate Nd:YAG (neodymium- 
doped yttrium  aluminium garnet; N d Y sA ^ O ^ ) lasers for MALDI-MS imaging pro­
duced improved signal intensity and sensitivity as well as decreased data  acquisition 
time [156-158].
1.3.2.4.2 M ass analysers
A variety of mass analysers have been used for MALDI-MSI. Among them  TOF, 
T O F/T O F and QqTOF are the most used [159]. MALDI-TOFMSI has been found to 
provide both acceptable mass accuracy and spectral resolution power [160].
The use of Fourier-transform ion cyclotron resonance (FT-ICR) for MS imaging has 
produced high spectral quality in terms of achieved spectral resolution and M S n anal­
yses [160]. However, long data  acquisition times may be associated with such m ethod­
ologies.
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1.3.2.5 M ALDI-M SI applications
Several studies have reported the successful use of MALDI-MSI to map protein and 
peptide distribution within biological tissue sections and tumour biopsies [145, 161]. 
This provided the localisation of tumour regions within tissue sections and the study 
of protein expressions associated with tumour grade and stage. Therefore this demon­
strates the possibility of using the technique for high-throughput protein analysis [140] 
and generating tumour sub classification as well as predicting clinical outcome.
The potential of the technique has also been demonstrated for the analysis of drug 
distribution within tissue and whole body rat tissue sections with no requirement for 
labeled analytes [162]. This presents huge benefits for drug metabolism and pharm a­
cokinetic (DMPK) studies in terms of cost and time of analysis.
The use of IMS combined with MALDI-MSI is a very promising approach as it brings 
another dimension of separation and may generate less complex mass spectral data  than  
conventional MALDI-MSI. Ion mobility separation between proteins, peptides, lipids 
and small molecules can be achieved prior to direct MALDI-MS characterisation, hence 
resulting in more specific and sensitive data  imaging information [117, 132, 163].
The use of on-tissue enzymatic digestion has been found to produce complex mass 
spectral data where numerous signals are observed in the mass range m /z 800-3000 [163]. 
Another benefit of such a technology is the use of IMS-MS/MS analysis for specific and 
sensitive in situ identification of peptides/proteins resulting from on-tissue digestion.
More detailed reviews of the applications of MALDI-MSI are given in the introduc­
tion sections of chapters 2, 3, 4, 5, 6 and 7.
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1.4 A im s of th e  S tudy
The need for protein biomarkers to improve early detection, diagnosis and prognosis 
of cancer diseases is of importance, since this can help in tumour classification and the 
development of targeted approaches for therapeutic treatm ents. Such aims require pow­
erful, reproducible and robust tools and technologies tha t can provide insights into the 
molecular organisation of the tum our micro environment, localise and identify proteins 
and protein interactions as well as allow high-throughput analysis. MALDI-MSI is a 
technology which has a huge potential as a translational research technology for cancer 
biomarker discovery [164].
The aims of the study reported in this thesis are firstly to develop and improve 
efficient methodologies for the study of protein distribution and identification directly 
within both frozen and FFP E  tumour tissue sections.
These methodologies were further applied to examine a range of tumour samples but 
in particular to identify and study the distribution of proteins significantly associated 
with the UPR within FFP E  adenocarcinoma tissue sections.
The methodologies developed in this study aimed also to explore other complex 
molecular processes occurring within the tumour micro-environment, including hypoxia, 
and to achieve high-throughput protein analysis within tumour tissue sections in order 
to design tumour classification models.
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CH A PTER 2
Direct Proteom ic Investigation in
T um our Tissue Sections using
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2.1 Introduction
Growth and invasion of an organ or tissue by tumour cells require signalling between 
tum our cells and the tissue in order th a t the tumour grows without the inflammatory 
response tha t could inhibit such progression [1-3]. Biomarkers are biological molecules 
th a t are measurable indicators of a specific physiological state and changes occurring 
during a disease process [4]. Enhancing the understanding of cancer relies heavily upon 
the identification of diagnostic biomarkers i.e. proteins and other biomolecules which 
are correlated to disease states or represent potential therapeutic targets [5-7]. Proteins 
play a fundamental function in cell process either via metabolism or cell signalling and 
immune responses. The ability to use proteomic profiling to differentiate tissue section 
regions and to discriminate between relevant biomolecules can improve the selection and 
identification of those whose expression is closely associated with the tum our growth 
and/or progression, and thus improve the development of chemotherapeutic agents [8- 
10].
MALDI-MSI is a technique tha t enables the screening of proteomic information di­
rectly from a tissue section with no requirement for specific targets and could aid the 
identification of target proteins whose functionality can help biomarker discovery [11]. 
Several papers have already reported the successful use of the technique to investigate 
the distribution of proteins directly within tissue sections [12-16]. MALDI-MSI has also 
been used to investigate changes in protein profiles within tumour tissue sections [17-19] 
and changes occurring in response to therapeutic agents [20, 21]. These studies show 
th a t MALDI-MSI can be used to distinguish between cancerous and normal tissues, 
thus highlighting the benefit of the technique for rapid characterisation of a disease a t 
the protein level.
Xenografts are human cells or human cell lines grown in immunodeficient mice. 
Tumour xenografts are mainly produced in two ways: human tumour cells are either in­
jected subcutaneously into a nude mouse to generate an ectopic xenograft or to  produce 
an orthotopic tumour model, which involves the implantation of the tum our into the 
animal organ from which it arose, so tha t tum our cells grow in their equivalent native 
environment. Tumour xenografts are extensively used in cancer research as they can
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be used to produce a broad spectrum of major tumour types [22]. The possibility also 
exists of ex vivo genetic or therapeutic manipulation before xenotransplantation. The 
progression of a large number of easily observable synchronized tumours can be moni­
tored, so th a t initiation of treatm ent can begin when the tumours reach an optimal size.
In the work reported here, xenograft tissue samples, grown from the MCF-7 breast 
cancer cell line, were used for method development for direct proteomic profiling and 
imaging within tumour tissue sections by MALDI-MS. Numerous protein signals were 
detected and their distribution studied directly within MCF-7 xenograft tum our tissue 
sections. This allowed discrimination of tumour regions from necrotic areas.
MALDI-MSI is a potential tool for aiding both biomarker discovery and clinical in­
vestigations as several studies have shown th a t the technique is complementary to  other 
imaging techniques tha t require labelled analytes (i.e. autoradiography, fluorescence 
imaging) because of its molecular specificity. However as each MALDI-MSI experiment 
generates a large set of data, data  pre-processing is required in order to facilitate result 
interpretation as well as statistical analysis. For this purpose, a workflow for MALDI- 
MSI data  pre-processing was described by Norris et al. [23]. Several da ta  pre-processing 
software packages are commercially available, but most of them  are specific to  an ap­
plication or an instrument, thus making data  pre-processing relatively difficult in some 
cases. In the work reported here the use of a freely available software tool SpecAlign
[24] to aid data  pre-processing prior to statistical analysis is described. A report of the 
results shown in this chapter can be found in Djidja et al [25].
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2.2 M aterials and Sam ples
2.2.1 C hem icals and m aterials
Sinapinic acid (SA), a-cyano-4-hydroxycinnamic acid (a-CHCA), ethanol (EtOH), 
methanol (MeOH), acetonitrile (ACN), chloroform (CHCI3 ), xylene, trifuoroacetic acid 
(TFA), haematoxylin, eosin, trifluoroacetic acid (TFA) and human haemoglobin protein 
standard were obtained from Sigma-Aldrich (Dorset, UK).
2.2 .2  T issu e sam ples
2.2.2.1 R at liver tissues
R at liver samples were obtained from the Sheffield Hallam University laboratory 
(Biomedical Research Centre, Sheffield Hallam University, Sheffield, UK) directly after 
animal sacrifice. Samples were immediately snap-frozen in a beaker containing cold 
isopentane, which was previously immersed in liquid nitrogen. Frozen tissue samples 
were stored at -80° C to minimize protein degradation through enzymatic proteolysis 
and to preserve the sample’s morphology.
2.2.2.2 M CF-7 Breast tumour xenografts
All animal procedures including animal treatm ent and tum our system and trans­
plantation were carried out at the Institute of Cancer Therapeutics (Bradford, UK).
2.2.2.2.1 A nim al treatm ent
Investigations and all animal procedures were carried out under a project licence 
issued by the UK Home Office and the United Kingdom Co-ordinating Committee on 
Cancer Research (UKCCCR) [26]. Female B alb/C  immunodeficient nude mice (Har­
lan UK, Blackthorn, UK) aged 6 - 8  weeks were used. Mice received CRM diet (SDS, 
W itham, UK) and water ad libitum. Animals were kept in cages in an air-conditioned 
room with regular alternating cycles of light and darkness.
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2.2.2.2.2 Tumour system
MCF-7 breast tumour xenografts were obtained from the Institute of Cancer Ther­
apeutics (Bradford, UK). The transplantation of tumour was performed as follows: 
briefly, 24 hours prior to tumour transplantation, in order to stimulate tumour growth, 
a slow-release oestrogen pellet (Innovative Research, Sarasota, FL, USA) was implanted 
subcutaneously in the upper dorsal area of the animal under brief general inhalation 
anaesthesia. MCF-7 human mammary adenocarcinoma tumours were excised from a 
donor animal, placed in sterile physiological saline containing antibiotics and cut into 
small fragments of approximately 2 mm3. Under brief general inhalation anaesthesia, 
tumour fragments were implanted in the left and right flank of each mouse using a tro­
car. Once the tumours had reached a desired volume, usually between 200 and 400 mm3, 
as measured by callipers, mice were sacrificed. Tumours were excised and immediately 
snap-frozen in liquid nitrogen and stored at -80° C to minimise protein degradation and 
keep the original sample’s morphology until further analysis.
2.2 .3  T issu e preparation
R at liver and MCF-7 xenograft samples were sectioned using a cryostat (Leica Mi­
crosystems, Milton Keynes, UK) operating at -20°C. 10 y m  sections were cut and thaw- 
mounted on either a TLC foil, from which the stationary phase had been previously 
removed, or on histological Polysine™  glass slides (Menzel-Glaser, Germany).
Rinsing procedures were established to increase the MS data quality. These rinsing 
steps consisted of immersing sections for one minute through a series of ethanol solutions 
of decreasing water concentrations from 50 to 90%. Washing the tissue sections with 
EtOH aims to remove residual salts as well as fixing the tissue section. After the 
EtOH washes the section was immersed in CHCI3  in order to decrease the lipids in the 
tissue section [27]. Indeed lipids present within the tissue section may interfere with 
the desirable analyte, here proteins, thus making potentially difficult the detection of 
proteins by direct MALDI-MSI analysis.
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2.3 M e th o d s  a n d  In s t ru m e n ta t io n
2 .3 .1  M a t r i x  d e p o s i t io n
For direct protein analysis, sinapinic acid (SA) was used as matrix. For direct 
protein profiling the m atrix was prepared at 25 mg/mL in ACN:dH20:TFA (1:1:0.2 in 
volume). Several spots (300 nL) of matrix were directly deposited onto specific regions 
of the section according to the histological study using an automatic pipette. Figure
2.1 shows a digital scan of a tumour xenograft section in which the darker region in the 
center represents necrotic tissues and the surrounding part is mainly tumour cells. The 
small circles on the image show where m atrix spots were deposited in order to generate 
average mass spectra of the different regions. For imaging experiments, SA solution 
was prepared at 25 m g/mL in 100% EtOH: 0.2% TFA. The matrix solution was spray 
coated onto the tissue section using a gravity fed pneumatic air spray gun set to 40 psi. 
Approximately 15 to 20 spray cycles gave a homogeneous m atrix coverage.
O
O oo oo o
o
Figure 2.1: S chem atic  show ing th e  d e p o s itio n  o f m a tr ix  sp o ts  o n to  a  M C F -7  
b re a s t  tu m o u r  x en o g ra ft tis su e  section .
A digital scan of a breast tumour xenograft tissue section is shown. Depositions of 
matrix spots are represented by circles on the tissue section image.
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2.3 .2  H aem atoxy lin  and eosin  (H E ) sta in in g  p rotoco l
Frozen MCF-7 breast tumour xenograft tissue sections were allowed to dry at room 
tem perature and then fixed by using a series of EtOH solutions of increasing water 
concentration (100, 95 and 70%) stored at -20°C for three minutes in each solution. 
The sections were then dipped in tap  water for two minutes until clear. The nuclei were 
stained by immersing the tissue sections in haematoxylin for 30 seconds, followed by 
a wash under running tap  water (a gentle stream of water running into a staining jar 
was used). The sections were then dehydrated in 70 and 95% EtOH solutions for three 
minutes and immersed for 20 seconds in eosin solution made at 5% in EtOH. Following 
eosin staining, the tissue sections were washed twice in 95% EtOH solutions for five 
minutes each time until clear, followed by two washes in 100% EtOH for five minutes. 
Tissue sections were then fully dehydrated in xylene for 15 minutes and coverslipped.
2.3 .3  M A L D I-M SI d ata  acq u isition
MALDI-MSI data  were acquired in the linear and positive mode using both an 
Applied Biosystems (Ontario, Canada) Voyager D E ™  PRO and a Voyager D E ™  
STR equipped with a 337 nm nitrogen (N2 ) laser operating at a repetition rate of 20 
Hz. Full scan mass spectra were recorded in the m /z between 2000 to 50000. 200 to 500 
laser shots were averaged to create a spectrum from each droplet. Mass spectra were 
internally calibrated using signals from the a  and (3 chains of haemoglobin peaks in the 
spectra.
2 .3 .4  M A L D I-M S profiling and im aging d ata  processin g
Protein profiles were pre-processed using SpecAlign which has the ability to perform 
spectral alignment as an additional pre-processing step [24, 25]. Imaging da ta  acquisi­
tion was performed at a spatial resolution of 250 /mi. Protein images were generated 
with BioMap 3.7.5.5 software (Novartis, Basel, Switzerland) capable of monitoring the 
amplitude of selected mass signals and reconstructing 2-D ion density maps.
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2.4 R esu lts and D iscussion
2.4 .1  E valuation  and  op tim isa tion  o f  th e  m atrix  concentration
The development and improvement of the MALDI-MSI method for the investigation 
of protein directly within tum our tissue sections was performed using frozen ra t liver 
tissue sections. For most applications sinapinic acid has been found to be an excellent 
m atrix for protein analysis resulting in a superior quality mass spectrum containing over 
300 individual signals [28]. It also provides good signal-to-noise ratio (S/N) and a low 
baseline compared to a-CHCA for instance, which is more suitable for low molecular 
weight compounds. However some improvements were made to increase the crystalliza­
tion process on the tum our tissue sections. This demonstrates tha t adjustments of the 
concentration of the m atrix solution and the TFA can provide increased protein signal 
intensities.
Figure 2.2 shows th a t higher m atrix concentrations result in improved quality spec­
tra. MS analyses performed on each droplet clearly show that a 25 m g/mL m atrix 
solution yields the highest number of ion signals with an improved resolution when 
compared with a 10 mg/mL solution.
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Figure 2.2: E ffect o f m a tr ix  c o n c e n tra tio n  on  th e  re su ltin g  m ass s p e c tra  from  
a  r a t  liver section .
Solutions of SA were made up in E t0 H:dH2 0 :TFA (1:1:0.1) at concentrations of (a) 
10 mg/mL and (b) 25 mg/mL. 300 nL m atrix spots were deposited on ra t liver tissue 
sections and direct protein profiles were acquired. Protein signals are detected above 
m /z 20000 when using a m atrix concentration of 25 mg/mL.
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The TFA concentration was also found to affect the obtained protein profiles. Figures 
2.3a, b and c show that an increased concentration of TFA improved the observed protein 
signal intensities. However a TFA concentration of 1% was found to inhibit some ion 
signals. Using 0.5% TFA was found to be an optimum concentration of TFA added 
to the m atrix solution. The analysis of the rat liver samples allowed the improvement 
of the sample preparation as well as the optimisation of the MALDI-MSI method for 
direct protein analysis in tumour tissue sections.
a) 0.1% TFA
3938 12100 b) 0.5% TFA
M ass (m/2)
11348.82100
c) 1 % TFA
Figure 2.3: E ffect o f T FA  c o n c e n tra tio n  on  th e  p ro te in  profiles o b ta in e d  from  
a  r a t  liver section .
Solutions of SA (25 mg/mL) were made up in 50% ethanol with various concentration 
of TFA set at 0.1% (a), 0.5% (b) and 1 % (c) respectively. 300 nL m atrix spots were 
deposited on rat liver tissue sections and direct protein profiles were acquired. 0.5% 
TFA yields improved protein profiles.
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2.4 .2  D irect p rotein  profiling and im aging in  M C F -7 xenograft tissu e  
section s u sing  M A L D I-M S
The method previously described in section 2.4.1 was optimised and used to inves­
tigate protein expression in MCF-7 breast tumour xenograft samples. As breast tissues 
are primarily adipose tissues the detection of low molecular mass compounds only may 
result from the limited access to proteins due to the high lipid content. Therefore a 
tissue-washing procedure previously described by Lemaire et al. was applied and im­
proved [27]. In this published work, a washing method using organic solvents such as 
chloroform (CHCI3 ), hexane, toluene, acetone and xylene was studied. This allowed the 
extraction of lipids from the tissue before analysis by MALDI-MSI. This procedure im­
proved detection of peptides/proteins (m /z 5000-30000) by enhancing signal sensitivity.
In the work reported here, tissue sections were first washed in increasing concentra­
tions of ethanol (from 50% to 90%) for 1  minute followed by a wash with CHCI3  for 30 
seconds. This aimed to remove residual salts from the tissue sections as well as reduce 
lipid content. Figure 2.4 shows protein profiles obtained from a xenograft section. A 
good number of proteins were observed, after rinsing the section with CHCI3 .
Spectra were acquired from the necrotic and tumour regions of the section. Different 
profiles were obtained from each region in terms of protein intensities. Numerous protein 
signals were observed in the tumour area, some of which were detected only in the 
tumour cells. Protein signals at m /z 11298.8 and m /z 3999.9 were mostly detected in 
the tumour area compared to the necrotic region. This shows the specificity of the 
technique for a given sample.
In both necrotic and tumour region spectra, peaks a t m /z 7654.4 and m /z  15328 may 
correspond to haemoglobin doubly and singly charge peaks respectively. Haemoglobin 
peaks were used to calibrate all spectra and so minimise the observed shifts in apparent 
mass values.
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Figure 2.4: M A L D I-M S  p ro te in  profiles a n d  m icroscop ic  im ages o b ta in e d  d i­
re c tly  from  a  M C F -7  x e n o g ra ft tis su e  section .
Panel a displays the obtained protein profiles from both tumour and the necrotic regions. 
The green trace displays protein profile obtained from the tumour region and the blue 
trace shows the protein profile obtained from the necrotic region. Numerous protein 
signals were detected. Differences in protein signal intensities were noticed, this can be 
highlighted in both the entire mass spectrum and the zoomed in spectrum (panel b). 
Panels c and d display the microscopic images obtained after HE histological staining 
of the section: the microscopic images were obtained from tumour and necrotic regions 
respectively.
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MALDI-MS imaging was also performed to investigate protein distribution within 
the section. Figures 2.5a, b and c show images obtained following HE staining of a 
MCF-7 xenograft section. Protein distributions within the tumour and necrotic area 
were generated. Figure 2.5d shows the section after m atrix coverage. MALDI-MS im­
ages were acquired at a spatial resolution of 250 /mi. The protein distributions shown 
in figures 2.5e, f, g and h were in good agreement with results from profiling analy­
sis as well as the histological staining since protein localisation as well as difference 
observed in signal intensities allowed the discrimination between necrotic and tum our 
regions. Signals at m /z 14154 and m /z 24995 were abundant in the tum our region. 
The protein signal at m /z 12422 was predominantly found in the necrotic region. Ad­
ditional observations can be made from these data. Protein signals can be observed 
outside of the tissue section on the resulting images. This may be due to the m atrix 
coverage method, which was performed by manually spraying the m atrix solution onto 
the section. Several papers have reported the minimisation of protein delocalisation 
from m atrix application by using other devices such as robotic printers, which allow 
an improved m atrix deposition [29, 30]. However, the MALDI images were found to  be 
in general agreement with the results from direct profiling analysis in terms of specificity.
The method developed here allows direct protein profiling and imaging to be carried 
out on the MCF-7 tum our tissue sections. The ability of the technique to differentiate 
regions within tumour tissue sections was shown using both direct protein profiling 
and imaging MALDI-MSI analysis. However, statistical analysis is required for disease 
classification and biomarker validation purposes from such data  and the development 
of methodology for this is described in the next sections [31, 32].
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necrotic area
tumour area
Figure 2.5: Im ages o f p ro te in  d is tr ib u t io n  w ith in  M C F -7  b re a s t  tu m o u r  
x en o g ra ft tis su e  sections.
Optical and MALDI-MSI images of a MCF-7 breast tumour xenograft section are dis­
played. Panel a displays a digital scan of a HE staining of a MCF-7 breast tumour 
xenograft tissue section: the necrotic region (light colour) is surrounded by the tumour 
area (strong purple). Panels b and c display the microscopic images of the tumour and 
necrotic area respectively: the image were acquired at xlO magnification. Panel d shows 
the section after m atrix coverage before acquiring MALDI images. Panels e, f, g, and h 
are MALDI-MS images of protein distributions at m /z 11781, 12422, 14151 and 24995 
respectively within the tissue section. However, protein signals can be observed outside 
the tissue section in the outlined (in red) region on panel g and h, probably due to the 
matrix deposition method.
e) m/z 11781
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2.4 .3  M eth od  d evelopm en t for M A L D I-M SI d ata  pre-processing
The use of MALDI-MSI for direct profiling and imaging of biological tissues is 
of interest for clinical purposes and diagnosis. However, before validation in clinical 
fields, statistical analysis is required. As each MALDI-MSI experiment generates a 
large amount of data, a workflow has been described by Norris et al. showing the need 
for pre-processing of such data  prior to statistical analysis [23]. These pre-processing 
stages consist of baseline correction, noise removal, normalisation, calibration and spec­
tral alignment.
2.4.3.1 D ata alignment using SpecAlign
Using standard instrument software (such as Applied Biosystems D ata Explorer™  
as used here) one can easily achieve baseline correction, noise suppression and calibration 
of mass spectra. Indeed proper calibration of the instrument allows reasonable mass 
accuracy in the linear mode for protein profiling. In some cases the use of an internal 
calibrant aids alignment of the spectra [23]. Figure 2.6 shows an overlay of protein 
profiles obtained from tumour and necrotic regions of a xenograft section. Haemoglobin 
peaks were used as an internal calibrant. Manual calibration was performed using 
D ataExplorer™  software. On these profiles mass shifts between similar compounds 
were observed. This can be noticed in the zoomed-in spectra where signals a t m /z 
11312 have been highlighted. Therefore, even if the use of an internal calibrant helps 
with aligning spectra, the irregularity of the tissue section flatness and/or thickness may 
induce mass measurement variabilities, meaning an appropriate spectral alignment tool 
is needed.
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In this work, SpecAlign, which is a freely available software tool, was used to aid 
data pre-processing prior to statistical analysis [24, 33]. The same data  were imported 
into SpecAlign as text files for spectral pre-processing. The pre-processing step con­
sisted of baseline correction, noise removal, normalization by the to tal ion count (TIC) 
and finally alignment according to a peak matching method available with the software. 
Normalising the data  allows the projection of all ion intensities onto an average intensity 
scale to facilitate and improve spectral comparison. In TIC normalisation all spectra 
are adjusted so they become the same and equal to the average TIC for all spectra 
[23, 24].
Figure 2.7 shows the aligned spectra produced using SpecAlign. Spectra were aligned 
using a peak matching method provided by the software. Spectra are presented from 
m /z 11000 to 12800. The mass shift between spectra is minimised and data  are easy to 
compare.
11311.7
tumour region
17233 116498
12076.300  —
11000.5 11720
11311.7
necrotic region52051
3470.1
17350 12561S
00110005 11360 3 11720 120798 124395 127993
Figure 2.7: M A L D I-M S  p ro te in  p ro files  o b ta in e d  d ire c tly  from  M C F -7  
x e n o g ra ft t is su e  sec tio n s  a n d  p ro cessed  w ith  S pecA lign .
Spectra were cropped from m /z 11000 to m /z 12800. D ata were imported into SpecAlign 
as text files. Spectra were baseline corrected, noise removed, normalized with the TIC 
and finally aligned following a peak matching method.
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Five serial MCF-7 xenograft tissue sections were used for direct MALDI-MS profil­
ing analysis in order to generate average protein profiles from both tumour and necrotic 
regions. Figure 2.8 shows examples of the resulting MALDI mass spectra after data 
pre-processing using SpecAlign software (i.e. baseline correction, noise removal, nor­
malisation and spectral alignment). The average mass spectra are displayed in the mass 
range m /z 3000 to 35000, as signals were not detected above 35000.
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Figure 2.8: D irec t M A L D I-M S  p ro te in  p rofiles o b ta in e d  a f te r  d a ta  acq u is i­
t io n  a n d  p ro cess in g  w ith  S pecA lign  from  a  M C F-T  tu m o u r  x e n o g ra ft tis su e  
section .
Average mass spectra are displayed for both necrotic and tumour regions in the m /z 
range 4400 to 35000. The mass spectra obtained from both necrotic and tum our regions 
were cropped from (1) m /z 4400 to 9800, (2) m /z 8280 to 16060 and (3) m /z  16390 to 
35000.
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Many protein signals were observed and different profiles were obtained from tu ­
mour and necrotic regions in terms of signal intensities. The necrotic area was found 
to be data  rich in the m /z range between 4000 and 10000 compared to the tumour 
region. Necrosis is a non-specific mode of cell death in which lysis of cells takes place. 
The increased number of observed signals in the necrotic protein profiles could relate 
to proteolysis occurring during cell death. Some signals were mostly detected in the 
tumour area including those at m /z 6904.6 and 7673.4. The protein a t m /z 7673.4 
may correspond to the doubly charged species of haemoglobin alpha. These data  are in 
agreement with those already reported by Reyzer et.al. [2 0 ], in which this signal was 
found to be abundant in transgenic breast tumour samples.
It has been reported tha t histones represent good targets for MALDI-MSI in tumour 
tissue sections [20, 34]. The obtained profiles from the tumour region were also data  
rich in the histone mass range (m /z 10000 to m /z 15000). Signals a t m /z 11358, 13787 
and 15314 are detected in the tumour and necrotic area and may correspond to histone 
species.
Although the signal-to-noise ratio of protein signals decreased considerably in the 
mass range above m /z 30000, the obtained protein profiles allow the detection of protein 
signals in the tumour region. This can clearly be seen in the zoomed in spectra (m /z 
17000 to 35000, figures 2.83a and b). Signals at m /z 24642.2, 24772.72, 27765.9 and 
30638.8 were only detected in the tumour region.
The use of SpecAlign, which combines calibration and alignment steps, was found 
to improve data comparison and provides accurate peak assignments. However, whilst 
it has been reported tha t spectral alignment carried out before calibration minimises 
errors in m /z assignment [23], it is not currently possible to import files from SpecAlign 
back into D ataExplorer™ , because the file formats are not compatible.
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2.4.3.2 Benefit of data pre-processing for statistical analysis
2.4.3.2.1 Use o f SpecAlign fo r  data pre-processing o f M A LD I-M S protein
profiling
For statistical analysis, principal component analysis (PCA) was carried out using 
aligned text spectra obtained from the xenografts. Five spectra were acquired from 
both tumour and necrotic regions. These spectra were then aligned with SpecAlign 
software and converted into text files. PCA was performed using a pre-release version 
of Applied Biosystems/MDS Sciex M arkerview™  statistical analysis software (Applied 
Biosystems/MDS Sciex, Ontario, Canada). A supervised analysis was carried out with 
a Pareto scaling.
As can be seen in figure 2.9A, the scores plots show clearly 2  different groups cor­
responding to the tumour and necrotic regions of the tissue section (red and blue plots 
respectively). Positive and negative principal components 3 (PC3) are observed in the 
scores plots for the tum our region. This can be explained by the fact th a t each data  set 
results from a spot analysis, hence showing protein signals highly or less intense within 
the same region. However, the results are still in agreement with those obtained from 
direct protein profiling with MALDI-MS. In the loading plots (figure 2.9B) the outly­
ing highlighted ions account for the observed difference between spectra. For example 
protein species at m /z 11266 and m /z 15308 were found to be abundant in the tumour 
region.
The same statistical analysis was performed using non aligned data; these were 
simply calibrated using D ataExplorer™  (Figure 2.10). In the scores plots it can be 
noticed tha t both the positive and negative principal components 1  and 3 (PC I and 
PC3) are observed for the tumour area. The groups are not clearly distinguished, hence 
making the data difficult to explain. These data  demonstrate th a t spectral alignment 
with SpecAlign prior to statistical analysis improves the results obtained.
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Figure 2.9: S u p erv ised  p rin cip a l co m p o n en t a n a ly sis  (P C A ) re su lts  o b ta in e d  
from  a lign ed  p ro te in  profiles o f  M C F -7  x en o g ra ft t is su e  sec tio n s.
Panel (A) displays the score plots which indicate the obtained groups after PCA analysis: 
red (a) and blue (b) plots correspond to tumour and necrotic regions respectively. Panel 
(B) shows the corresponding loading plots where characteristic m /z values for the groups 
defined by the score plots are highlighted.
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Figure 2.10: S u p erv ised  p rin cip a l co m p o n en t a n a ly sis  (P C A ) r e su lts  o b ta in e d  
from  n on  a lign ed  p ro te in  profiles o f  M C F -7  x en o g ra ft t is su e  sec tio n s .
Panel A shows the score plots: red (a) and blue (b) plots are corresponding to necrotic 
and tumour regions respectively. No distinguished groups are noticed. Panel B displays 
the corresponding loading plots.
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2 .4 .3 .2.2  Use o f  S pecA lign  f o r  d a ta  p re -p ro c ess in g  o f  M A L D I - M S  p r o te in
im a g in g
SpecAlign has also proved to be a valuable tool for aiding MALDI-MSI data pre­
processing. Images were acquired from xenograft samples. Figure 2.11a represents the 
histological (H&E) staining of the section. Figure 2.11b shows the m atrix coverage onto 
the section. The resulting images were generated using BioMap software. The regions 
of interest (ROI) R i, R 2  and R 3  were then analysed using BioMap and average spectra 
for each ROI were generated. To represent each ROI, 10 spectra obtained from each 
were imported into SpecAlign for pre-processing. The method previously described 
for protein profiling experiments was used (described in section 2.4.3.1). Figure 2.11c 
shows the resulting spectral alignment of profiles from Ri. Then, supervised PCA was 
performed (Figure 2.12).
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Figure 2.11: S p ectra l a lig n m en t p erform ed  w ith  S p ecA lig n  u sin g  M A L D I-M S  
im ag in g  data.
Panel a shows a HE staining picture of the tissue section. Panel b displays the digital 
scan of the tissue section after matrix deposition onto the section: R i, R 2  and R 3  
represent the regions of interest analysed with BioMap software. Spectral alignment 
achieved with SpecAlign using protein profiles from Ri imported from BioMap into 
SpecAlign is shown in panel c.
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As can be seen in figure 2 .1 2 A, groups are easily distinguished in the score plots. 
The plots from R 2  and R 3  overlap because these ROIs represent regions of necrotic 
tissue. Histological analysis conducted previously indicated that R 3  contained more 
lymphocyte cells in comparison to R 2 , explaining the differentiation between the two 
groups. In the corresponding loadings plots (figure 2.12B, proteins a t m /z 7749.58 and 
15120.58 were found highly expressed in R i and m /z 13933 was mainly detected in R 2 .
In summary, protein profiles and images were obtained directly from tissue sections 
using an optimised MALDI-MSI method. By combining a good tissue pre-treatm ent 
protocol with an appropriate m atrix choice and deposition method, protein distributions 
within the section were generated. Using MALDI-MSI for direct protein profiling and 
imaging within the tissue section, it was possible to correlate protein abundance to  a 
specific area of the section. Table 2.1 summarises the results obtained from protein 
profiling analysis: the relative intensities observed from protein signals are displayed. 
SpecAlign was found to be a valuable tool for aiding data pre-processing, prior to 
statistical analysis.
Loadings foi PCI (38.1 Z) versus PC2 (10.3 Z). Pareto. Use Groups 
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Figure 2.12: Supervised PC A results obtained from aligned MALDI-MS imaging data obtained from MCF-7 x e n o g ra ft 
tissue s e c t io n .
Panel A displays the score plots where groups are clearly differentiated. In the scores plots, The spectra exported from the regions of 
interest Ri, R 2  and R 3  are represented by the red, green and purple plots respectively. (B) The loading plots show the difference between 
them.
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Observed
m /z
Tissue
region
Relative
intensity
%
Observed
m /z
Tissue
region
Relative
intensity
%
Observed
m /z
Tissue
region
Relative
intensity
%
4236.4 Necrotic 5.64 7665.2 Necrotic 5.96 21267.2 Tumour 1.22
4623.1 Necrotic 4.86 7675.7 Necrotic 5.37 22411.3 Tumour 1.73
4781.3 Necrotic 10.93 7748.3 Necrotic 4.29 22456.3 Tumour 1.15
Tumour 1.65 7787.7 Necrotic 3.24 22553.9 Tumour 0.51
4796.1 Necrotic 10.85 8568.7 Necrotic 10.01 22609.4 Tumour 0.79
Tumour 2.86 Tumour 3.65 23505.1 Tumour 1
4973.586 Necrotic 6.19 8631.7 Necrotic 9.47 23667.9 Tumour 0.89
Tumour 1.86 8708 Necrotic 6.05 23772.7 Tumour 0.59
5054.6 Necrotic 6.11 8723.3 Tumour 1.39 24642.2 Tumour 3.76
Tumour 2.14 8748.4 Tumour 1.55 24772.7 Tumour 3.01
5205.2 Tumour 3.53 8941.4 Tumour 2.4 26580.3 Tumour 1.36
5214 Tumour 3.95 9351.9 Necrotic 5.07 27765.9 Tumour 0.79
5267.4 Necrotic 7.11 9400.7 Necrotic 8.46 27807.9 Tumour 0.55
Tumour 2.07 9812 Necrotic 13.09 27991.2 Tumour 0.58
5315.6 Tumour 3.43 Tumour 4.04 29081.7 Tumour 0.8
5349.5 Necrotic 23.96 9775.2 Necrotic 8.67 29253 Tumour 0.83
Tumour 1.21 9954.6 Necrotic 35.39 29289.3 Tumour 0.39
5366.7 Necrotic 24.58 10036.1 Necrotic 8.44 29797.3 Tumour 0.62
Tumour 7.43 10067.5 Necrotic 6.42 30638.8 Tumour 0.92
5437.7 Necrotic 6.08 11189.9 Necrotic 7.73 30567.4 Tumour
5657.2 Necrotic 20.57 11293.3 Necrotic 100 30634.7 Tumour
Tumour 18.17 Tumour 100 30697.9 Tumour
5664.2 Tumour 3.01 11358.7 Necrotic 52.37 32590.9 Tumour
5700.2 Tumour 3.15 11163.2 Tumour 62.74
6075.2 Necrotic 13.81 12327.9 Necrotic 22.05
6123.2 Necrotic 22.68 Tumour 13.38
Tumour .4.03 12336.6 Tumour 8.62
6270.2 Necrotic 4.5 12482.3 Necrotic 8.14
6559.6 Tumour 5.74 12527.8 Necrotic 13.72
6657.7 Necrotic 16.36 13787.4 Necrotic 28.55
Tumour 4.75 Tumour 65.14
6639.1 Tumour 1.53 13855.1 Necrotic 17.08
6717.4 Necrotic 6.09 Tumour 23.77
6799.4 Necrotic 4.37 13984.7 Necrotic 18.06
6825.5 Necrotic 9.65 Tumour 58.18
6904.6 Necrotic 9.78 14938.2 Necrotic 35.87
Tumour 13.77 15314.2 Necrotic 33.38
6957.1 Necrotic 8.44 Tumour 68.17
Tumour 11.3 16457.7 Necrotic 8.34
6974.1 Tumour 4.08 Tumour 9.07
7011.4 Necrotic 5.61 16488.2 Necrotic 3.57
Tumour 1.07 Tumour 3.84
7573.7 Necrotic 9.48 17879.6 Necrotic 5.3
Tumour 5.26 Tumour 2.78
7664.2 Necrotic 13.76 17917.1 Tumour 1.19
Tumour 25.11 18357.9 Tumour 1.42
Table 2.1: L ist o f d e te c te d  p ro te in s  a f te r  d ire c t  M A L D I-M S I an a ly s is  o f  M C F - 
7 b re a s t  tu m o u r  x e n o g ra ft t is su e  sections.
Observed masses are displayed with their corresponding relative intensities in tum our 
and/or necrotic regions
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2.5 C oncluding R em arks
Understanding the biological processes th a t occur in cancer remains challenging and 
still requires not only the investigation of the molecular compounds involved in these 
mechanisms, but also their spatial localisation within the tissue section itself. In this 
chapter, the use of MALDI-MSI for a direct investigation of the proteomic informa­
tion within tumour tissue sections was described. MALDI-MSI can easily be applied to 
several types of tissues even if specific tissue treatm ent and matrices are required. By 
using this technique direct protein profiling and imaging were performed; additionally 
regions of interest within the section were differentiated. Some proteins were found 
to be abundant and mainly located in the tumour regions of MCF-7 xenograft tissue 
sections. Differences observed in signal intensities allow discrimination between tum our 
and necrotic regions. This is beneficial because by combining both MALDI da ta  and 
histological studies, some proteins can be selected regarding their function or involve­
ment in the disease progression. Another interesting aspect of the technique is that 
unknown proteins or proteins not detected by the histological analysis can be visualised 
with MALDI MS imaging. The technique was powerful in generating both  protein pro­
files and images across MCF-7 breast tum our tissue sections.
Each MALDI-MSI experiment generates a large amount of data. Variations related 
to the tissue section itself, the sample preparation as well as the instrument can be 
observed, and so data pre-processing is required prior to statistical analysis. Here, a 
pre-processing method was developed using SpecAlign software. Combining SpecAlign 
with D ataExplorer™  has been shown to improve data  pre-processing, leading to  ac­
ceptable statistical analysis and facilitating the interpretation of results. I t  has been 
demonstrated that SpecAlign can be used as a complementary tool for MALDI-MS 
imaging data  pre-processing in order to decrease instrument variations considerably. 
However, the method still needs to be optimised in order to import aligned spectra 
back into D ataExplorer™  for the calibration process.
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Direct protein profiling and imaging from tumour tissue sections with MALDI-MS 
enabled the acquisition of protein distribution. However, to help in understanding 
the biological process occurring during disease progression, the identification of these 
proteins is required. Even more desirable is the in situ identification and distribution 
of proteins directly within tumour tissue sections as this will m aintain their spatial 
localisation.
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CHAPTER 3
I n  s i t u  Protein  Identification  
w ithin Breast Tumour Tissues by
M ALDI-M SI
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3.1 Introduction
The identification of proteins involved in tumour progression or those which might 
permit improved or novel therapeutic targeting is essential for cancer research. Tissue- 
based proteomics is becoming an attractive research field as it provides opportunities 
for biomarker discovery related to disease state, hence improving early detection and 
diagnosis. Current protein identification techniques are based on the use of LC/M S/M S 
and 2D gel electrophoresis [1, 2]. Several studies have reported the use of these classical 
methods for high-throughput proteomic approaches for the identification and quantifi­
cation of proteins obtained from complex matrices such as cancer cell and tissue lysates 
[3, 4]. However these techniques require protein extraction, and hence a relatively 
large amount of tissue sample, prior to protein identification. Furthermore all informa­
tion regarding the spatial distribution of biomolecules within the tissue sample is lost. 
Immunohistochemistry (IHC) techniques are commonly used to investigate protein dis­
tribution within a tissue section. However IHC requires a target-specific reagent as well 
as knowledge of individual proteins being analysed.
Direct MALDI-MS analysis of tissue sections is rapidly demonstrating its potential 
for protein imaging and profiling in the investigation of a range of disease states includ­
ing cancer [5-9]. Several improvements and advances in the technique have been made 
including the use of robotic devices to achieve accurate m atrix deposition on the tissue 
section. This has been found to be useful in decreasing protein delocalisation within the 
tissue section as well as for improving the sensitivity of the technique [10, 11]. One of the 
most recent and exciting developments in the technique is the use of on-tissue tryptic 
digestion in order to achieve direct identification of proteins within a tissue section while 
having at the same time information regarding their spatial distribution. Lemaire et al. 
reported a strategy combining the use of in situ  micro-digestion and in situ  extraction 
of proteins from formalin fixed paraffin embedded (FFPE) tissue sections followed by 
nano RPLC/M S for the identification of proteins [9]. This approach facilitated and 
improved the identification and study of the distribution of proteins within archived 
samples [12]. The use of in situ digestion on frozen tissue sections which allowed the 
identification and distribution of numerous signals within rat brain tissue sections has 
also been reported [11, 13].
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In the work reported here, MALDI-mass spectrometry imaging (MALDI-MSI) has 
been used to investigate the distribution and for the in situ  identification of proteins 
in breast tumour tissue section samples. In the work reported in this thesis, the devel­
opment and improvement of the in situ methodology by incorporating a surfactant in 
the trypsin digest protocol in a study of frozen and FFPE  breast tum our tissue sections 
is described. This aims to enhance the detection and identification of proteins which 
are of low abundance or difficult to detect by direct MALDI-MSI. The method was 
shown to be successful for the identification of numerous protein signals and was able 
to differentiate between tissue regions within the section. The signal overlap generally 
encountered after performing on-tissue digestion tha t makes direct protein identifica­
tion challenging, is addressed here, by using ion mobility separation (IMS) prior to 
MALDI-MSI and MALDI-MS/MS. The advantages of using the combination of these 
technologies following in situ digestion are discussed.
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3.2 M aterials and M ethods
3.2 .1  C hem ical and  m aterials
Modified sequence grade trypsin was purchased from Promega (Southampton, UK). 
All other materials, including sinapinic acid (SA), alpha-cyano-4-hydroxycinnamic acid 
(cn-CHCA), aniline (ANI), ethanol (EtOH), methanol (MeOH), chloroform (CHCI3), 
xylene, octyl-o://?-glucoside (OcGlc), trifuoroacetic acid (TFA), haematoxylin, eosin, 
indium-tin-oxide (ITO) glass slides, hydrogen peroxide (H2 O2 ), tri-sodium citrate and 
ammonium bicarbonate, were purchased from Sigma-Aldrich (Dorset, UK).
3 .2 .2  T issu e sam ples
3.2.2.1 M CF-7 breast tumour xenograft samples
MCF-7 breast tumour xenografts were obtained from the Institute of Cancer Thera­
peutics (Bradford, UK). Investigations and all animal procedures were carried out under 
a project licence issued by the UK Home Office and guidelines from the United Kingdom 
Co-ordinating Committee on Cancer Research (UKCCCR) were followed [14]. Female 
B alb/C  immunodeficient nude mice (Harlan UK, Blackthorn, UK) aged 6 - 8  weeks were 
used. Mice received CRM diet (SDS, W itham, UK) and water ad libitum. Animals 
were kept in cages in an air-conditioned room with regular alternating cycles of light 
and darkness. The transplantation of tum our is the same as described in chapter 2 
(section 2 .2 .2 .2 ).
3.2.2.2 Human formalin fixed paraffin em bedded (FFPE) breast tum our 
samples
Ex vivo human breast tumour tissue samples were obtained following fully informed 
patient consent and local ethical committee approval (Study Number SSREC/04/Q2305 
/67 and subsequent amendments). Tissue samples were fixed in 10% buffered formalin 
for 24 hours, dehydrated in 70% EtOH and paraffin embedded. 5 f im .  sections were cut 
using a cryostat (Leica Microsystems, UK) and mounted onto histological Polysine™  
glass slides (Menzel-Glaser, Germany). FFPE  tissue sections were stored at room tem ­
perature until further analysis.
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3.2 .3  T issu e preparation  prior to  M A L D I-M SI d ata  acq u isition
Frozen MCF-7 xenograft tissue samples were cut using a cryostat (Leica Microsys­
tems, UK) operating at -20°C. 10 fim  sections were cut and thaw-mounted onto either a 
TLC foil, from which the stationary phase had been previously removed, or an indium- 
tin-oxide (ITO) glass slide (Sigma-Aldrich, Dorset, UK). Washing procedures were per­
formed to increase the MS data  quality: the rinsing steps consisted of immersing the 
section for 1 min in cold ethanol solutions (stored at -20°C) at 70 and 90% followed by 
a 30 sec wash in chloroform (CHCI3 ) [15]. Sections were then allowed to dry at room 
tem perature before digestion and matrix deposition.
Paraffin wax was removed from FFPE  tissue sections according to procedures pre­
viously described [3, 9]. Briefly, sections were immersed twice in xylene solution for 
10 minutes each time. The sections were then gently hydrated for 3 minutes in 100% 
EtOH, 95% EtOH and 70% EtOH consecutively. Endogenous peroxidase activity was 
blocked by incubating the section for 1 2  minutes in a hydrogen peroxide solution (2 % 
in MeOH). Antigen retrieval (AR) was performed in a microwave oven for 13 minutes 
at 90°C using a tri-sodium citrate buffer at 0.01M (pH =  6.3) [16, 17]. The 13 minute 
heating was divided into 2 cycles of 5 minutes and 1 cycle of 3 minutes with a 30 sec 
interval between cycles in order to check the buffer level in the jar as well as the tissue 
section. After AR the section was cooled to room tem perature and then rinsed with 
water.
3 .2 .4  In  s itu  en zym atic  d igestion
In situ enzymatic digestion was performed using trypsin. The trypsin solution was 
prepared at 50 /ig/m l in deionised water (dH2 0 ) containing 0.1% octyl glucoside (OcGlc). 
The trypsin solution was deposited on the section using either an autom atic pipette 
or robotic devices such as a Chemical Inkjet Printing technology CH IP-1000™  (Shi- 
madzu Biotech, Japan), an Im agePrep™  (Bruker Daltoniks, Bremen, Germany) or 
a SunCollect™  MALDI-Spotter (SunChrom, Friedrichsdorf, Germany) which can be 
used as an automatic spotter or sprayer.
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3.2.4.1 Manual trypsin deposition using an autom atic p ipette
Using an autom atic pipette, several spots of 2 jA of trypsin solution were deposited 
onto the tissue section surface at room tem perature. Every 5 minutes, the trypsin 
solution was deposited on the same spots; a total volume of 30 fil of trypsin solution 
was used.
3.2.4.2 Trypsin deposition using a Chemical Inkjet P rin ter™  (C H IP-1000™ )
The CHIP-1000™  (Shimadzu Biotech, Japan) is a robotic device which uses piezo­
electric technology in order to deposit micro-scale reagent onto a target surface [18]. 
Small droplets of solution can be applied onto specific surfaces including tissue sections 
[11, 13]. Here using the CH IP-1000™ , 100 pL drops were delivered in 5 drop rounds 
until 20 nl of trypsin solution/per spot were printed onto the section. The spot-to-spot 
distance was set at 300 /mi.
3.2.4.3 Trypsin deposition using an Im agePrep™
The Im agePrep™  (Bruker Daltoniks, Bremen, Germany) is an autom atic device 
which allows reagent deposition onto tissue section surfaces by creating vibrational va­
porisation under controlled conditions [19]. It is fitted with an optical sensor th a t 
monitors reagent (such as trypsin and matrix) depositions as well as sample prepara­
tion parameters including the deposition periods, m atrix layer thickness, wetness and 
drying time. Using the Im agePrep™ , a method for trypsin deposition was developed 
and optimised: 600 /d of trypsin solution were sprayed onto the tissue section over 60 
spraying cycles, thus ensuring the tissue is not over wetted. The tissue section was then 
incubated for 2  hours in a humid chamber at 37°C.
3.2.4.4 Trypsin deposition using a SunCollecL™  M ALDI-Spotter
Using the SunCollect™  MALDI-Spotter (SunChrom, Friedrichsdorf, Germany) 150 
nl of trypsin solution per spot was deposited onto the section. The spot-to-spot distance 
was set a t 400 /mi.
The spraying function of the SunCollect™  MALDI-Spotter (SunChrom, Friedrichs­
dorf, Germany) allows the deposition of fine reagent droplets including trypsin and ma­
trix solution onto the tissue section. Briefly the automatic sprayer is equipped with a
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concentric needle connected to a compressed air supply which is fed through the outer 
section of the concentric needle. The inner section of the concentric needle is a cap­
illary which continuously feeds a stream of reagent solution. This results in a plume 
of fine solution droplets, the size of which can be changed by adjusting the solution 
flow rate and/or the compressed air pressure. Using the SunCollect™  MALDI-Spotter 
the trypsin solution was deposited on the tissue section at increased flow rate over five 
layers. The first layer was performed at 1 /d/m in, the second at 2 fiL /m m  and the last 
three layers set at 4 //L/min. Humid environmental conditions were maintained while 
depositing the trypsin on the tissue section. After trypsin deposition the section was 
incubated for 2  hours in a humid chamber at 37°C with 5% CO2  to perform enzymatic 
digestion.
3.2 .5  M atrix  preparation  and d ep osition
For most applications a-CHCA has been found to be a suitable MALDI m atrix for 
the analysis of low molecular weight compounds [20]. However, alternative matrices have 
been proposed to improve the co-crystallization process for on-tissue digested peptides, 
this involved the use of ionic matrices [15, 21, 22]. Here, a-CHCA mixed with aniline 
(a-CHCA/ANI) was used as an ionic m atrix for the analysis of peptides obtained after 
on-tissue digestion. M atrix solutions were made at 10 m g/m l in ACN:dH2 0 :TFA (1:1:0.2 
in volume) and contained an equivalent amount of aniline (i.e 4.8 \xL).
Following enzymatic digestion and incubation, m atrix deposition was performed us­
ing either an automatic pipette, a CHIP-1000™ , an Im agePrep™  or a SunC ollect™  
MALDI-Spotter. When using the CH IP-1000™ , the method for m atrix deposition was 
the same as the trypsin deposition. When using the Im agePrep™ , 2 ml of m atrix solu­
tion were sprayed onto the tissue section over 50 cycles allowing a homogenous m atrix 
coverage to be obtained. When using the SunCollect-™ MALDI-Spotter, the m atrix 
was sprayed onto the tissue section was performed at increased flow rate between lay­
ers. The first layer was performed at 1 //L/m in allowing a m atrix seeding process. The 
second and last three layers were performed at 2 /LiL/min and 3.5 ^L /m in  respectively.
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3.2 .6  In  s i tu  p ep tid e  an alysis and d irect p rotein  id en tifica tion  by  
M A L D I-M S profiling and im aging
3.2.6.1 M ALDI-M S profiling and imaging of peptides obtained after in  situ  
digestion of breast tumour tissue sections
MALDI-MS profiling and imaging data  were acquired in the reflector and positive 
mode using either an U ltraflex™ II M ALDI-TOF/TOF instrument (Bruker Daltoniks, 
Bremen, Germany) equipped with a Sm artbeam ™  laser or in the V-mode and positive 
mode using a MALDI SYNAPTrM HDMS system (Waters Corporation, Milford, MA) 
operating with a 200 Hz Nd:YAG laser.
When using the U ltraflex™ II M ALDI-TOF/TOF instrument, full scan mass spec­
tra  and images were recorded from m /z 600 to 5000. Flexlm aging™  2.0 software 
(Bruker Daltoniks, Bremen, Germany) and BioMap 3.7.5 software (Novartis, Basel, 
Switzerland) were used for image reconstruction. Standards for spectral calibration 
consisted of a mixed solution of peptides (Bruker Daltoniks, Bremen, Germany) rang­
ing between m /z 900 and 3500.
When using the MALDI SYNAPT™ HDM S system, full scan mass spectra were 
recorded from m /z 600 Da to 2500. Images were generated and reconstructed using 
BioMap 3.7.5 software. Standards consisted of a mixture of poly(ethylene glycol) stan­
dards (Sigma-Aldrich, Dorset, UK) ranging between m /z 100 to 3000.
3.2.6.2 M ALDI-IM S-M S/M S analysis for direct protein identification from 
breast tumour tissue sections after in situ  digestion
MALDI-MS/MS analyses were acquired using a MALDI SYNAPT™ HDM S ( Wa­
ters Corporation, Manchester, UK) operating in ion mobility separation (IMS) mode 
directly from the digested tumour tissue sections. A full description of the MALDI 
SYNAPT™ HDM S instrument has been reported previously [23] and also described 
in the introduction of this thesis. Briefly the configuration of the instrument allows 
the separation of ions in the Trap T-W ave™  (pre-IMS) and the Transfer T -W ave™  
(post-IMS), operating as two separate collision cells. Collision induced dissociation was 
performed in the Transfer T-W ave™  after ion mobility separation and optimised based 
on the precursor ion mass [24]. The obtained spectra were processed using MassLynx-™
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(Waters Corporation), mass spectral processing software. Spectral processing consisted 
of smoothing, baseline correction and the use of a lock mass correction for improving 
mass accuracy. Spectra were then processed with the MaxEnt 3 algorithm which aims to 
de-isotope mass spectrometric da ta  and enhance the signal-to-noise ratio [25]. The re­
sulting files were submitted to a MASCOT (Matrix Science, London, UK) query search 
and searched against the Swissprot database.
W ithin the MASCOT search engine the parent and fragment ion tolerances were 
set at 30 ppm and 0.1 Da respectively. The criteria also included up to two missed 
cleavages and the variable modifications allowed were histidine/tryptophan oxidation 
and methionine oxidation. De novo sequencing was performed manually and using the 
PepSeq™  (Waters Corporation) de novo interactive MS/MS sequencing tool. The 
parent and fragment ion tolerances were set at 0.1 Da and the threshold was set at 1%. 
Protein Blast searches against the Swissprot database were also performed to confirm 
tryptic sequences.
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3.3 R e su lts  a n d  D iscussion
3 .3 .1  In s itu  p r o t e i n  i d e n t i f i c a t i o n  i n  f r o z e n  M C F - 7  b r e a s t  t u m o u r  
x e n o g r a f t s
3.3.1.1 M a tr ix  o p tim isa tio n
Direct protein imaging and profiling analysis from xenograft tissue sections with 
MALDI-MS has enabled the acquisition of protein distribution information. However, to 
help the understanding of the biological processes occurring during tumour progression, 
identification of these proteins is required. The possibility of identifying such analytes 
directly from tissue sections has been assessed. To improve the peptide extraction 
and direct analysis of digested proteins, micro digestion was performed using a robotic 
printer. Figures 3.1a and b display digital scans of a MCF-7 breast tumour xenograft 
tissue section before and after on-tissue digestion and matrix deposition performed using 
a CHIP-1000™ .
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Figure 3.1: Im ages o f a  M C F -7  x en o g ra ft tis su e  sec tio n  b e fo re  a n d  a f te r  
t ry p s in  a n d  m a tr ix  d e p o s itio n  using  a  C H IP - 1 0 0 0 TiU a u to m a tic  p r in te r .
(a) Digital scan of a MCF-7 xenograft tissue section prior to on-tissue digestion and 
matrix deposition, (b) Digital scan of the same tissue section after on-tissue digestion 
and matrix deposition using a CHIP-1000™  automatic printer: the m atrix solution 
was spotted onto the trypsin spots after on-tissue digestion. The spot-to-spot distance 
was 300 pm.
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Additionally, the m atrix solution and the deposition methodology were improved in 
order to provide the optimum co-crystallisation with the obtained peptides after enzy­
matic digestion. Figure 3.2 displays peptide profiles obtained after 0 1 1-tissue digestion 
of MCF-7 breast tumour xenografts using different m atrix concentrations as well as 
different trypsin and m atrix deposition methods. D ata acquisition was performed using 
an Ultraflex2 MII M ALDI-TOF/TOF instrument. Examination of the obtained mass 
spectra shows that a higher matrix concentration results in improved quality spectra. 
Additionally, the use of a robotic device for matrix deposition enhanced peptide extrac­
tion and hence increased the number and intensity of detected peptides from the tissue 
section after in situ tryptic digestion.
ill
a) trypsin and matrix deposition performed with 
an automatic pipette 
matrix solution: 5 mg/mLa-CHCA/ANI
b) trypsin and matrix deposition performed with 
an automatic pipette 
matrix solution: 10 mg/mLa-CHCA/ANI
c) trypsin and matrix deposition performed with 
a CHIP-1000™
matrix solution: 10 mg/mLa-CHCA/ANI
LLuL nil
Figure 3.2: Im p ro v e m e n t o f t ry p s in  a n d  m a tr ix  d e p o s itio n  for in  s itu  d ig es tio n  
o f M C F -7  x e n o g ra ft tis su e  sections.
Peptide profiles obtained after manual trypsin and matrix deposition using an autom atic 
pipette (a, b) and robotic deposition using a CHIP-10002 M (c). MS analysis performed 
on each spot clearly shows tha t a 1 0  m g/m l matrix solution yields an increased number 
of detected ion signals with an improved sensitivity compared to a 5 m g/m l solution. 
Performing on-tissue digestion and matrix deposition using a robotic device improved 
peptide extraction, hence the sensitivity.
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3 .3 .1 . 2  D irec t p e p tid e  an a ly sis  w ith in  M C F -7  b re a s t  tu m o u r  x en o g ra ft t is ­
sue  sec tions  using  M A L D I-M S I a f te r  on  tis su e  d ig es tio n
Here in situ digestion and m atrix deposition on xenograft tissue sections were per­
formed using a SunCollect2  M MALDI-Spotter. Mass spectra were obtained from each 
printed spot. Figures 3.3a and b show a digital scan of a xenograft section before di­
gestion and after trypsin/m atrix  deposition respectively. Mass spectra can be obtained 
from each printed spot. Figure 3.3c displays a mass spectrum acquired after in situ di­
gestion and m atrix deposition using an U ltraflex™ II M ALDI-TOF/TOF instrument. 
Numerous peptide signals were detected up to m /z 4000 with a S /N  > 3. MS/MS 
analyses were also performed directly onto the tissue section and allowed the identifica­
tion of a few proteins. Table 3.1shows a list of the identified peptides. Peptide signals 
resulting from the most abundant proteins such as actin (m /z 1198.7), haemoglobin 
(m /z 1529.7) and albumin (m /z 1467.8) were readily detected. These signals were used 
for spectral recalibration purposes. This aimed to improve mass accuracy as well as to 
enhance database search results.
2500 3000
Figure 3.3: D ig ita l scans o f th e  tis su e  sec tio n  a n d  M A L D I-M S I d ire c t  p e p tid e  
profiles o b ta in e d  a f te r  in  s itu  d ig es tio n  o f a  M C F -7  x e n o g ra ft t is su e  sec tion .
Digital scans of a xenograft section before (a) and after (b) matrix deposition are dis­
played. Panel c shows peptide profiling obtained by MALDI-MSI after on-tissue diges­
tion.
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P ro te in  A s­
s ig n m e n t/  
A ccess io n  
num ber
Protein 
mass (Da)
Observed
m /z
with
MALDI-
MSI
signal-
to-noise
ratio
(S/N)
Sequence MS/MS
ion
score
Molecular
function
A c tin , aortic 41982 1198.7 15.6 AVFPSIVGRPR 25 Cell mobil­
sm o o th  m us­ ity
c le /  P 6 2 7 3 6
1790.9 12.2 SYELPDGQVITIGNER 82
A lb u m in / 69367 1467.8 6.4 RHPDYSVVLLLR 60
P 0 2 7 6 8
H a em oglob in 15085 1529.7 5.4 VGAHAGEYGAEALER 115
su b u n it a l­
p h a /  P 0 1 9 4 2
H isto n e  H 2 A / 13545 944.5 22.6 AGLQFPVGR 26 gene regu­
P 0C 0 S 5 lation
Table 3.1: L is t o f a b u n d a n t  p ro te in s  d e te c te d  a f te r  d ire c t M A L D I-M S I a n a l­
ysis o f M C F -7  b re a s t  tu m o u r  x e n o g ra ft t is su e  sec tio n s
3 .3 .1 .3  A n  im p ro v ed  m e th o d  for d ire c t p ro te in  id en tif ica tio n  in  frozen  M C F - 
7 b re a s t  tu m o u r  x e n o g ra ft t is su e  sec tio n s
In order to improve the detection of low abundance proteins and high mass pro­
teins such as stress proteins and/or membrane-associated proteins, several experimental 
conditions including different reagents, humidity, digestion time and tem perature were 
evaluated. Figure 3.4 shows a comparison of results obtained after in situ digestion 
performed with trypsin in either water (figure 3.4a) or in a solution containing the de­
tergent octyl glucoside (figures 3.4b and 3.4c).
Examination of the data  obtained from in situ digestion with trypsin in water only 
(figure 3.4a) shows tha t the majority of the signals detected were from the most abun­
dant proteins present in tissue samples i.e. actin, haemoglobin and albumin as described 
above. The use of octyl glucoside (OcGlc) has been found to greatly improve the solubil­
ity of the proteins. OcGlc is a non ionic detergent and it has been reported to enhance 
protein solubilisation, hence improving in gel protein digestion [26-28]. Here octyl glu­
coside was added to the trypsin buffer, here water, for in situ digestion. Adding 0.1% 
OcGlc to the trypsin solution resulted in the detection of numerous signals in addition 
to those resulting from the most abundant proteins Therefore, it improved the in situ 
digestion of several proteins. The concentration, i.e. 0.1%, used has been found to be 
compatible with direct MALDI-MSI analysis.
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Figure 3.4b shows the resulting peptide profile after in situ  digestion with a trypsin 
solution containing OcGlc followed by incubation at room tem perature for 18 hours. 
This increased the number of signals detected and improved protein identification. 
Hence these data  show th a t incubating the section in a humid environment after trypsin 
deposition enhances the activity of the trypsin and improves the digestion of low abun­
dance proteins. However optimal trypsin performance was found to be after a digestion 
time of 2  hours at 37°C with a trypsin solution containing 0.1% OcGlc in a humid 
chamber (figure 3.4c).
In addition to peptides resulting from the most abundant proteins including actin, 
haemoglobin and albumin, signals from histone species and stress proteins such as Grp75 
(a member of the heat shock protein 70 family, resident within the mitochondria) [29] 
were identified. Direct protein analysis (profiling and imaging) results were found to 
be data  rich in the histone mass range (see Results and Discussion section in Chapter 
2: section 2.4.3.1). Here these results obtained from direct protein identification were 
in good agreement with those from direct protein analysis as numerous signals were 
assigned to histone species, including histone H2A, H2B, 113 and H4. Figure 3.5 shows 
the MS/MS spectrum of m /z 944 which was assigned to peptide T 8  arising from histone 
H2A.
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Figure 3.4: E v a lu a tio n  o f m e th o d  im p ro v em en t for in  s itu  d ig es tio n  o f frozen  
M C F-T  x en o g ra ft tis su e  sections.
Peptide profiles were obtained directly from MCF-7 xenograft tissue sections after in situ 
digestion performed using a SunCollect7 M MALDI-Spotter. a) displays the observed 
peptide profiles after an in situ digestion performed with trypsin in water a t room 
tem perature in no humid atmosphere, b) shows the observed peptide profiling after in 
situ digestion with a trypsin solution containing 0.1% of OcGlc for 18 hours at room 
tem perature in a humid atmosphere, c) reports the in situ digested protein profile when 
using a trypsin solution containing 0.1% of OcGlc and incubating the section at 37°C 
for 2 hours in a humid atmosphere.
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Figure 3.5: M A L D I-M S /M S  s p e c tru m  o f th e  ion  a t  m /z  944 o b ta in e d  d ire c tly  
from  a  M C F -7  x e n o g ra ft tis su e  section .
On-tissue MALDI-MS/MS spectrum of the ion at m /z 944 allowed the identification of 
the peptide T8 arising from histone H2A. The y and b ion series are displayed [30, 31].
Table 3.2 gives a list of some observed and identified signals in both tumour and 
necrotic regions: observed m /z values with direct MALDI-MS/MS analysis and protein 
assignments are reported. The signal at m /z 715 has been assigned to peptide T13 from 
Grp75, a heat shock protein 70 kDa (Iisp70), using direct MALDI-MS/MS. Hsp70 exists 
as several isoforms ranging from 66 to 78 kDa and these are known to be molecular 
chaperones. Hsp70 has been reported previously to be highly expressed in tumour 
tissues, in a study carried out using immunohistochemistry methods [32]. Here the 
obtained MALDI-MS data were in good agreement with those results.
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P ro te in
A ssig n ­
m ent
Accession
number
Protein
mass
(Da)
Observed 
m /z with 
MALDI- 
MSI
Sequence MS/MS
ion
score
Molecular
function
A c tin ,
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sm o o th
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Cell mobil­
ity
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1
P60709 41710 1954.1 VAPEEHPVLLTEAPLNPK 48 Cell mobil­
ity
A lb u m in P02768 69367 1467,8 RHPDYSVVLLLR 60
E stro g en
recep tor
b e ta
Q92731 59178 837.4 RSGGHAPR 15, de 
novo
Nuclear
hormone
F ib rob last  
grow th  
factor  13
Q92913 27564 844.5
958.6 
1361.7
SGKVTKPK
VTKPKEEK
MSGKVTKPKEEK
67,
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nervous 
system de­
velopment
H aem oglobiiP01942
su b u n it
alph a
15085 1529.7 VGAHAGEYGAEALER 115
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H S P  70  
kD a, 
m ito­
chondrial
P38646 73635 715.4 LVGMPAK 18 Molecular 
chaperone, 
control of 
cell pro­
liferation 
and call 
aging
H isto n e
H 2 A
P0C0S5 13545 944.5
2104.2
2915.6
AGLQFPVGR 26
HLQLAIRNDEELNKLLGK 24 
VGAGAPVYLAAVLEYLTAEILEL 44 
AGNAAR
gene regu­
lation
H isto n e
H 2B
P33778 13819 901.5
1743.8
LAHYNKR
AMGIMNSFVNDIFER
25
28
H isto n e
H 3
Q6NXT2 15204 788.5
831.5 
1032.6 
1489.9
KLPFQR
STELLIR
YRPGTVALR
RSAPATGGVRKPHR
28
26
18
55,
Blast
H isto n e
H 4
P62805 11360 1325.7
1466.8
DNIQGITKPAIR
TVTAM DW YALKR
35
29
H igh
m o b ility
group
p ro te in
B 1
P09429 24878 1944.9 RPPSAFFLFCSEYRPK 35 DNA bind­
ing
M eta sta s is -  
a sso cia ted  
p ro te in  2
094776 75023 2428.2 DISSSLNSLADSNAREFEEESK 50,
PMF
regulation 
of gene 
expression 
as repres­
sor and 
activator
Table 3.2: List of identified proteins after in  situ  digestion and direct M ALDI- 
MSI analysis of MCF-T xenograft tissue sections
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3 .3 .1 .4  P ro te in  lo ca lisa tio n  w ith in  a  M C F -7  b re a s t  tu m o u r  x e n o g ra ft tis su e  
sec tio n  b y  M A L D I-M S  im ag ing
MALDI-MS imaging analyses were also performed on serial MCF-7 xenograft tissue 
sections after in situ tryptic digestion. Images were acquired at a spatial resolution 
of 150 fim  using an U ltraflex™ II M ALDI-TOF/TOF instrument. Figure 3.6 shows 
MALDI images of the distribution of some of the identified peptides within a MCF- 
7 tissue section. Difference in intensities can be observed between the necrotic and 
tumour areas. The signal a t m /z 1489, corresponding to peptide T12-13 from histone 
H3, was mainly located in the tumour area while the signal at m /z 944, corresponding 
to peptide T 8  from histone H2A, was found in both the necrotic and the tumour regions. 
The in situ digestion method described here enables the identification and localisation 
of proteins which are hardly detected by direct MALDI-MSI protein analysis due to 
their high masses or low abundances in tissue samples. These results demonstrated 
th a t direct protein analysis and identification through in situ digestion of frozen MCF- 
7 breast tumour xenograft sections has been achieved using MALDI-MSI. However the 
method still requires further development in order to improve direct MS/MS analysis. 
Several other biomolecules such as lipids and also m atrix adducts can interfere with the 
ion precursor selection of the analyte of interest.
tu m o u r  region
a) m/z 944 histone H2A c) m/z 1325 histone H4
necro tic  region
e) m/z 1529 haemoglobin a 0 m/z 2916 histone H2A
Figure 3.6: M A L D I-M S  im ages o f  p e p tid e  d is tr ib u t io n  w ith in  a  M C F -7  
x e n o g ra ft t is su e  section .
The localisations of histone peptide species including H2A, H3 and H4, fibroblast growth 
factor and haemoglobin alpha chain are displayed.
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3.3 .2  In  s i tu  p rotein  in vestiga tion  in  hum an F F P E  b reast cancer t is ­
sue section s
Formalin fixed paraffin embedded (FFPE) tissue samples are the commonest type of 
preserved tissue in clinical practice. These tissue samples are widely used by histopathol- 
ogists for assisting the diagnosis and assessing the prognosis of cancers and other dis­
eases. The ability to analyse proteins directly from archival tumour tissue samples th a t 
have known outcomes is of im portant clinical interest since it could provide molecular 
insights into disease processes and may lead to improved diagnosis and prognosis as well 
as treatm ent and prevention. Direct protein analysis by MALDI-MSI analysis of FFPE  
tissue sections remains challenging because of the presence of protein cross-linking via 
methylene bridge formation making the analysis difficult to perform. An alternative 
approach to get as much information as possible from these tissues is to perform in situ  
enzymatic digestion and then to analyse the resulting peptides for protein identification 
purposes [9].
3.3.2.1 Effect of the use of octyl glucoside (OcGlc) on the in  situ  digestion  
of FFPE breast tumour tissue sections
The use of a detergent was also assessed for in situ digestion of FFP E  tum our tissue 
sections. Adding 0.1% octyl glucoside to the trypsin solution increased the number 
of peptide signals detected as well as improving signal intensities. Figure 3.7 shows a 
comparison between direct peptide MALDI-MS profiling obtained after two hours in 
situ digestion from FFPE  breast tumour tissue sections either with a trypsin solution 
containing OcGlc (Figure 3.7a) or with no OcGlc (Figure 3.7b). Spectra were acquired 
using a MALDI SYNAPT™ HDM S system. It can be clearly seen (Figures 3.7a and b) 
th a t more peptide signals are observed after on-tissue digestion with a trypsin solution 
containing 0.1% OcGlc. The signal at m /z 1790.9, which was identified as peptide T23 
from actin, is increased when adding OcGlc to the trypsin buffer for in situ digestion.
In addition to the most abundant proteins, several peptide signals assigned to other 
proteins including membrane-associated proteins have been identified and their distri­
bution within the tissue section studied after in situ digestion using detergent addition 
to the tryptic buffer. This can be seen in the zoomed in spectra. The detection of the
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signal at m /z 1095.6, which was assigned to retinoic acid early transcript 1G protein (a 
single-pass type I membrane protein), was improved.
a ) w ith  o c ty l g lu c o s id e , 
2 h o u rs  d ig e s tio n  tim e
b) w ith  n o  o c ty l g lu c o s id e  
2 h o u rs  d ig e s tio n  tim e
TO F MS LD-t- 
454100-]
a) w ith  o c ty l g lu c o s id e , 
2 h o u rs  d ig e s tio n  t im e
,1283.1144 1467 8617 1640 8563
TOF MS LD+ 
454100-]
b ) w ith  n o  o c ty l g lu c o s id e  
2 h o u rs  d ig e s tio n  tim e
1607.7906 1791 <
800       —
1-  m /z2000 34006 00 1400 2200 2400 2600 2800 3000 3200
Figure 3.7: E v a lu a tio n  o f th e  use  o f o c ty l g lucoside  in  th e  t ry p s in  bu ffe r for 
in  s itu  d ig es tio n  o f F F P E  b re a s t  tu m o u r  tis su e  sections.
Panel a shows the direct peptide profile after on-tissue digestion with a trypsin solution 
containing 0.1% of OcGlc. Panel b displays the direct peptide profile with no OcGlc in 
the trypsin buffer. Both spectra were acquired after the same digestion time.
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Figure 3.8 shows MALDI images of the localisation of tryptic peptides within a 
FFPE breast tumour section. Images were acquired at a spatial resolution set at 200 
/iin using the MALDI SYNAPT™ HDM S.
■ a*)e) m/z 1790 actin
Figure 3.8: Im ages o f p ro te in  lo ca lisa tio n  w ith in  F F P E  b re a s t  tu m o u r  tis su e  
sections.
Panel a shows a scan of a histological staining of a FFPE  breast tumour section. Panels 
b and c show histological images of tum our cells within the tissue section acquired at 
a magnification xlO. Panels d, e, f and g display the distribution of serum albumin, 
actin, histone H3 and histone H2A respectively within the tissue section, obtained by 
MALDI-MSI.
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3.3.2.2 Combining ion mobility separation (IMS) w ith M ALDI-M SI yielded  
improved direct protein identification from FFPE tum our tissue  
sections
In  situ digestion has been found useful for proteomic analysis by MALDI-MSI as 
it provides direct protein identification and localisation from the tissue section with­
out any need for sample fractionation or extraction of proteins from the tissue section. 
As numerous peptides are generated this results in a complex m ixture of signals from 
the individual components. As a consequence, signal overlap from peptides and other 
biomolecules is observed, hence making direct MS/MS analysis difficult to achieve in 
some cases. Previous methods reported the coupling of nanoLC -nanoESI to MALDI- 
MSI analysis in order to achieve a better identification of proteins [9]. Here ion mobility 
separation (IMS) has been found to be a powerful technique for direct analysis of pep­
tides generated after in situ digestion.
Coupling IMS to MALDI-MSI aims to improve the selectivity and enhance database 
searching. Figure 3.9a shows the ion mobility separation of 2 isobaric species of m /z 
850 arising from the direct MS/MS analysis. When a MASCOT search was performed 
on the entire MS/MS spectrum without taking into account the mobility separation, 
no significant results or potential identification were obtained. However the IMS data  
can be processed in order to extract individual MS/MS spectra corresponding to each 
analyte. Figures 3.9b and c display the obtained MS/MS spectra after IMS data  pro­
cessing of the isobaric ions at a driftim e™  plot of 3.9 msec and 4.9 msec respectively. 
These data  were imported into MASCOT search, resulting in a better search for protein 
assignment. The MS/MS spectrum displayed in Figure 3.9b allowed the identification 
of the ion signal at m /z 850 as a peptide T18 arising from histone H2A.
Using a combination of both IMS and MALDI-MSI has been found to be a valuable 
tool for the in situ identification of proteins in FFP E  breast tumour tissue sections. 
Numerous proteins were identified. Table 3.3 displays a list of identified proteins from 
FFPE  breast tumour tissue sections.
However further method development is still required in order to improve the de­
tection and identification of stress proteins directly from FFPE  tissue sections after in 
situ digestion.
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m/z 850 tryptic peptide of histone H2A 
U - L — Q — L—A — I — R
430 27 y * 4
325 850 875
•iS rn/2
Figure 3.9: M A L D I-IM S -M S /M S  s p e c tru m  o f th e  ion  signal a t  m /z  850 o b ­
ta in e d  a f te r  in  s itu  d ig es tio n  o f h u m a n  F F P E  b re a s t  tu m o u r  tis su e  sec tion .
The observed driftimeT plot (a) displays interference between species in IMS-MS/MS 
analysis mode. These species can be separated using their mobility. Different MS/MS 
spectra (b and c) can be extracted using the ion mobility separation.
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(HW)
20 structural con­
stituent of 
ribosome
U  ncharacter ized
p ro te in
C 2orf34
Q7Z624 36105 1094.6 GPVVSAPLGAAR 23
T um our pro­
te in  63
Q9H3D4 76736 1127.6 RCPNHELSR +  Oxidation (HW) 15+
de
novo
Acts as a se­
quence specific 
DNA binding 
transcriptional 
activator or 
repressor
Table 3.3: List of protein identified after in  situ  digestion and direct M ALDI- 
IM S-M S/M S analysis on human FFPE breast tumour tissue sections using  
a M ALDI S Y N A P T ™  instrument.
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3.3.2.3 Effect of antigen retrieval (AR) on the in situ  digestion of FFPE  
breast tum our tissue section
Immunohistochemistry (IHC) is currently one of the techniques of choice for the 
investigation of protein distribution within FFPE  tissue sections. IHC protocols for the 
analysis of FFPE  tissue sections include several pre-treatm ents before the immunostain- 
ing of the tissue sections. These pre-treatm ents are commonly referred to as antigen re­
trieval (AR). Antigen retrieval is a method based on high tem perature heating of FFPE  
tissue sections immersed in water or buffer solution and aims to reverse the chemical re­
action of protein cross-linking resulting from the formalin fixation and return  the tissue 
section to its native form as much as possible [16, 17, 33]. Several improvements of AR 
methods allowed the standardisation of IHC protocols and demonstrated their values 
in several studies for retrieving genomic and proteomic information from archived sam­
ples [34, 35]. For protein identification from FFPE  tissue samples, LC/M S and 2D gel 
electrophoresis methods have been reported after applying AR to these tissue samples
[3],
In the work reported here, the method for in situ digestion of FFP E  breast tumour 
tissue sections was improved by applying AR as sample pre-treatm ent. A classical 
protocol of AR used for IHC was applied. After AR, on-tissue digestion was performed 
using a trypsin buffer containing 0.1 % OcGlc. Figure 3.10 shows the plots of the average 
intensities of the peptide ion signals corresponding to actin (m /z 1198.7) and retinoic 
acid early transcript 1G protein (m /z 1095.6), with and without AR. Three spectra 
were used and average peak intensities were calculated. It is clearly observed th a t the 
ion signal intensities are increased after applying AR.
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Figure 3.10: E ffect o f th e  use o f a n tig e n  re tr ie v a l p r io r  to  in  s itu  d ig es tio n  o f 
F F P E  b re a s t  tu m o u r  tis su e  sections.
The average peak intensities of the peptide T3 signal arising from actin (m /z 1198.7) 
and the peptide T25 from retinoic acid early transcript 1G protein (m /z 1095.6) are 
shown in the absence and use of AR prior to in situ digestion. The use of AR as sample 
pre-treatm ent before on-tissue digestion is shown to significantly increase the intensity 
of the ions detected. Here, n=5.
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The method sensitivity is improved when using AR as sample pre-treatm ent. More 
signals are detected after using AR prior to in situ digestion of FFPE  tumour tissue 
sections with a good signal-to-noise ratio (S/N). This can be noticed in figure 3.11, in 
which peptide profiles obtained after in situ digestion of FFPE breast tumour tissue 
sections with or without AR as sample pre-treatm ent are displayed.
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Figure 3.11: E ffect o f th e  use  o f a n tig e n  re tr ie v a l p r io r  to  in  s i tu  d ig estio n : 
S p e c tra l com parison .
Peptide profiles obtained after antigen retrieval prior to in situ digestion. When com­
paring figures 3.11a and b, numerous signals are detected after incorporating AR as 
sample pre-treatm ent prior to in situ digestion.
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MALDI-MS images were also obtained from FFPE  breast tumour tissue sections 
after AR and on-tissue digestion as sample pre-treatment. Here trypsin and matrix 
depositions were achieved using an Im agePrep™ . D ata acquisition was performed using 
an U ltraflex™ II M ALDI-TOF/TOF instrument. Figure 3.12a displays a digital scan of 
a tissue section. Several peptides were detected and images of their distributions within 
the tisue section were obtained with a good S/N ratio. Images were normalised against 
the matrix adduct peak at m /z 867. No delocalisation of signals was noticed. Figures 
3.12b-g display the distribution of tryptic peptides of histone H2A, haemoglobin alpha, 
N a+ /  K+- AT P ase and histone H4 respectively. When examining the data, it can be 
noticed that tryptic peptides arising from the same protein show the same distribution. 
This adds confidence to the identification of the given protein. The use of AR in sample 
pre-treatm ent does not lead to protein precipitation and/or degradation, but appears 
to unlock protein information.
b) m/z 850 histone H2A Id) m/z 1087 haemoglobin a  | f ) m/ z 1002 Na+/K*-ATPas
M
/ &  *• • .
U f
a) digital scan of the  section
BC041493.A_rrtax_div (MEAN :849.993-850 7!?1i 1/1 |  BC041493AjTaxjJiv/MEANMOS?.21-1088 i I L ld  I  BC041493A_max_div (MEAN: 1002.00-1003 JB3) 1/1
c) m/z 944 histone H2A |e )m /z  1529 haemoglobin a  I g)m /z 1466 histone H4
3** '< V
BC041493A_rr.a>c_.jiv i7i4EAM.944.000-944SIEl^ 1/1 I  BC041493A_max_div ilutEAR: 1530.45-153 1 1/1 I  BC041493A_max_div (MEAN.1 4 6 5 .2 4 - 1 4 6 8 1/1
Figure 3.12: D ig ita l scan  o f a  F F P E  b re a s t  tu m o u r  tis su e  sec tio n  a n d  M A L D I- 
M S im ages o f th e  d is tr ib u t io n  o f p e p tid e s  w ith in  a  F F P E  b re a s t  tu m o u r  
tis su e  sec tio n  a f te r  p e rfo rm in g  a n tig e n  re tr ie v a l p r io r  to  in  s itu  d ig estio n .
(a) Digital scan of a FFPE breast tumour tissue section, (b-g) display the obtained 
distribution of tryptic peptides arising from histone LI2A, haemoglobin alpha, Na+ /K +- 
ATPase and histone H4, respectively after in situ digestion following AR, within a FFP E  
breast tumour tissue section.
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3.4 Concluding Rem arks
MALDI-MSI is continuing to show its potential for the investigation of protein dis­
tribution directly from tissue sections. It has been shown here tha t the use of on-tissue 
digestion enables the direct identification of proteins from both frozen and F F P E  tu ­
mour tissue sections. The strategy described here highlights an improved methodology 
for in situ protein investigation and identification within frozen and FFPE  tumour tissue 
sections.
The use of automatic micro-scale reagent deposition devices was found to greatly 
increase the extraction of peptides from tumour tissue sections while performing in 
situ digestion. This improved the sensitivity of the MS method. Another method 
development involved the use of ionic matrices for the analysis of peptides following on- 
tissue digestion. o;-CHCA/ANI was found to provide an acceptable even crystalisation 
across both frozen and FFPE  breast tum our tissue sections.
One of the key findings of this study has been tha t the addition of a non-ionic 
detergent, octyl glucoside, in the trypsin buffer enhanced the detection and localisation 
of low-abundance proteins and tumour-related proteins within frozen and FFP E  tissue 
sections. Ionisation and detection of membrane-associated proteins were obtained. In 
the case of FFPE  tumour tissue sections, incorporating antigen retrieval as a sample pre­
treatm ent step was also found to unlock several proteins, hence increasing the amount 
of peptide detected after in situ digestion.
Additionally, the use of IMS has been shown to improve the sensitivity as well as 
the database search results. However, further improvement of the m ethod and protocol 
refinements may lead to the identification of more proteins. The identification of proteins 
directly from tissue with MALDI-MSI following in situ enzymatic cleavage is a new 
proteomic approach and has the potential to deliver localisation and identification of 
tumour protein targets such as stress proteins, angiogenesis factors or drug-resistant 
biomolecules.
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CHAPTER 4
Targeting of H ypoxia in 
A Q 4N -treated Tumour 
Xenografts by M ALDI-Ion  
M obility Separation-M ass 
Spectrom etry Im aging
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4.1 Introduction
Hypoxia is a common feature observed in solid tumours [1, 2]. It arises since solid 
tumours develop abnormal vasculature systems to permit growth and expansion. This 
results in a poor delivery of oxygen and a lack of nutrients to localised regions within the 
tumour. Tumour hypoxia is a target of interest in oncology as it has been found to be 
closely associated with tumour progression, metastasis and aggressiveness and confers 
resistance to a variety of chemotherapeutic agents as well as radiotherapy [3]. On a 
cellular level, hypoxia involves a complex molecular response of the hypoxia-inducible 
factor 1 (HIF-1) pathway which leads to an alteration of the expression of several pro­
teins such as HIF-1, carbonic anhydrase IX (CAIX), glucose transporters (GLUT-1 and 
GLUT-3), plasminogen activator inhibitor-1 (PAI-1), vascular endothelial growth fac­
tor (VEGF) and osteopontin (OPN), which are all potential endogenous hypoxia-related 
markers [4]. A better understanding of the regulation of these markers in hypoxia may 
lead to an improvement of current therapeutic options [5].
Several therapeutic strategies designed to target hypoxia are currently under in­
vestigation. One of these approaches aims to improve tum our oxygenation, however 
there is not a method widely accepted in clinical practice [6 ]. An alternative ap­
proach consists of the use of tumour-activated prodrugs (TAP) [7]. Prodrugs are 
therapeutic compounds tha t are transformed into pharmacologically active molecules 
either by metabolism or spontaneous chemical breakdown mechanisms after adminis­
tration. TAPs are designed to be less toxic anticancer drugs th a t are selectively acti­
vated in tumour tissues [7]. Hypoxia-selective cytotoxins are a new generation of TAP 
that are selectively activated into cytotoxic agents under hypoxic conditions. Among 
them is a compound called AQ4N, which is currently undergoing Phase I clinical trials. 
AQ4N is also known as banoxatrone or l,4-bis-[2-(dimethylamino-N-oxide)ethyl]amino- 
5,8-dihydroxyanthracene-9,10-dione and is a very promising bioreductive prodrug. The 
physical properties and pharmacokinetic studies of AQ4N have been fully reviewed and 
described [7-10]. Briefly, under hypoxic conditions, AQ4N is reduced by reductase en­
zymes of the P-450 family including the CYP3A isozyme of NADPILcytochrome C (P- 
450) reductase to its active cytotoxic metabolite AQ4 (l,4-bis-[2-(dimethylamino)ethyl] 
amino-5,8-dihydroxyanthracene-9,10-dione). AQ4 has a high DNA affinity and is the
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only bioreductive tha t inhibits the enzyme topoisomerase II. The inhibition of topoi- 
somerase II by AQ4N synchronises cell growth and therefore AQ4N has been found to 
sensitise tumours to radio- and chemotherapy treatm ents [8 ]. AQ4N has been found to 
improve and enhance the therapeutic response to radiotherapy and other chemother­
apies [11]. Figure 4.1 displays a schematic mechanism of the reductive metabolism of 
AQ4N in tissue [8 ].
OH OH OH
+2e +2e
OH OH OHAQ4N AQ4M AQ4
Figure 4.1: Schematic representation o f the reductive m etabolism  of AQ4N  
in tissue under hypoxic conditions [8].
Under hypoxic conditions AQ4N is metabolised by enzymes of the p450 family to the 
intermediate metabolite AQ4M and then to its active cytotoxic metabolite AQ4.
MALDI-MSI has been previously used to study the distribution of AQ4N and AQ4 
in tumour tissue sections. Using this technology, the distribution of AQ4N and AQ4 
in AQ4N-treated H460 colon tumour xenograft tissue sections were simultaneously ob­
tained [12]. This was found to be very beneficial as it allowed the localisation of hypoxic 
regions within the tumour tissue sections. However, to date no studies have reported 
the investigation of the distribution, expression and in-situ identification of hypoxia- 
related protein markers in correlation with the distribution of AQ4N and its active 
metabolites in tumour tissue sections using MALDI-MSI. In this chapter, an applica­
tion and improvement of the methodology explained in chapter 3 is described. It aims 
to obtain proteomic data  from AQ4N dosed tum our xenograft tissue sections and to cor­
relate these data with the drug distribution using MALDI-ion mobility separation-mass 
spectrometry imaging.
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4.2 M aterials and Sam ples
4.2 .1  C hem icals and m ateria ls
Materials included a:-cyano-4-hydroxycinnamic acid (o-CHCA), aniline, ethanol 
(EtOH), methanol (MeOH), acetonitrile (ACN), chloroform (CHCI3 ), xylene, octyl-a://?- 
glucoside (OcGlc), trifluoroacetic acid (TFA), haematoxylin, eosin and carboxymethyl 
cellulose (CMC) were obtained from Sigma-Aldrich (Dorset, UK). Trypsin was obtained 
from Promega (Southampton, UK). AQ4N and AQ4 standards were obtained from the 
Institute of Cancer Therapeutics (Bradford, UK).
4 .2 .2  T issu e sam ples
All animal procedures including animal treatm ent, tumour system and transplanta­
tion and drug administration were carried out at the Institute of Cancer Therapeutics 
(Bradford, UK). The methodologies used are briefly described here in sections 4.2.2.1 
and 4.2.2.2. All the animal procedures and handling in this work abide by UK Home 
Office Regulations and Guidelines [13]. Female Balb/C  immunodeficient nude mice 
(Harlan UK, Blackthorn, UK) aged 6 - 8  weeks were used. Mice received Teklad 2018 
diet (Harlan, UK) and water ad libitum. Animals were kept in cages in an air-conditioned 
room with regular alternating cycles of light and darkness.
4.2.2.1 Transplantation and treatm ent of tumour samples
SW620 colon tumour xenografts were obtained from the Institute of Cancer Thera­
peutics, Bradford, UK. The transplantation of tum our is described as follows: SW620 
Human colon adenocarcinoma tumours were excised from a donor animal, placed in 
sterile physiological saline containing antibiotics and cut into small fragments of ap­
proximately 2 mm3. Under brief general inhalation anaesthesia, tum our fragments were 
implanted in the left and right flank of each mouse using a trocar, and tum our growth 
was monitored frequently.
4.2.2.2 Drug administration
Once the tumours had reached a volume of 200-400 mm3, as measured by callipers, 
mice were administered AQ4N (synthesised in house at the ICT Bradford) a t 60 m g/kg
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intraperitoneally (ip) and/or pimonidazole hydrochloride (Hypoxyprobe-1), obtained 
from HPI, Inc. (Burlington, MA) and administered at 60 m g/kg 90 min prior to sam­
pling. Mice were sacrificed and tumours were excised, immediately snap-frozen in liquid 
nitrogen and stored at -80°C to minimise protein degradation and keep the original 
sample morphology until further analysis.
4 .2 .3  T issu e preparation
Frozen tissue samples were embedded in carboxymethyl cellulose (CMC) in order 
to facilitate the cryosectioning. A CMC gel was made by dissolving 0.1% CMC (by 
weight) in deionised water. The tissue samples were placed into plastic cryomoulds 
containing the CMC gel and then frozen using liquid nitrogen. The obtained CMC 
embedded tissue blocks were cut using a cryostat (Leica Microsystems, UK) operating 
at -20°C. 10 fim  sections were obtained and thaw-mounted onto histological Polysine™  
glass slides (Menzel-Glaser, Germany). Tissue sections were rinsed for 1 minute in cold 
EtOH solutions a t 70 and 90% (stored at -20°C) followed by a 15 seconds wash in 
CHCI3 . The sections were then allowed to dry at room tem perature prior to in situ 
digestion and m atrix deposition. No rinsing steps were performed prior to drug analysis 
with MALDI-IMS-MSI.
4.3 M ethods and Instrum entation
4.3 .1  T issu e preparation  for th e  stu d y  o f  th e  d istr ib u tion  o f  A Q 4N  
and A Q 4 in  A Q 4N -trea ted  S W 620 tu m our xenografts
Controls of AQ4N and AQ4 drug standards were diluted to 0.1 and 0.01 mg/mL. 
0.5 fiL of the obtained solutions were either spiked onto non-treated xenograft tissue 
sections or spotted alongside AQ4N treated xenograft tissue sections. The spots were 
allowed to dry at room tem perature prior to m atrix deposition. a-CHCA was used 
as the matrix. The m atrix solution was prepared at 25 mg/mL in 100% EtOH with 
1% TFA as reported previously [12]. Approximately 10 mL of m atrix solution were 
spray coated onto the tissue sections using a gravity fed pneumatic air gun set to 40 psi 
(Iwata-Medea Inc., Portland, OR, USA).
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4.3 .2  T issu e preparation  for th e  s tu d y  o f  p ep tid e  d istr ib u tion  and  
id en tification  w ith in  n on -trea ted  and A Q 4N -trea ted  xenograft  
tissu e  section s
In  situ digestion was performed in order to obtain peptide distribution and identifica­
tion directly from non-treated and AQ4N-treated xenograft tissue sections. The trypsin 
solution was made at 20 /zg/mL in 50 mM ammonium bicarbonate buffer (pH =  8.1) 
containing 0.1 % octyl glucoside (OcGlc) for in situ enzymatic digestion. The trypsin 
solution was sprayed onto the tissue sections using a SunCollect™  autom atic sprayer 
(SunChrom, Friedrichsdorf, Germany). Using the SunCollect-™ autom atic sprayer, the 
trypsin solution was deposited on the tissue section at increased flow rate over five lay­
ers. The first layer was performed at 2 /zL/min, the second at 3 /zL/min and the last 
three layers set at 4 /iL/min. Humid environmental conditions were maintained while 
depositing the trypsin on the tissue section. After trypsin deposition the tissue section 
was incubated for 2  hours at 37°C (5% CO2 ) in a humid chamber.
An ionic matrix, here a-CHCA mixed with aniline (a-CHCA/ANI), prepared at 
5 m g/mL in 50% ACN:0.2%TFA, was used for peptide analysis. The m atrix solution 
was sprayed onto the section using a SunCollect™  automatic sprayer. The m atrix 
deposition onto the tissue section was performed at increased flow rate between layers. 
The first layer was performed at 1.5 /iL/m in allowing a m atrix seeding process. The 
second and last three layers were performed at 2.5 /zL/min and 3.5 /zL/min respectively.
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4 .3 .3  M A L D I-IM S-M SI analysis o f  drug and p ep tid e  d istr ib u tion s  
w ith in  n on -treated  and A Q 4N -trea ted  SW 620 xenograft t issu e  
section s
4.3.3.1 M ALDI-IM S-M S profiling and imaging of drug and in situ  digested  
peptide distribution within non-treated and AQ 4N-treated SW 620  
xenograft tissue sections
Prior to MALDI-IMS profiling (MS and MS/MS) and imaging experiments, digital 
scans of the tissue sections to be analysed were obtained using a CanoScan 4400F 
flatbed scanner (Canon, Reigate, UK) and then imported into MALDI Imaging Pattern  
C reato r™  software (Waters Corporation, Milford, MA).
For small molecule and peptide analysis, the instrument calibration was performed 
using standards consisting of a mixture of polyethylene glycol (Sigma-Aldrich, Gilling­
ham, UK) ranging either between m /z 100 to 1000 or between m /z 100 to 3000 respec­
tively prior to MALDI-IMS-MSI analysis. D ata were acquired in V-mode and positive 
mode using a MALDI SYNAPT™ HDM S system (Waters Corporation, Manchester, 
UK) operating with a 200 Hz Nd:YAG laser. All data  were acquired with ion mobility 
separation in the mass range from m /z 1 0 0  to 1 0 0 0  for small molecule analysis or from 
m /z 800 to 3000 for peptide analysis. Ion images were acquired at a spatial resolution 
set at 150 //m with 400 to 600 laser shots per position. Using D riftscope™  software 
(Waters Corporation, Manchester, UK) ion mobility separation data were extracted and 
ion images were generated with BioMap 3.7.5.5 software (Novartis, Basel, Switzerland).
4.3.3.2 M ALDI-IM S-M S/M S analysis for direct protein identification from  
non-treated and AQ4N-treated SW 620 xenograft tissue sections af­
ter in  situ  digestion
MALDI MS/MS analyses were performed using the MALDI SYNAPTrM HDMS 
(Waters Corporation, Manchester, UK) operating in ion mobility separation (IMS) 
mode directly from the digested tumour tissue sections. Transfer fragmentation was 
performed and optimised based on the precursor ion mass [14, 15]. Briefly peptide 
ions were first separated based on their mobility and then collision-induced dissociation 
(CID) was performed in the Transfer T -W ave™  (Waters Corporation, Manchester,
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UK), thus maintaining the same fragment ion drift time as the corresponding precur­
sor ion. The obtained spectra were processed in M assLynx™  (Waters Corporation, 
Manchester, UK). MS/MS spectral processing consisted of smoothing, baseline correc­
tion and the use of a lock mass based mass correction. Spectra were then processed 
with the M axEnt 3 algorithm to de-isotope mass spectrometric da ta  and enhance the 
signal-to-noise ratio. The resulting files were submitted to a MASCOT (Matrix Sci­
ence, London, UK) query search and searched against the SwissProt database (release 
56.0). W ithin the MASCOT search engine, the parent and fragment ion tolerances 
were set at 30 ppm and 0.1 Da respectively. The criteria also included up to two missed 
cleavages and the variable modifications allowed were protein N terminus acetylation, 
histidine/tryptophan oxidation and methionine oxidation . De novo sequencing was 
performed manually and using the PepSeq™  de novo interactive MS/MS sequencing 
tool. The parent and fragment ion tolerances were set a t 0.1 Da and the threshold was 
set at 1%. Protein Blast searches against the Swissprot database were also performed 
to confirm tryptic sequences.
4 .3 .4  S ta tistica l analysis
4.3.4.1 Principal component analysis-discriminant analysis (PC A -D A)
Principal component analysis (PCA) is one of the methods of choice used in chemo- 
metrics to obtain an overview of existing variation within multivariate da ta  sets and 
identify possible clusters and differences between groups. Here principal component 
analysis-discriminant analysis (PCA-DA) was carried out using M arkerView™  1.2 soft­
ware (Applied Biosystems/MDS Sciex, Concord, Canada). Ten spectra from each tissue 
section including non-treated, AQ4N and AQ4N Pimonidazole treated SW620 xenograft 
tissue sections were selected from the obtained MALDI-IMS imaging data  using Biomap 
3.7.5.5 software and exported as text files where m ass/intensity pairs were listed. These 
text files were loaded into MASCOT D istiller™  (Matrix Science, Boston MA) for 
spectral de-isotoping purposes. W ithin MASCOT D istiller™ , the criteria included a 
minimum signal to noise ratio (S/N) set at 3, a correlation threshold set at 0.6 and a 
minimum peak half width set at 0.008. The resulting de-isotoped mass spectra were 
then imported into M arkerView™  1.2 software for principal component and discrim­
inant analysis (PCA-DA). Prior to PCA-DA, data  were normalised to their total area
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sum. A supervised PCA-DA was then carried out with a pareto scaling.
4.3.4.2 Orthogonal partial least-squares-discriminant analysis (OPLS-DA)
Orthogonal partial least-squares-discriminant analysis (OPLS-DA) was also per­
formed using M arkerLynx™  (Waters Corporation) software package. The OPLS m ethod 
consists of an orthogonal correction of the partial least-square technique. It aims to sep­
arate predictive variations (such as differences between 2  groups of samples, i.e. treated 
and non-treated) and also show variations present within a given sample due to ex­
perimental errors (instrumentation or data acquisition). In the work reported here, 6 6  
spectra were acquired from each tissue section and processed using M assLynx™  and 
M arkerLynx™  software packages (Waters Corporation, Manchester, UK). The auto­
matic peak detection algorithm (Waters Corporation, Manchester, UK) was applied to 
the obtained mass spectra in order to remove noise. Using MALDIMerge-™ software 
(Waters Corporation, Manchester, UK), mass sufficient exclusion lists were generated 
with a peptide tolerance set at 400 mDa, then a mass spectrum/chrom atogram  for each 
data file was recreated using D ataB ridge™  software (Waters Corporation, Manch­
ester, UK) prior to OPLS-DA with MarkerLynx7'^  software. W ithin M arkerLynx™  
software, the criteria included an intensity threshold set at 1 0 0  counts and spectra were 
normalised against the total intensity count. OPLS-DA was then performed.
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4.4 R e su lts  an d  D iscussion
4 .4 .1  I n v e s t ig a t io n  o f  A Q 4 N  a n d  A Q 4  d r u g  d i s t r i b u t i o n  w i t h i n  S W 6 2 0  
c o lo n  c a n c e r  x e n o g a f t s
4.4 .1 .1  C h a ra c te r is a tio n  o f A Q 4N  a n d  A Q 4 d ru g  s ta n d a rd s  w ith  M A L D I- 
IM S -M S
0.5 /rl of AQ4N and AQ4 drug standard solutions, made at 10 n g/m l mixed with 
m atrix solution, were spotted onto a MALDI target plate. Figure 4.2 shows the obtained 
mass spectrum of AQ4N drug standard: the protonated molecule of AQ4N and its 
sodium adduct ion were observed at m /z 445.2 and 467.2 respectively as well as a 
fragment ion of AQ4N at m /z 384.2.
[M-MCR.kOjr
Figure 4.2: M A L D I-M S  s p e c tru m  o f A Q 4N  d ru g  s ta n d a rd .
A fragment ion of AQ4N at m /z 384.2, the protonated molecule [M+H]+ and sodium 
adduct [M+Na]+ of AQ4N at m /z 445.4 and 467.2 respectively were observed.
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MALDI-IMS-MS/MS analysis of AQ4N was performed. Figure 4.3a displays the 
obtained driftscope™  plot of the MS/MS fragmentation of AQ4N. This plot shows 
the mobility of the ions on the x axis against their m /z values on the y axis. Since 
the dissociation of the selected ion, here AQ4N, was performed within the transfer 
region of the instrument, the obtained product ions retained the same drift time as 
their respective precursor ions.
MCD_090202_02raw: 1
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Figure 4.3: D r i f t s c o p e ™  p lo t  a n d  M A L D I - I M S - M S / M S  s p e c t r u m  o f  A Q 4 N  
d r u g  s ta n d a r d .
(a) D riftscope™  plot of MS/MS fragmentation of AQ4N where peak interference with 
m atrix ions was noticed, (b) MS/MS spectrum of AQ4N drug standard.
Since the MS/MS fragmentation is performed in the transfer cell, the product ions 
retain the same driftime as their precursor ions. Here one can notice th a t 2 species are 
simultaneously detected when examining the driftscope™  plot (figure 4.3a). In fact, 
the AQ4N product ions display a driftime of 3.85-4.30 msec and the interfering product 
ions arising from the matrix display a driftime of 2.8-3.4 msec. Using D riftscope™  and 
M assLynx™  software packages, each individual MS/MS spectrum can be extracted. 
Figure 4.3b displays the MS/MS spectra of the AQ4N protonated molecule [M-tTI]+ at 
m /z 445.2. The y axis of driftscopez A/ plot (figure 4.3a) indicates tha t the AQ4N drug 
has a drift time of 3.85-4.30 msec. The obtained results related to the ion mobility sepa­
ration of AQ4N were further used to minimise peak interferences and hence specifically
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select and reconstruct images of the distribution of the drug within the tissue sections. 
Examination of the resultant AQ4N MS/MS spectrum shows the presence of the frag­
ment ion at m /z 384.2, thus confirming that AQ4N fragmentation was induced in MS 
mode. Hence three ions, which are the signals at m /z 384.2, 445.2 and 467.2 correspond­
ing to the AQ4N fragment ion, protonated molecule and sodium adduct respectively, 
can be used for investigating the distribution of AQ4N within the tissue section in MS 
and MS/MS mode.
The analysis of AQ4 drug standard was also performed using MALDI-IMS-MS/MS. 
Figures 4.4a and b show the MS/MS fragmentation of AQ4 with ion mobility separa­
tion and the resulting driftscope7  M plot. The drift time of AQ4 protonated molecule 
[M+H]+ at m /z 413.2 was observed between 3.80 and 4.5 msec.
:423mteMCL>_090202_05J,T
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Figure 4.4: D r i f t s c o p e 7^ 7 p lo t  a n d  M A L D I - I M S - M S / M S  s p e c t r u m  o f  A Q 4  
d r u g  s ta n d a r d .
(a) D riftscope™  plot of MS/MS fragmentation of AQ4. (b) MS/MS spectrum of AQ4 
drug standard.
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4 .4 .1 . 2  M A L D I-IM S -M S I an a ly is  o f A Q 4N  a n d  A Q 4 d ru g s  sp iked  o n to  
SW 620 colon can ce r x e n o g ra ft tis su e  sec tions
An expanded region from mass spectra acquired from AQ4N and AQ4 spiked on non­
treated SW 620 colon cancer xenograft tissue sections are displayed in figure 4.5. It can 
be noticed that both AQ4 ([M+H]+ at m /z 413.2) and AQ4N ([M+Na]+ m /z 467.2) 
were detected within signal-rich regions of the spectra, where numerous ions arising 
either from the matrix or other endogenous molecules such as lipids are observed.
409 410 412 413411 414
Figure 4.5: M ass s p e c tra  o f A Q 4 a n d  A Q 4N  d ru g  s ta n d a rd s  sp ik ed  o n to  
SW 620 colon  can ce r x en o g ra ft tis su e  sections.
The protonated molecule of AQ4 observed at m /z 413.2 (a) and the sodium adduct 
of AQ4N observed at m /z 467.2 (b) were detected in signal-rich regions of the spectra 
along with several potentially interfering peaks.
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The use of IMS combined with MALDI-MSI was found to improve the acquired 
MALDI-MS images of the distribution of AQ4N and AQ4 drug standards spiked onto 
xenograft tissue sections. Figure 4.6 displays the localisation of AQ4 at m /z 413.2 and 
AQ4N at m /z 467.2 within the tissue sections with and without IMS. Prior to IMS 
data extraction, interferences were still noticed. However, when the ions of interest 
were selectively extracted using their mobility prior to image reconstruction, the exact 
distribution of both AQ4 and AQ4N spiked onto the tissue sections were obtained.
Conventional MALDI-MS images, w ithout ion mobility separation
a) ,
AQ4
' MALDI-IMS-MS im ages, with ion mobility separation
/AQ4N
Figure 4.6: D ig ita l scan  o f a  SW 620 co lon  ca n ce r x en o g ra ft tis su e  se c tio n  a n d  
M A L D I-M S  im ages o f th e  d is tr ib u t io n  o f A Q 4 a n d  A Q 4N  d ru g  s ta n d a rd s  
sp iked  o n to  SW 620 colon  can ce r x e n o g ra ft tis su e  sections.
(a) Digital scan of the xenograft tissue section spiked with AQ4N and AQ4 drug stan­
dards. (b) and (c) Images of the distribution AQ4 (m /z 413.2) and AQ4N (m /z 467.2) 
without ion mobility separation: peak interferences were noticed in the resulting im­
ages. (e) and (f) The use of IMS allowed the true distributions of both AQ4 and AQ4N 
drug standards spiked onto the tissue section to be obtained, (d) and (g) show overlay 
images of AQ4N and AQ4 spiked onto the tissue section.
e) AQ4 m /z  413 f) AQ4N m /z 467 g) im age overlay
b) AQ4 m /z 413 c) AQ4N m /z 467 d) image overlay
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These results demonstrate th a t a concentration of 10 fig/m l of AQ4N and AQ4 drugs 
can be detected when spiked onto tumour tissue sections. Additionally the distribution 
of the spiked drugs within the tissue section can be obtained. Using the IMS, it was pos­
sible to minimise peak interferences with AQ4N and AQ4 drugs due to m atrix adducts 
and endogenous compounds such as lipids present in the tissue sample. Hence im­
proved characterisation and localisation of AQ4N and AQ4 within SW620 colon cancer 
xenograft tissue sections were obtained.
4.4.1.3 MALDI-IM S-M S imaging of the distribution of AQ4N and AQ4 in 
treated SW620 colon cancer xenografts
MALDI-IMS-MS imaging was then used to study the localisation of AQ4N and its 
active metabolite AQ4 in AQ4N-treated colon tum our xenograft tissue sections. This 
work aimed to target tumour regions, and more specifically hypoxic regions, within 
the tumour tissue sections. Figures 4.7b and c display the distribution of lipid species 
including the phosphocholine head group at m /z 184 and sphingomyelin(16:0)+Na+ 
at m /z 725, which have been reported to be highly abundant in tumour regions [16]. 
AQ4N distribution within treated tumour was also obtained. It can be noticed th a t the 
drug was selectively located in the tumour region of the tissue sections (figure 4.7d). 
These results were found to be in good agreement with HE histological staining pictures 
(figure 4.7a) in which the tumour and necrotic area are indicated.
The distribution of AQ4 within the treated tissue sections was not obtained. This 
can be explained either by the sample preparation or the dose of the drug used for 
animal treatm ents. It has been shown th a t a high concentration of TFA in the m atrix 
solution enhances the crystallisation of AQ4 with the matrix, hence the detection of 
the drug in tissue sections with MALDI-MS [12]. However a high concentration of TFA 
may inhibit the AQ4N signal, hence 1% TFA in the m atrix solution has been found as 
an optimum in order to detect both compounds simultaneously [1 2 ].
Results and Discussion 152
b) m /z  184
MCO_AQ4Ndosed1OQBOH_O05_max_div
d) AQ4N m /z  467
 3.00
I f - 1.5$
O/spots of
AQ4N ( ) LLo.H0MCD AQ4Ndosed 100 B  0  H test467 fctOI 08B Wto
tumour area
necrotic ar<
tumour area
; X tumour area
c) m /z  725
MC D_AQ4Ndosed 100 B  0  H_005_max_div (KffiANf?j
Figure 4.7: Im ages o f th e  d is tr ib u t io n  o f lip ids a n d  A Q 4N  d ru g  in  t r e a te d  
SW 620 colon  can ce r x e n o g ra ft tis su e  sections.
(a) HE staining digital scans of AQ4N-treated SYV620 xenograft tissue sections, (b) and 
(c) MALDI-MS images showing the distribution of lipid species within AQ4N-treated 
SW620 xenograft tissue sections which were mainly found in the tum our region, (d) 
MALDI-MS images of the localisation of AQ4N within the treated tissue section ; spots 
of AQ4N drug standard were used as positive control.
The poor detection of AQ4 in AQ4N-treated xenografts may also result from the 
concentration of the drug used for animal treatm ent. In previously reported studies, 
simultaneous distributions of AQ4N and AQ4 within xenograft tissue sections were ob­
tained using MALDI-MSI; however these analyses were conducted on xenograft tissue 
sections obtained from animals treated with AQ4N at a concentration of 100 m g/kg
[12]. In the work reported here, the animals used for the study were dosed with AQ4N 
at a concentration of 60 mg/kg. It has also been reported that a low level of AQ4 in 
plasma was observed post animal treatm ent, demonstrating the strong AQ4 dependence 
on low oxygen level and hence a very low diffusion of the drug out of hypoxic regions of
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tumour [9]. An increase in anti-tumour efficacy was observed with AQ4N doses between 
50 m g/kg and 200 m g/kg [9]. Improvements of the methodology used here are required 
for localising AQ4 directly with tumour xenograft tissue sections at such drug dosage 
level (i.e. 60 mg/kg).
AQ4M is also known as an intermediate metabolite of AQ4N detectable in plasma 
and whose protonated molecule [M+H]+ is observed at m /z 429.2 with MS. Figure 4.8b 
displays the distribution of AQ4M within the treated tissue sections. The examination 
of the MALDI-MS images shows that AQ4M, the intermediate metabolite, is located 
within the tumour regions but also within the necrotic area which often contain hypoxia 
regions. By combining information gained from both AQ4N and AQ4M localisation 
within the treated xenograft tissue sections, tumour regions as well as hypoxic regions 
within the tumour area were observed. To summarise, the study of the distribution of 
AQ4N drug and its metabolites within xenograft tissue sections allowed the localisation 
of hypoxia within tumour regions.
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Figure 4.8: Im ages o f th e  d is tr ib u t io n  A Q 4M  d ru g  in  A Q 4 N -tre a te d  SW 620 
colon  ca n ce r x en o g ra ft tis su e  sections.
(a) HE staining digital scans of AQ4N-treated SW620 xenograft tissue sections.(b) 
MALDI-MS images showing the distribution of AQ4M within the treated tissue sec­
tion; the AQ4N spots used as positive control are not highlighted.
tumour area 
tumour area
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4.4 .2  M A L D I-IM S-M S im aging o f  p ep tid es  after in  s i tu  d igestion  o f  
n on -treated  and A Q 4N -trea ted  SW 620 colon cancer xenografts
MALDI-MSI technology can be used as a discovery tool as it provides molecular 
insights such as protein identification and distribution within cancerous tissue sections, 
and can hence contribute to a better understanding of the morphology and molecular 
pathology of cancer [17]. Currently there are no hypoxia-related markers that have 
been identified in correlation to response to AQ4N treatm ent. In the work reported 
here, images of peptide distribution were obtained after in situ digestion of non-treated 
and AQ4N-treated SW620 xenograft tissue sections. The animals used for the study 
were either treated with AQ4N drug only or with AQ4N and pimonidazole, which is a 
nitroimidazole compound widely used as a qualitative and quantitative marker of tu ­
mour hypoxia [18]. Figure 4.9 displays the localisation of some observed peptides within 
the xenograft tissue sections.
Numerous peptide signals were detected after on-tissue digestion. Examination of 
the data shows differences in protein intensities when comparing peptide images ob­
tained from non-treated and AQ4N-treated tissue sections. MALDI-MS images of pep­
tide distribution within the tissue section were normalised against the m atrix signal at 
m /z 1066. The peptide signal at m /z 904, which was identified as peptide T210-211 
arising from selectin-like osteoblast-derived protein, was found to be highly abundant 
in non-treated xenograft tissue sections compared to treated samples. This protein is 
also known as polydom or Sushi, von Willebrand factor type A, EGF and pentraxin 
domain-containing protein 1 (SVEP1) and plays a biological role in cellular adhesion 
and may be involved in regulation of cell proliferation, differentiation, and apoptosis
[19]. In contrast, the signal a t m /z 1032, identified as peptide T12 arising from histone 
H3, was more intense in AQ4N-treated samples compared to non-treated xenografts.
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Figure 4.9: M A L D I-IM S -M S  im ages o f th e  p e p tid e  d is tr ib u t io n  w ith in  non- 
t r e a te d  a n d  A Q 4 N -tre a te d  SW 620 colon  can ce r x en o g ra ft t is su e  se c tio n s  
a f te r  in  s itu  d igestion .
Several peptide distributions were obtained; here the localisation of ion signals a t m /z 
904, 1027, 1256 and 1032 is shown. Peptide signals at m /z 904 and 1032 were identified 
as polydom and histone H3. No identification was obtained for the peptide signals at 
m /z 1027 and 1256. The peptide signal at m /z 1027 was found to be highly abundant 
in non-treated tissue sections compared to AQ4N-treated and AQ4N and pimonidazole 
(AQ4N Pimo)-treated tissue sections.
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Iii order to improve and facilitate data interpretation of the obtained MALDI-MS 
images, principal component analysis-discriminant analysis (PCA-DA) was performed. 
PC A is usually used to identify and detect possible clusters from multivariate data sets
[20]. Combining PC A with discriminant analysis (DA) involves a further step which 
consists of identifying classes between samples and is therefore a supervised analysis [2 1 ]. 
In this study, 10 individual mass spectra were exported as text files from each image for 
a supervised PCA-DA using M arkerView™  software (Applied Biosystems/MDSciex, 
Canada). Figures 4.10a and b show the resulting scores and loading plots respectively.
AQ4NJ3 M ■" AQ4N.non treated
AQ4N treated
i?3: o:AQ4M Ptmomdazole treated
1 83140
Figure 4.10: P r in c ip a l co m p o n e n t an a ly s is-d isc rim in a n t an a ly sis  (P C A -D A ) o f 
M A L D I-IM S -M S  im ages o f p e p tid e s  o b ta in e d  a f te r  in  s itu  d ig e s tio n  o f non- 
t r e a te d  a n d  A Q 4 N -tre a te d  SW 620 colon  ca n ce r x e n o g ra ft t is su e  sec tions.
(a) and b display the scores and loadings plots respectively. Non-treated tum our sam­
ples are separated from AQ4N dosed xenografts. More interstingly, PCA-DA analysis 
distinguished between treatm ents administrated to the animals.
In the scores plot (figures 4.10a), discrimination between peptide images obtained 
from non-treated and AQ4N-treated xenograft tissue samples is observed. There is also 
a separation between AQ4N-treated and AQ4N and pimonidazole-treatcd samples. Here 
PCA-DA allowed the discrimination between peptide profiles according to the type of 
treatm ent administer to the animals.
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In the loading plots (figures 4.10a), several peptides were found to be characteristic 
of either the non-treated samples or the AQ4N-treated xenografts. The histone H3 pep­
tide signal at m /z 1032 was found to be predominantly characteristic of AQ4N-treated 
xenografts. Alternatively the peptide signal at m /z 1027 was found to be highly intense 
in non-treated tissue sections. These results obtained with PCA-DA analysis were found 
to be in good agreement with the obtained MALDI-MS images (figure 4.9).
4 .4 .3  M A L D I -I M S -M S  p r o f il in g  o f  p e p t id e s  a f te r  i n  s i t u  d ig e s t io n  o f  
n o n - tr e a te d  a n d  A Q 4 N -t r e a t e d  S W 6 2 0  c o lo n  c a n c e r  x e n o g r a f t s
MALDI-MS imaging and PCA-DA analyses allowed the discrimination between pep­
tide images obtained from non-treated and AQ4N- or AQ4N +  Pimonidazole-treated 
xenograft tissue sections. In order to assess if possible markers can be highlighted, 
MALDI-1MS-MS profiling was performed followed by orthogonal partial least-squares- 
discriminant analysis (OPLS-DA). Figure 4.11 displays a digital scan of the tissue sec­
tions which were analysed. 66 mass spectra were obtained from each region defined using 
MALDI Imaging Pattern  Creatorril/ software (Waters Corporation, Milford, MA). An 
average spectrum was generated for each sample (figure 4.12). Differences in peptide 
intensities were observed when comparing spectra.
non-treated Pimo treated  AQ4Ntreated AQ4N+Pimo
treated
Figure 4.11: D ig ita l scans o f SW 620 x e n o g ra ft tis su e  sec tio n s  p r io r  to  M A L D I- 
IM S -M S  p rofiling  analysis.
Regions of interest,which were analysed, are highlighted.
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Figure 4.12: M A L D I-IM S -M S  average  p e p tid e  profiles o b ta in e d  from  non - 
tr e a te d ,  p im o n id a z o le -tre a te d  a n d  A Q 4 N -tre a te d  SW 620 x e n o g ra ft tis su e  
sections.
Several peptide signals were detected. Differences in peptide intensities were noticed 
when comparing peptide profiles obtained from each tissue section.
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OPLS-DA was performed using M arkerLynx™  software. Partial least-squares (PLS) 
is a multivariate statistical anlytical method often used to obtain a quantitative rela­
tionship between two data tables which display spectral data  and quantitative values
[22]. However, variations due to sample preparation, complexity of the sample m atrix 
and data acquisition are often corrected using OPLS analysis, which aims to  filter the 
data sets, thereby facilitating improved separations and data interpretation of the dif­
ferent types of the innate variations present in the data  set [22, 23]. OPLS-DA can also 
be used to generate a class discrimination between samples. Combining the information 
obtained from PCA-DA and OPLS-DA may result in an improved method for target­
ing hypoxia-related markers and also assess the robustness and reproducibility of the 
method.
Figure 4.13 displays the S-plot of the comparison between non-treated and AQ4N- 
treated xenograft tissue sections obtained after OPLS-DA. The x axis shows the inter 
variation between the different samples. Here it can be noticed tha t groups are clearly 
separated, as peptide signals a t m /z 1032, 1059, , 1060, 1220 and 1347 enable to dis­
criminate AQ4N-treated samples from non-treated samples. Hence peptide signals th a t 
significantly represent a group of samples can be highlighted. However direct identifi­
cation of these peptides is required in order to elaborate further conclusion regarding 
biologic processes and/or the effect of the drug treatm ent. The results obtained from 
OPLS-DA were found to be in good agreement with those obtained from PCA-DA and 
also with MALDI-IMS-MS profiling and imaging.
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Figure 4.13: S -p lo t a f te r  O P L S -D A  o f M A L D I-IM S -M S  p e p tid e  p ro files  from  
n o n - tre a te d  a n d  A Q 4 N -tre a te d  SW 620 x e n o g ra ft tis su e  sections.
Discrimination between peptide profiles obtained from treated and non-treated samples 
was noticed. Several peptides were found to be characteristic of a given sample. The 
ion signal at m /z 1032, arising from histone H3, was found to be more intense in AQ4N- 
treated samples compared to non-treated.
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The peptide profiling comparative study enabled the selection of peptide ion signals 
for MS/MS fragmentation. However the MS/MS analyses performed directly on-tissue 
did not allow the identification of several proteins. Table 4.1 displays a list of identified 
proteins.
P ro te in
A ssig n ­
m ent
Accession
number
Protein
mass
(Da)
Observed 
m /z with 
MALDI- 
MSI
Sequence MS/MS
ion
score
Molecular
function
A ctin ,
aortic
sm o o th
m uscle
P62736 41982 1198.7 AVFPSIVGRPR 18 Cell mobil­
ity
A ctin ,
c y to ­
p lasm ic
1
P60709 41710 976.4 AGFAGDDAPR 31
A lb u m in P02768 69367 1467,8 RHPDYSVVLLLR 60
H isto n e
H 2 A
Q96QV6 14225 944.5 AGLQFPVGR 32 gene regu­
lation
H isto n e
H 3
Q6NXT2 15204 1032.6 YRPGTVALR 18
H isto n e
H 4
P62805 11360 1325.7 DNIQGITKPAIR 87
P o ly d o m Q4LDE5 390248 1163.6 KWSGASPR, oxidation (HW) 32 Involved 
in cell 
adhesion, 
cell prolif­
eration
T um or
necrosis
factor
recep tor
su p er­
fam ily
m em b er
10A
000220 50029 1105.6 AGRAPGPRPAR 19 mediating
apoptosis
Table 4.1: List of detected proteins after direct M ALD I-M S/M S analysis of 
non-treated and AQ 4N-treated SW 620 xenograft tissue sections.
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4.5 Concluding Rem arks
MALDI-MSI has developed into a new technique tha t can help in the understanding 
of the cancer process as well as the responses to treatm ent. In the work reported here, 
the methodology used was divided into two parts. First, the distributions of AQ4N and 
its active metabolites were studied within non-treated and treated SW620 colon cancer 
xenograft tissue sections. This aimed to localise tumour regions as well as the hypoxic 
tumour area. However, limitations can be encountered with MALDI-MSI for such stud­
ies. In this case isobaric ion interferences with the target compounds, i.e. AQ4N and its 
active metabolites, were noticed. This limitation was addressed in this study by using 
ion mobility separation in combination with MALDI-MSI. This resulted in generation of 
the exact distributions of the compounds of interest with no interfering ions. The in situ 
analysis of AQ4N and its metabolites within the tissue sections allowed the targeting of 
hypoxia within the tumour section.
The second part of the work aimed to identify hypoxia-related markers. This was 
achieved using in situ digestion followed by MALDI-MSI analysis of non-treated and 
AQ4N-treated xenograft tissue sections. Indeed, the sensitivity offered by MALDI-MSI 
analysis of intact proteins directly from tissue sections is in most cases low and results 
in the detection of mainly the most abundant proteins present in tissue sections such 
as actin and histone. Therefore the use of in situ digestion strategies prior to MALDI- 
MSI analysis is now a methodology of choice [24, 25], since it leads to direct protein 
identification. In the work reported here, several peptide signals were observed after 
in situ digestion of non-treated and treated xenograft tissue sections and differences in 
intensities were observed when comparing profiles and images. Using statistical analysis 
for data interpretation allowed discrimination between samples as well as the type of 
treatm ent administrated to the animals. Several peptides were found to be different in 
their signal intensities when comparing sample groups.
A problem encountered in this study has been the direct identification of proteins 
following on-tissue MS/MS fragmentation. Several peptides were found to be abundant 
and characteristic of a given sample, however the identification of these peptides remains 
crucial. In this study, several MS/MS analyses allowed good fragmentation of given
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peptides, however the database search did not lead to protein identification. This may be 
explained by existing post-translational modifications, splice variants and the presence 
of different adducts.
Therefore improvements are required including de novo sequencing, the coupling of 
MALDI-MSI with other molecular imaging techniques and standard analytical proto­
cols used for tissue lysates in order to achieve improved identification and quantification 
of proteins associated with spatial localisation information. In summary, the methodol­
ogy described here demonstrates th a t MALDI-MSI shows huge potential as a powerful 
biomarker discovery tool.
References
[1] Kunz M. and Ibrahim S.M. Molecular responses to hypoxia in tum or cells. Molec­
ular Cancer, 2:23-35, 2003.
[2] Hockel M. and Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, 
and molecular aspects. Journal of the National Cancer Institute , 93:266-276, 2001.
[3] Vaupel P. and Mayer A. Hypoxia in cancer: significance and impact on clinical 
outcome. Cancer Metastasis Reviews, 26:225-239, 2007.
[4] Rademakers S.E., Span P.N., Kaanders J.H.A.M., Sweep F.C.G .J., van der Ko- 
gel A. J., and Bussink J. Molecular aspects of tumour hypoxia. Molecular Oncology, 
2:41-53, 2008.
[5] Cairns R.A., Papandreou I., Sutphin P.D., and Denko N.C. Metabolic targeting of 
hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proceedings 
of the National Academy of Sciences, 104:9945-9450, 2007.
[6 ] Rosenberg A. and Knox S. Radiation sensitization with redox modulators: 
A promising approach. International Journal of Radiation Oncology, Biology, 
Physics, 64:343-354, 2006.
[7] Denny W.A. Tumor-activated prodrugs-a new approach to cancer therapy. Cancer 
Investigation, 22:604-619, 2004.
[8 ] Patterson L.H. and McKeown S.R. AQ4N: a new approach to hypoxia-activated 
cancer chemotherapy. British Journal of Cancer, 83:1589-1593, 2000.
[9] Loadman P.M., Swaine D.J., Welham K.J., and Patterson L.H. A preclinical phar­
macokinetic study of the bioreductive drug AQ4N. Drug Metabolism and Disposi­
tion, 29:422-426, 2001.
[1 0 ] Albertella M.R., Loadman P.M., Jones P.H., Phillips R.M., Rampling R., Burnet 
N., Alcock C., Anthoney A., Vjaters E., Dunk C.R., Harris P.A., Wong A., Lalani 
A.S., and Twelves C.J. Hypoxia-selective targeting by the bioreductive prodrug 
AQ4N in patients with solid tumors: results of a phase I study. Clinical Cancer 
Research, 14:1096-1104, 2008.
[11] Patterson L.H., McKeown S.R., Ruparelia K., Double J.A., Bibby M.C., Cole S., 
and Stratford I.J. Enhancement of chemotherapy and radiotherapy of murine tu ­
mours by AQ4N, a bioreductively activated anti-tum our agent. British Journal of 
Cancer, 82:1984-1990, 2000.
REFERENCES 165
[12] Atkinson S.J., Loadman P.M., Sutton C., Patterson L.H., and Clench M.R. Exam­
ination of the distribution of the bioreductive drug AQ4N and its active metabolite 
AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass 
spectrometry. Rapid Communication in Mass Spectrometry, 21:1271-1276, 2007.
[13] Workman P., Balmain A., Hickman J.A., Rohas A.M., Mitchison N.A, Pierrepoint 
C.G., Raymond R., Rowlatt C., Stephens T.C., Wallace J., and Straughan D.W. 
UKCCCR guidelines for the welfare of animals in experimental neoplasia. Labora­
tory Animals, 22:195-201, 1988.
[14] Pringle S.D., Giles K., Wildgoose J.L., Williams J.P., Slade S.E., Thalassi- 
nos K., Bateman R.H., Bowers M.T., and Scrivens J.H. An investigation of 
the mobility separation of some peptide and protein ions using a new hybrid 
quadrupole/travelling wave IMS/oa-ToF instrument. International Journal of Mass 
Spectrometry, 261:1-12, 2007.
[15] Riba-Garcia I., Giles K., Bateman R.H., and Gaskell S.J. Evidence for structural 
variants of a- and b-type peptide fragment ions using combined ion mobility/mass 
spectrometry. Journal of the American Society for Mass Spectrometry, 19:609-613, 
2008.
[16] Shimma S., Sugiura Y., Hayasaka T., Hoshikawa Y., Noda T., and Setou M. 
MALDI-based imaging mass spectrometry revealed abnormal distribution of phos­
pholipids in colon cancer liver metastasis. Journal of Chromatography B , 855: 
98-103, 2007.
[17] Heeren R.M.A., Smith D.F., Stauber J., Kkrer-Kaletas B., and MacAleese L. Imag­
ing Mass Spectrometry: Hype or Hope? Journal of the American Society fo r Mass 
Spectrometry, 20:1006-1014, 2009.
[18] Bennewith K.L., Raleigh J.A., and Durand R.E. Orally administered pimonidazole 
to label hypoxic tumor cells. Cancer Research, 62:6827-6830, 2002.
[19] Gilges D., Vinit M.A., Callebaut I., Coulombel L., Cacheux V., Romeo P.H., and 
Vigon I. Polydom: a secreted protein with pentraxin, complement control pro­
tein, epidermal growth factor and von W illebrand factor A domains. Biochemical 
Journal, 352:49-59, 2000.
[2 0 ] Jackson J.E. A User’s Guide to Principal Components. Wiley, 1991.
[21] Defernez M. and Kemsley E.K. The use and misuse of chemometrics for treating 
classification problems. Trends in Analytical Chemistry, 16:216-221, 1997.
[22] Trygg J. and Wold S. Orthogonal projections to latent structures (O-PLS). Journal 
of Chemometrics, 16:119-128, 2002.
[23] Stenlund H., Gorzss A., Persson P., Sundberg B., and Trygg J. Orthogonal projec­
tions to latent structures discriminant analysis modeling on in Situ FT-IR  spectral 
imaging of liver tissue for identifying sources of variability. Analytical Chemistry, 
80:6898-6906, 2008.
REFERENCES 166
[24] Lemaire R., Desmons A., Tabet J.C., Day R., Salzet M., and Fournier I. Direct 
analysis and MALDI imaging of formalin-fixed, paraffin-embedded tissue sections. 
Journal of Proteome Research, 6:1295-1305, 2007.
[25] Wisztorski M., Lemaire R., Stauber J., Menguelet S.A., Croix D., M ath O.J., Day 
R., Salzet M., and Fournier I. New developments in MALDI imaging for pathology 
proteomic studies. Current Pharmaceutical Design, 13:3317-3324, 2007.
CHAPTER O
IMS-Tag M ALDI-M S Im aging of  
Protein Biomarkers in FFPE  
Adenocarcinom a Tissue Sections
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5.1 Introduction
Advances in genomic and proteomic technologies have been found to provide insights 
into the complex molecular processes of cancer [1 ]. Cancer biomarkers are required in 
order to aid the design and development of tools for early detection, prevention, clinical 
diagnosis and prognosis as well as treatm ent [2]. Biomarkers are defined as biological 
molecules tha t are measurable indicators of a physiologic state and changes occurring 
during a disease process [2 , 3]. Strategies for cancer biomarker discovery based on the 
study of mRNA expression have been found to be very informative and beneficial as they 
have allowed the identification of several potential gene biomarkers. However, mRNA 
expression very rarely correlates with protein concentration or identify functional pro­
teomic content such as proteolytic cleavage or post-translational modification (PTM)
[4]. Proteomic-based strategies for the identification of cancer biomarkers using mass 
spectrometry (MS) are becoming more and more popular as they provide comprehen­
sive protein characterisation and identification from a wide variety of samples including 
plasma, cells and tissues [5].
MS analysis of tissue samples has allowed studies of differential protein expres­
sion in normal and cancerous tissues leading to the identification of clinical diagnostic 
and prognostic protein markers [1]. Even more interesting is the use of MALDI-mass 
spectrometry imaging to obtain the spatial distribution and expression of proteins di­
rectly from tissue sections [6 ]. This approach presents several advantages for improving 
biomarker discovery as it allows the detection of proteomic information such as protein 
localisation, relative expression and identification, directly from tum our tissue sections 
with no requirement for pre-defined targets.
The combination of ion mobility separation (IMS) with MALDI-MSI is a new and 
promising technology, which has been found to be powerful in improving the m ethod’s 
specificity and selectivity [7]. A new concept called IMS-Tag M ALDI-M SI, developed in 
this work, is described for the detection and analysis of biomarkers in human formalin 
fixed paraffin embedded (FFPE) tumour tissue sections. IMS-Tag MALDI-MSI consists 
of the use of the efficiency, selectivity and specificity of the IMS to specifically target 
the ions of interest with no interfering isobaric peaks and then to generate the exact
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distribution of this ion within the tissue sections as well as identifying the selected ion 
using MALDI-MSI.
Using IMS-Tag MALDI-MSI, several known and potential new biomarkers were lo­
calised and identified directly from human FFPE  adenocarcinoma tissue sections includ­
ing pancreatic and breast tumours. The methodology used here allowed the targeting 
and in situ identification of glucose regulated protein 78kDa (Grp78), which is known 
as a tum our biomarker related to the unfolded protein response (UPR), in pancreatic 
FFPE  tumour tissue sections. Additionally using IMS-Tag MALDI-MSI, it was possible 
to achieve a comparative study between FFPE  early stage breast tumour and m etastatic 
lymph node tissue sections, and hence localise and identify tumour biomarkers as well 
as potential breast tumour metastasis-associated proteins such as heat shock proteins 
(hsp) and tumour necrosis factor receptor.
It was reported in Chapter 3 (section 3.3.2.3) tha t the use of antigen retrieval (AR) 
prior to on-tissue enzymatic digestion was found to be beneficial for in situ proteomic 
investigation as it enabled unlocking of several proteins, hence enhancing the resulting 
mass spectral signals. However, direct MS/MS analyses for on-tissue protein identifica­
tion was limited since only a few proteins were identified following a MASCOT database 
search. In the work reported here, the identification of proline residue oxidation, re­
sulting from the AR protocol, is described. Adding proline oxidation as a variable 
modification to the MASCOT search criteria greatly increased the number of identified 
proteins. The limitations and benefits of the methodology used here are described.
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5.2 M aterials and M ethods
5.2 .1  M ateria ls
Modified sequence grade trypsin was purchased from Promega (Southampton, UK). 
A sample of recombinant Grp78 protein was gifted by Dr Valerie Corrigal, Kings College 
London. All other materials, including alpha-cyano-4-hydroxycinnamic acid (cr-CHCA), 
aniline (ANI), ethanol (EtOH), methanol (MeOH), xylene, octyl-a://?-glucoside (OcGlc), 
trifluoroacetic acid (TFA), haematoxylin, eosin, hydrogen peroxide (H2 O2 ), tri-sodium 
citrate, ammonium bicarbonate, iodoacetamide and tributylphosphine were purchased 
from Sigma-Aldrich (Dorset, UK).
5.2 .2  T issu e sam ples
Following fully informed patient consent and full ethical committee approval anonymi- 
sed 5 fim  ex vivo human FFPE  pancreatic and breast tum our tissue sections were 
obtained (Study Number SSREC/04/Q2305/67 and subsequent amendments). Tissue 
samples were fixed in 10% buffered formalin for 24 hours, dehydrated in 70% EtOH and 
paraffin embedded. 5 //m sections were cut using a cryostat (Leica Microsystems, UK) 
and mounted onto a histological glass slide. FFPE  tissue sections were stored at room 
tem perature until further analysis.
5 .2 .3  T issu e preparation
Paraffin film was removed from FFPE  tissue sections according to methods previ­
ously described in chapter 3 (section 3.2.3). Endogenous peroxidase activity was blocked 
by incubating the section for 12 minutes in a hydrogen peroxide solution made at 3% 
in MeOH. Antigen retrieval was then performed by heating the section in a microwave 
oven for 15 minutes at 90°C in a tri-sodium citrate buffer at 0.01M (pH =  6.3) [8 ]. 
Three cycles of 5 minutes with a 30 sec interval between cycles in order to check the 
buffer level in the ja r as well as the tissue section were achieved. The section was cooled 
to room tem perature, rinsed with water and then allowed to dry a t room tem perature 
before trypsin and m atrix deposition.
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5.2.3.1 In-solution and in  situ  digestion
The trypsin solution was made at 20 fig /m b  in 50 mM ammonium bicarbonate buffer 
(pH =  8.1) containing 0.1 % octyl glucoside (OcGlc). The recombinant Grp78 standard 
was digested in solution using the following method: 20 fib  of recombinant Grp78 at 
0.05 fig /fib  was reduced and alkylated using tributylphosphine and iodoacetamide ac­
cording to the manufacturer’s protocol. 2 0  fib  of trypsin solution was then added and 
the digestion was performed for 2 hours at 37°C (5% CO 2 ) in a humid environment. 
The digestion was stopped with ice and the resulting peptide solution was purified using 
ZipTip C18 pipette tips (Millipore, Hampshire, UK) before MALDI-IMS-MSI analysis.
In  situ digestion was performed on FFPE  pancreatic and breast tumour tissue sec­
tions using a trypsin solution, made at 20 fig /m b  in 50 mM ammonium bicarbonate 
buffer (pH =  8.1) containing 0.1 % octyl glucoside (OcGlc), which was deposited onto 
the tissue section using either a SunCollect™  MALDI-Spotter (SunChrom, Friedrichs- 
dorf, Germany) or a Portrait® 630 automatic spotter (Labcyte Inc., Sunnyvale, USA).
Using the SunCollect™  MALDI-Spotter, the spraying method used for trypsin de­
position was the same as described in Chapter 3 (section 3.2 .4.4). The trypsin solution 
was deposited on the tissue section at increased flow rate over five layers. The first layer 
was performed at 1 //L/m in, the second at 2 fib /m m  and the last three layers set a t 4 
fib /m m . Humid environmental conditions were maintained while depositing the trypsin 
onto the tissue section. After trypsin deposition the tissue section was incubated for 2  
hours at 37°C (5% CO2 ) in a humid environment.
The P o rtra it® 630 spotter (Labcyte Inc., Sunnyvale, USA) is an acoustic reagent 
m ultispotter and has been described by Aerni et al [9]. Briefly the technology consists 
of using acoustic energy focused under an open reservoir containing the reagent solution 
toward the sample situated above the reagent reservoir. This results in the ejection and 
deposition of precise microdroplets onto the targeted sample surface [9]. The volume of 
a droplet is about 170 pL and a minimum spot-to-spot spatial resolution of 175 fim  can 
be achieved. In the work reported here, 52 cycles were performed for trypsin deposition 
onto FFPE  tissue sections. One drop per position was deposited across the tissue section
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during each cycle, hence a total volume of approximately 9 nL of trypsin solution per 
spot was printed onto the tissue sections. The spot-to-spot spatial resolution was set at 
400 /im. After trypsin deposition, the tissue section was incubated for 2  hours a t 37°C 
(5% CO2 ) in a humid environment.
5.2.3.2 M atrix deposition
cr-CHCA mixed with aniline (cr-CHCA/ANI), prepared at 5 and 10 m g/m L in 50% 
ACN:0.2%TFA, was used as the m atrix for peptide analysis.
W hen using a SunCollect™  automatic sprayer, the matrix solution was made at 
5 mg/mL in 50% ACN:0.2%TFA and deposited onto the tissue section at increased 
flow rate between layers. The first layer was performed at 1 /iL/m in allowing a m atrix 
seeding process. The second and last three layers were performed at 2 /rL/m in and 3.5 
fiL/mm. respectively.
When using a P o rtra it® 630 spotter, o-CHCA/ANI was made at 10 m g/m L in 
50% ACN:0.2%TFA. Since the technology is based on acoustic ejection, there are no 
limitations in terms of m atrix concentrations which can be used as long as the m atrix 
is well dissolved in the solvent. Here, 25 cycles of 5 drops/cycle were deposited onto the 
tissue section at a spatial resolution of 400 fim, allowing an acceptable crystallisation 
of the m atrix onto the tissue section surface.
5 .2 .4  D irect M A L D I-IM S -M S /M S  and M A L D I-M S /M S  an a lysis  o f  
F F P E  adenocarcinom a tissu e  section s
MALDI-MS/MS analyses were performed using the MALDI SYNAPT™ HDM S 
(Waters Corporation, Manchester, UK) operating in ion mobility separation (IMS) mode 
directly from the digested tum our tissue sections. Transfer fragmentation was performed 
and optimised based on the precursor ion mass [10, 11]. The transfer fragmentation 
method was described in chapter 3 (section 3.2 .6 .2 ). MALDI-MS/MS spectra were also 
acquired using an automatic run. To do so, mass spectra were first obtained directly 
from the tissue section. Using M ALDIM erge™  software (Waters Corporation), the 
resulting mass spectra were merged together in order to obtain peptide m ass/intensity 
lists. Excel (Microsoft) was then used to randomly select peptide masses for M S/MS 
fragmentation. The tissue sections were further defined as a spot target and M S/MS
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spectra were automatically acquired based on transfer fragmentation dissociation energy 
pre-registered in the instrument setting parameters. Figure 5.1 displays an overlay of a 
standard spot target plate (Waters Corporation) and the tissue section area (highlighted 
in red).
Figure 5.1: D efin itio n  o f th e  tis su e  sec tio n  a re a  as a  s ta n d a rd  sp o t ta r g e t  p la te  
p r io r  to  M A L D I-M S /M S  a u to m a tic  acqu isition .
Overlay of a standard spot target plate and the tissue section area which is highlighted 
in red.
After both manual and automatic MALDI-MS/MS acquisitions, the obtained MS/MS 
spectra were processed in M assLynx™  (Waters Corporation, Manchester, UK). MS/MS 
spectral processing methods were the same as described in chapter 3  (section 3 .2 .6 .2 ). 
The resulting files were submitted to a MASCOT (Matrix Science, London, UK) query 
search and searched against the SwissProt database (release 56.0). W ithin the MAS­
COT search engine, the parent and fragment ion tolerances were set at 30 ppm and 0.1 
Da respectively. The criteria also included up to two missed cleavages and the variable 
modifications allowed were protein N terminus acetylation, histidine/tryptophan oxida­
tion, methionine oxidation and proline oxidation. De novo sequencing was performed 
manually and using the PepSeq™  (Waters Corporation, Manchester, UK) de novo in­
teractive MS/MS sequencing tool. The parent and fragment ion tolerances were set at 
0.1 Da and the threshold was set at 1 %. Protein Blast searches against the Swissprot 
database were also performed to confirm tryptic sequences.
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5 .2 .5  M A L D I-m ass sp ectrom etry  im aging
Digital scans of tissue sections were obtained prior to MALDI-IMS-MSI experiments 
using a CanoScan 4400F flatbed scanner (Canon, Reigate, UK) and then imported into 
MALDI Imaging Pattern  C reato r™  (Waters Corporation, Milford, MA) software. This 
allowed the generation of patterns containing the x and y coordinates of each pixel of 
the image. The instrument calibration was performed using a standard mixture of 
polyethylene glycol (Sigma-Aldrich, Gillingham, UK) ranging between m /z 100 to 3000 
prior to MALDI-IMS-MSI analysis. D ata were acquired in V-mode and positive mode 
using a MALDI SYNAPT™ HDM S system (Waters Corporation) operating with a 200 
Hz Nd:YAG laser. All data were acquired with ion mobility separation in the mass 
range from m /z 800 to 3000. Peptide images were acquired at a spatial resolution set at 
200 /im with 600 laser shots per position. Using Driftscope™ 2.1 (Waters Corporation, 
Manchester, UK) software, mobility data  of individual peptide signals were selected 
and extracted using MALDIExtract-™  (Waters Corporation) software. The extracted 
data  were converted into imaging files using MALDI Imaging Convertor™  (Waters 
Corporation) software and ion images were generated with BioMap 3.7.5.5 software 
(Novartis, Basel, Switzerland).
5.2 .6  Im m unoh isto  ch em istry
Immunohistochemistry (IHC) was performed on FFP E  pancreatic and breast tumour 
tissue sections using a peroxidase-based staining method. Paraffin was first removed 
from FFPE  tumour tissue sections followed by rehydration through a series of ethanol 
solutions of increasing water concentrations. Residual endogenous peroxidase activity 
was blocked by incubating the sections in 2% hydrogen peroxide in methanol for 30 
minutes at room tem perature followed by AR performed in a microwave oven for 15 
minutes until simmering. Sections were incubated for 30 minutes a t room tem perature 
in normal goat blocking serum (Vector Laboratories) diluted at 15:1000 to minimise non 
specific bindings and then incubated for an additional 30 minutes a t room tem perature 
with goat anti-human Grp78 antibody (Santa Cruz Biotechnology) at a dilution of 
1:100. Tissue sections were washed with phosphate buffered saline (PBS) solution and 
were incubated with the second antibody biotinylated anti-goat immunoglobulin (Vector 
Laboratories) at a dilution of 1:20, for 30 minutes at room tem perature. An avidin
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biotinylated horseradish peroxidase complex solution was then applied to the sections 
for an additional 30 minutes at room tem perature. Grp78 antibody on the sections 
was visualised using diaminobenzidine and tissue sections were counterstained with 
haematoxylin for 60 seconds before being dehydrated and coverslipped. Tissue sections 
were also stained for negative control. Images were obtained using a light microscope 
(Olympus BX51) operating in brightfield mode using CellD (Olympus) software.
5 .2 .7  H aem atoxy lin  and eosin  (H E ) sta in in g  p rotoco l
Paraffin was first removed from FFPE  tumour tissue sections followed by rehydration 
through a series of ethanol solutions of increasing water concentrations (100, 95 and 
70% ethanol) for three minutes in each solution. The sections were then dipped in 
tap  water for two minutes. The nuclei were stained by immersing the tissue sections 
in haematoxylin for 30 seconds, followed by a wash under running tap  water (a gentle 
stream of water running into a staining jar was used). The sections were then dehydrated 
in 70 and 95% EtOH solutions for three minutes and immersed for 20 seconds in eosin 
solution made at 5% in EtOH. Following eosin staining, the tissue sections were washed 
in 95% EtOH solutions for five minutes each time, followed by two washes in 100% EtOH 
for five minutes each time. Tissue sections were then fully dehydrated in xylene for 15 
minutes and coverslipped. Images were obtained using a light microscope (Olympus 
BX51) operating in brightfield mode using CellD software.
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5.3 R esu lts and D iscussion
5 .3 .1  T argeting o f  g lu cose-regu lated  p rotein  78 kD a (G rp78) in  hum an  
F F P E  pancreatic  tu m our tissu e  section s
5 .3 .1 . 1  D ire c t M A L D I-IM S -M S  im ag in g  a n d  v a lid a tio n  o f G rp 7 8  e x p re s ­
s ion  in  F F P E  p a n c re a tic  tu m o u r  tis su e  sec tio n s
Recombinant Grp78 protein was digested in-solution in order to assess the peptide 
mass fingerprint generated and to be expected when performing the same analysis on 
tissue. Figure 5.2 displays the obtained mass spectrum and some ion signals belonging 
to Grp78 according to the theoretical Grp78 tryptic digest peptide map are highlighted. 
The resulting peak list was de-isotoped using the M assLynx™  software and was im­
ported into the MASCOT search engine for a peptide mass fingerprint (PMF) search. 
M atrix adduct peaks and autolysis tryptic peptides were also removed from the peak 
list prior to the MASCOT search. Table 5.1a shows the list of tryptic peptide masses 
which were found to match for the identification of Grp78. The ion signals at m /z  1887, 
1934, and 1999 were further analysed using MALDI-MS/MS and sequence assignments 
were made using MASCOT, thus resulting in the positive identification of Grp78. Table 
5.1b displays the obtained peptide sequences.
11374 9I2016D6 I
mn.
Figure 5.2: M A L D I m ass s p e c tru m  o b ta in e d  a f te r  in -so lu tio n  d ig e s tio n  o f 
G rp 7 8  rec o m b in a n t p ro te in .
Grp78 tryptic peptides at m /z 1566, 1815, 1934 and 2164 are highlighted. M atrix cluster 
peaks including signals at m /z 861, 877, 1066 and 1277 can also be observed.
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(a) P ro te in  n a m e /  
A ccess io n  num ber
Mass
(Da)
Observed
peptide
m /z
Mass
error
(ppm)
Sequence MOWSE
Score
Sequence
coverage
(%)
78 k D a  g lu cose- 72288 1512.75 -4 AKFEELNMDLFR 68 22
reg u la ted  p ro te in
(G r p 7 8 ) / P 1 1 0 2 1
1566.78 1 ITPSYVAFTPEGER
1815.99 -5 IINEPTAAAIAYGLDKR
1887.97 -1 VTHAW TVPAYFNDAQR
1920.09 33 IQQLVKEFFNGKEPSR
1934.01 0 DNHLLGTFDLTGIPPAPR
1974.90 -2 IEWLESHQDADIEDFK
1999.02 -34 GVPQIEVTFEIDVNGILR
2164.97 -8 IEIESFYEGEDFSETLTR
(b ) P ro te in  n a m e / Mass Observed Mass Sequence obtained after M S/MS Database
A ccess io n  num ber (Da) peptide error MS/MS fragmentation ion
m /z (ppm) score
78 k D a  g lu cose- 72288 1887.963 12.9 VTHAW TVPAYFNDAQR 52 Swissprot
reg u la ted  p ro te in
(G rp 78) /  P 11 0 2 1
1934.006 6.23 DNHLLGTFDLTGIPPAPR 79
1999.086 13.9 GVPQIEVTFEIDVNGILR 32
Table 5.1: L ist o f p e p tid e  m asses u sed  fo r th e  id en tif ica tio n  o f G rp 7 8  a f te r  
in -so lu tio n  d ig es tio n  o f G rp 7 8  rec o m b in a n t p ro te in .
(a) List of peptide masses matched for the identification of Grp78 with PM F search.
(b) Sequence obtained after MS/MS analysis of selected tryptic peptides.
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On-tissue digestion was then performed on FFPE pancreatic tumour tissue sections 
which were subsequently subjected to MALDI-IMS-MSI analyses. A spot of in-solution 
digested Grp78 recombinant protein was also imaged along with the tissue section as a 
positive control (circled in figure 5.3c-e). To reconstruct the MALDI-MS images, only 
data resulting from the ion mobility separation were used. Figures 5.3a and b show 
digital scans of the tissue section before and after trypsin and matrix deposition using 
a P ortra it®  630 spotter respectively.
Figure 5.3: Im ages o f th e  d is tr ib u t io n  o f G rp78  w ith in  F F P E  p a n c re a tic  t u ­
m o u r sections.
(a, b) Digital scans of the tissue section before and after trypsin and m atrix deposi­
tion using a P ortra it®  630 spotter respectively, (c-e) MALDI-IMS-MS images of the 
distribution of Grp78 tryptic peptides within FFPE pancreatic tumour sections, (f) 
Digital scan of the tissue section after innnunohistochemical staining of Grp78. (g,h) 
Microscopic images of immunohistochemical staining of Grp78 within the tissue section 
showing a high expression of Grp78 in tumour cells (red arrows indicate tum our cells): 
the images were obtained at magnification xlO.
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Figures 5.3c, d and e display the localisation of tryptic peptides including signals 
at m /z 1934, 1887 and 1999 respectively within the tissue section. These signals were 
previously identified as arising from Grp78. These findings were confirmed using the 
positive control spot of Grp78 recombinant protein imaged simultaneously with the 
tissue section. In order to validate these results, immunohistochemical analysis was 
performed. Figures 5.3f, g and h show the IHC staining of Grp78 within the tissue 
section. Grp78 was found to be highly expressed in tumour cells. W hen comparing the 
IHC staining images and the MALDI-IMS-MS images obtained from the tum our tissue 
sections, Grp78 was found to be mainly located in the tum our region. The MALDI 
images were found to be in good agreement with those obtained by the IHC study.
5.3.1.2 D irect M ALDI-IM S-M S/M S analysis and in  situ  identification of 
Grp78 within FFPE pancreatic tumour tissue sections
Direct MALDI-IMS-MS and MS/MS analyses were performed on the FFP E  pan­
creatic tum our tissue sections in order to confirm the identification of Grp78. Figures 
5.4a and b display a mass spectrum and the corresponding DriftscoperM  plot obtained 
from the tumour region of the tissue section. This plot gives a graphical representation 
of the ion-mobility drift-time versus mass-to-charge ratio for detected ions. Using ion 
mobility, separation between doubly charged ions and singly charged peptides can be 
achieved. Examination of the data  shows the detection of tryptic peptides arising from 
Grp78 including ions at m /z 1887, 1934 and 2164. The ion at m /z 2164 can be seen in 
the zoomed in spectrum insert.
MS/MS analysis of the peptide signals at m /z 1887, 1934 and 1999 directly from the 
tissue surface allows confirmation of the assignment of these signals to Grp78. Figure
5.5 displays the MS/MS spectrum obtained for the peptide at m /z 1934.
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Figure 5.4: In v e s tig a tio n  o f th e  d e te c tio n  o f G rp78  t ry p t ic  p e p tid e s  w ith in  
F F P E  p a n c re a tic  tu m o u r  sec tio n s  by M A L D I-IM S -M S  profiling .
(a) MALDI-MS peptide profile obtained directly from the pancreatic tumour tissue 
section showing the detection of Grp78 tryptic peptides, (b) D riftscope™  plot obtained 
from direct MALDI-MS profiling of FFPE pancreatic tumour tissue sections where the 
peptide ions are separated based on their ion mobility.
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Figure 5.5: M A L D I-IM S -M S /M S  s p e c tru m  o f th e  p e p tid e  ion  a t  m /z  1934 
a c q u ired  d ire c tly  from  a  F F P E  p a n c re a tic  tu m o u r  tissu e  section .
The spectrum was normalised to the fragment ion signal at m /z 367. The peptide ion 
at m /z 1934 was identified as a Grp78 tryptic peptide.
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Several other peptide signals were also analysed by MS/MS directly from FFPE  
pancreatic tumour tissue sections. Here the use of IMS was found to be beneficial as it 
allowed separation of isobaric species including peptides, hence improving the database 
search for protein identification. Figure 5.6a displays the D riftscope™  plot obtained 
for the ion signal at m /z 1400 where two species were simultaneously detected. W hen 
performing a MASCOT search on the entire spectrum, a MASCOT MS/MS ion score of 
50 was obtained for periostin. However these peptides can be separated from each other 
based on their mobility (Figures 5.6b and c) which results in an increase in the level of 
confidence in assigning the protein identification, as shown by the resulting MASCOT 
MS/MS ion score of 75 for the same protein (see table 5.2).
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Figure 5.6: M A L D I-IM S -M S /M S  s p e c tru m  o f th e  ion  signa l a t  m /z  1400 
acq u ired  d ire c tly  from  a  F F P E  p a n c re a tic  tu m o u r  tissu e  section .
(a) DriftscopeTA/ plot of the MS/MS spectrum of the ion signal at m /z 1400, which 
shows the simultaneous detection of 2 isobaric peptides. These MS/MS spectra were 
separated using the ion mobility separation, thus allowing an improved database search 
result for the protein identification, (b) MS/MS spectrum of the peptide T27 arising 
from periostin. (c) MS/MS spectrum of another peptide signal at m /z 1400 which was 
not identified.
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Table 5.2 displays a list of peptides identified directly from FFPE  pancreatic tumour 
tissue sections.
P r o te in  n a m e / A c ­
c essio n  num ber
Mass
(Da)
Observed
peptide
m /z
Mass
error
(ppm)
Sequence MS/MS
ion
score
Sequence
coverage
(%)
A c tin , ao rtic  
sm o o th  m u sc le /  
P 6 2 7 3 6
41982 1198.72
1790.90
12.9
2.96
AVFPSIVGRPR
SYELPDGQVITIGNER
46
75
7.2
A c tin , cy to p la sm ic  
1 /  P 6 0 7 0 9
41710 1954.06
2215.08
0.78
4.22
VAPEEHPVLLTEAPLNPK
DLYANTVLSGGTTMYPGIADR
108
61
10.4
A lb u m in / P 0 2 7 6 8 69321 1149.63
1311.73
15.4
7.05
LVNEVTEFAK
HPDYSVVLLLR
37
57
3.6
C o lla g en  alpha- 
1 (1 ) /  P 0 2 4 5 2
138827 886.44
1297.62
1546.77
1690.78
0.87
8.77
13.88
0.74
GSEGPQGVR
GESGPSGPAGPTGAR
GETGPAGPAGPVGPVGAR
DGEAGAQGPPGPAGPAGER
30
39
74
45
6
C ollagen  alpha- 
2 (1 ) /  P 0 8 1 2 3
129209 1235.63
1477.73
1562.77
11.37
14.66
9.65
TGHPGTVGPAGIR, oxidation 
(HW)
GLHGEFGLPGPAGPR, oxida­
tion (HW)
GETGPSGPVGPAGAVGPR
30
20
36
4.7
78 k D a  g lu cose-  
reg u la ted  p ro te in  
(G rp 78) /  P 11 0 2 1
72288 1887.95
1934.00
12.9
6.23
VTHAW TVPAYFNDAQR
DNHLLGTFDLTGIPPAPR
10
76
5.5
H aem o g lo b in  a lph a  
/  P 6 9 9 0 5
15258 1087.57
1529.74
17.3
2.57
MFLSFPTTK, oxidation (M) 
VGAHAGEYGAEALER
26
115
17
H aem o g lo b in  b e ta  
/  P 68 8 7 1
15988 1274.73 2.22 LLVVYPWTQR 27
H isto n e  H 2 A .Z /  
P 0 C 0 S 5
13545 944.53 AGLQFPVGR 26
H isto n e  H 2B  /  
P 3 3 7 7 8
13942 1775.84 20.6 AMGIMNSFVNDIFER, 2 oxida­
tion (M)
36
H isto n e  H 3- 
lik e /Q 6 N X T 2
15204 1032.59 4.15 YRPGTVALR 19
H isto n e  H 4 /  
P 6 2 8 0 5
11360 1325.74
1466.80
7.59 DNIQGITKPAIR
TVTAM DW YALKR
39
29
24.5
P a n crea tic  a lph a- 
a m y la se / P 0 4 7 4 6
57670 1427.70 2.60 ALVFVDNHDNQR 59
P a n crea tic  tr ia cy l-  
g ly cero l lip ase  pre­
cursor /  P 1 6 2 3 3
51124 1746.90 19.58 FIWYNNVINPTLPR 58
P e r io s t in /  Q 15063 93255 1400.78 6.62 AAAITSDILEALGR 75
S e r in e /th r eo n in e -  
p ro te in  k in a se /  
Q 9Y 3S1
242525 1327.72 6.13 GLTLPCLPWRR, oxidation 23
Table 5.2: L is t o f som e t ry p t ic  p e p tid e s  id en tif ied  a f te r  in  s i tu  d ig e s tio n  o f 
F F P E  p a n c re a tic  tu m o u r  tis su e  sec tio n s  u sin g  d ire c t M A L D I-IM S -M S /M S .
All database searches for protein identification were performed using the Swissprot 
human database.
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IMS has been also found powerful to minimise peak interferences observed in MALDI- 
MS images. Images acquired by conventional MALDI-MS can be a composite of the 
distribution of multiple ions. Figure 5.7a shows a Driftscope7 M plot of detected pep­
tides where an isobaric peak interference was observed with an actin tryptic peptide 
at m /z 1198. Figure 5.7b displays the distribution of the ion signal at m /z 1198. The 
concept IMS-Tag MALDI-MSI, developed in this work, which combines high-efficiency 
ion mobility separations and MALDI-MS has been used to determine the distribution of 
an actin tryptic peptide at m /z 1198 without interference from simultaneously ionised 
isobaric ions (figures 5.7c and d).
m/z 1198 actin
interfering isobaric 
component
M C D _ P C 0 5 1 6 4 0 G 5 _ 0 1 .r a w : 10
Figure 5.7: D riftsc o p e TA/ p lo t, co n v en tio n a l M A L D I-M S  a n d  IM S -T ag
M A L D I-M S  im ages o f a c tin  t ry p t ic  p e p tid e  a n d  isobaric  p e a k  in te rfe re n c e  
o b ta in e d  from  a  F F P E  p a n c re a tic  tu m o u r  tis su e  section .
(a) DriftscoperM  plot of observed peptides in the mass range m /z 1196 to 1200: the red 
dots indicate the detected peptide peaks, (b) Distribution of the ion signal at m /z 1198 
using conventional MALDI-MSI, without ion mobility separation. Imaging with ion 
mobility separation allows the determination of the exact distribution of actin tryptic 
peptide at m /z 1198 (c) free of interfering isobaric component (d).
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Using the IMS-Tag MALDI-MSI, the distributions of some identified peptides within 
the FFPE pancreatic tumour tissue section are shown in figure 5.8. It can be noticed 
that peptide signals arising from the same protein display an identical distribution 
across the tissue section (figures 5.8b and c). This is very beneficial as it allows the 
confirmation of the identification of protein obtained by direct MS/MS analysis and 
protein database search. More interestingly, the information resulting from the imaging 
experiment can be used to target and identify other tryptic peptides arising from the 
same protein with only PM F searches with no requirement for MS/MS analysis since 
the same distribution across the tissue section should be observed.
b) m/z 1198 actin c) m/z 1790 actin
f) m/z 1746 pancreatic 
triacylgtycerol lipasee) m/z 1274 haemoglobin pd) m/z 1529 haemoglobin a
Figure 5.8: IM S -T ag  M A L D I-M S  im ages o f p e p tid e  d is tr ib u t io n  w ith in  a  
F F P E  p a n c re a tic  tu m o u r  tis su e  section .
The localisations of histone H2A, actin, haemoglobin and pancreatic triacyglycerol li­
pase are displayed.
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5.3.1.3 D iscussion
Pancreatic cancer is one of the most common malignant causes of death in the UK 
and is still associated with poor prognosis despite therapeutic options which include 
surgical resection and chemotherapy [12]. Direct proteomic analysis of tum our samples 
by MALDI-MSI is of great interest as it provides insights into protein distribution, 
abundance and identification within a given tissue section in a single experiment. Even 
more desirable is the possibility of investigating the proteome information directly from 
archived samples with known clinical outcome as it may assist biomarker discovery, 
hence resulting in the improvement of clinical diagnosis and prognosis.
In this section, the key outcomes are the localisation and identification of the glucose- 
regulated protein 78 kDa (Grp78), which is known as a tumour biomarker, directly 
within FFP E  pancreatic tumour tissue sections. Grp78 is a key molecular chaperone 
within the endoplasmic reticulum (ER) and member of the Hsp70 family [13-15]. It 
provides the trigger for the activation of the signal cascade known as the unfolded pro­
tein response (UPR), a cellular stress response [16, 17]. The UPR is activated when 
malfolded proteins are accumulated in the ER lumen [17, 18]. Briefly U PR activation 
aims to enhance cellular survival by preventing irreversibly malfolded proteins from be­
ing exported for use and stabilising the remaining protein production. This requires an 
up-regulation of molecular chaperones including Grp78. If adverse micro environmental 
conditions are severe or prolonged in normal cells, the UPR can initiate apoptosis. The 
tumour environment has been shown to be a region of physiologic endoplasmic retic­
ulum stress [16]. The UPR is poorly characterised in cancer, however it could be a 
key mechanism in perm itting tumour cell survival in an acidotic, hypoxic and glucose 
deprived environment and it has been shown to alter chemosensitivity to  a variety of 
established anticancer agents [19, 20]. Grp78 has been found to be highly expressed in 
several cancer cell lines as well as tumour tissues and has been correlated with tum our 
growth and aggressiveness as well as resistance to chemotherapies [21, 22]. This is the 
first time tha t the distribution and in situ identification of Grp78 has been described 
using MALDI-MSI combined with ion mobility separation. In the work reported here, 
Grp78 was found to be mainly located in tumour regions using MALDI-IMS-MSI. The 
specificity and selectivity of the method applied allowed the targeting of a relatively low 
abundance protein biomarker directly in archived pancreatic tum our tissue sections.
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The validation of Grp78 was achieved using immunohistochemistry staining which was 
found to be in good agreement with the obtained MALDI-IMS images.
Although MALDI-MSI is a technique tha t allows direct protein profiling and in situ 
identification within tissue sections, direct protein identification after in situ digestion 
of tissue sections can be challenging, as the biomolecules are contained in a complex 
mixture. The use of ion mobility separation, combined with MALDI-MS profiling and 
imaging, was found to be a valuable tool for direct protein identification after in situ 
digestion of FFPE  tissue sections. IMS has been found to allow the separation of 
a range of ions based on their collision cross-sections, i.e. based on their structure 
and conformation. Here, IMS has been found to be a powerful tool as it allowed the 
separation of isobaric tryptic peptides with an acceptable limit of detection and mass 
accuracy. Coupling IMS and MALDI-MSI has also been found to improve the specificity 
and selectivity as well as facilitate database searches for protein identification.
The experimental strategy described here allowed the rapid screening of the distri­
bution of peptides and their identification after in situ digestion of FFPE  pancreatic 
tumour tissue sections using MALDI-IMS-MS profiling and imaging. The localisation of 
peptides arising from the same protein can be used to confirm protein identification but 
also to target other tryptic peptides of the same protein and hence increase the level of 
confidence in the identification and localisation of the given protein. However optimisa­
tion of the protocol is still required in order to achieve the identification of more protein 
tumour markers, including those which are involved in the UPR cascade, directly from 
tissue sections using direct MALDI-IMS-MS/MS profiling and imaging. Further work 
was directed to the improvement of the in situ identification and in situ quantification 
of protein markers involved in tum our growth, including the identification of existing 
post-translational modifications and/or other chemical modifications (section 5.3.2).
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5.3 .2  A n tigen  retrieval prior to  in  s itu  d igestion  o f  F F P E  tissu e  sec­
tion s y ie ld s proline m od ification
The use of antigen retrieval as sample pre-treatm ent prior to in situ digestion of 
FFPE  tissue sections has been found to be beneficial for MALDI-MSI analysis of pro­
teins directly within FFPE  tissue sections as it allowed unlocking and enhancement of 
tryptic peptide signals (described in Chapter 3, section 3.3.2.3). However direct pro­
tein identification by MALDI-MS/MS from tissue sections remains challenging due to 
either overlapping signals, existing unidentified protein post-translational modifications 
and/or chemical protein modifications resulting from sample preparation. The use of 
IMS combined with direct MALDI-MS/MS analysis of FFP E  tissue sections has been 
found to improve the selectivity of the method and hence improved the database searches 
for protein identification [7]. However several peptide signals remain unidentified, thus 
requiring the elucidation of existing protein modifications in order to improve protein 
identification. Several papers described the mechanism involved in AR, however there is 
a lack of information on the chemical protein modification induced by the AR protocol
[23].
MALDI-MS/MS spectra were acquired directly from human FFPE  breast tum our 
tissue sections. Figure 5.9 displays the MS/MS spectrum of the peptide signal a t m /z 
1286. Using de novo sequencing, a modification of the proline residue was noticed a t a 
mass shift of M+16. This corresponded to addition of a hydroxyl group (OH) to proline 
amino acid, hence an oxidation (or hydroxylation) of proline residues.
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Figure 5.9: M A LD I-M S/M S spectrum  of the peptide signal at m /z  1286 ac­
quired directly from FFPE breast tum our tissue section.
Oxidation of histidine, methionine as well as proline residues as is observed. The peptide 
was identified as arising from histone-lysine N-methyltransferase protein.
Proline hydroxylation is a common protein modification which occurs in mammalian 
cells as well as plants [24, 25]. Among the amino acids, proline and lysine are the most 
likely to be hydroxylated [24]. Hydroxyproline is derived either from the oxidation of 
proline by hydroxyl radical compounds [24-26] or following hydroxylation of proline by 
prolyl hydroxylases during collagen synthesis [27].
In the work reported here, the identification of proline hydroxylation shown in figure 
5.9 may be explained by a chemical derivatisation occurring during the sample prepara­
tion. The method employed here described the use of AR prior to on-tissue enzymatic 
digestion with the aim of unlocking several protein signals. However, one of the steps of 
the AR protocol involves an incubation of the tissue section for 12 minutes at room tem ­
perature in a solution containing 3% hydrogen peroxide (H2 O2 ). It has been reported 
tha t hydroxyl radicals can be formed in several ways including by reduction of II2 O2  
by metals ions contained in biological systems in aqueous solution. Hydroxyl radicals 
are very active compounds and several studies reported the ability of proline to  quench 
hydroxyl radicals and form different compounds including hydroxyproline [24, 25]. Fig­
ure 5.10 displays the mechanisms of hydroxylation of proline [24]. Hence the oxidation
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of proline amino acid residues observed in figure 5.9 may result from hydroxylation of 
proline during the incubation of the tissue section in hydrogen peroxide solution.
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Figure 5.10: M ech an ism  o f p ro lin e  o x id a tio n  w ith  h y d ro x y l rad ic a ls  [24] (repro­
duced with permission from American Chemical Society publisher).
Following chemical or biochemical reactions of proline with hydroxyl radicals, hydrox­
yproline species can be obtained. This corresponds to an addition of +16 Da to the 
mass of proline residues. This modification does not lead to a cleavage of the amino acid 
chain backbone and hence can be observed after tryptic digestion followed by tandem  
mass spectrometric analysis.
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Adding proline oxidation as a variable modification to the MASCOT search crite­
ria allowed the identification of numerous proteins. 61 MALDI-MS/MS spectra were 
acquired directly from FFPE  breast tum our tissue sections using an autom atic data 
acquisition. W hen performing a MASCOT search without taking into account proline 
oxidation as a variable modification, only 11 peptides were identified. In contrast, 33 
peptide signals were identified when adding proline oxidation as a variable modification 
to the MASCOT search criteria. Table 5.3 displays a list of the peptide signals identi­
fied directly from FFPE  breast tumour tissue sections. It can be noticed th a t several 
peptides were identified as arising from collagen species. Hydroxyproline is the princi­
pal amino acid found in collagen proteins resulting from the hydroxylation of proline 
by prolyl hydroxylase enzyme during collagen synthesis. Figure 5.11 displays a MS/MS 
spectrum of the peptide signal at m /z 1303 which has been identified as a collagen 
species. It can be noticed tha t 3 proline residues were hydroxylated.
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Figure 5.11: M A LDI-M S/M S spectrum  of the peptide signal at m /z  1303 
acquired directly from FFPE  breast tum our tissue section.
The peptide was identified as arising from Collagen alpha-1 (III) chain.
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Several peptide signals arising from collagen species can be noticed in table 5.3. 
Collagen is one of the most abundant proteins present in connective and muscle tis­
sues. Using proline oxidation as a variable modification for MASCOT protein database 
searches may result in the selection of numerous collagen tryptic peptides which can 
be removed from the peptide mass list in order to perform the identification of other 
proteins present in lower abundance than collagen proteins.
In the work reported here, proline oxidations observed in tryptic peptide fragments 
other than those arising from collagen proteins, may derive from the hydroxylation of 
proline when incubating the tissue section in hydrogen peroxide solution. The Uniprot 
database showed th a t only the phosporylation of serine and threonine residues are 
listed as possible post-translational modifications which may occur to histone-lysine 
N-methyltransferase. Hence, the presence of hydroxyproline observed in the amino acid 
sequence (see table 5.3) derives from a chemical modification occurring during incuba­
tion in hydrogen peroxidase solution prior to the AR sample preparation.
Results and Discussion 193
Table 5.3: L ist o f  tr y p tic  p e p tid e s  iden tified  a fter  in  s itu  d ig estio n  
o f  F F P E  breast tu m o u r  tis su e  sec tio n s  usin g  d irect M A L D I-IM S -  
M S /M S .
P r o te in  n a m e / A c­ Mass Observed Mass Sequence MS/MS location
cessio n  num ber (Da) peptide error ion and
m /z (ppm) score function
A c tin , cy to p la sm ic 41710 976.43 -13.5 AGFAGDDAPR 21 Cyto­
1 /  P 6 0 7 0 9 plasm,
cell
mobility
1198.69 -9.60 AVFPSIVGRPR 12
C ollagen  alpha- 138827 836.43 -3.75 GPAGPQGPR 55
1 (1 ) /  P 0 2 4 5 2
852.43 -0.76 GPPGPQGAR, Oxidation (P) 31
1105.57 -8.06 GVQGPPGPAGPR, Oxidation
(P)
24
1546.79 -0.49 GETGPAGPAGPVGPVGAR 75
1585.76 -4.98 GAN GAPGIAGAPGFPGAR, 3 
Oxidation (P)
34
1775.87 2.81 GARGEPGPTGLPGPPGER, 
Acetyl (N-term); 2 Oxidation (P)
11 Extra
cellular
matrix,
secreted
Fibril
organi­
sation,
blood
vessel
develop­
ment
C ollagen  alpha- 129209 868.45 -18.3 VGAPGPAGAR, Oxidation (P) 14
2 (1 ) /  P 08 1 2 3
960.45 -11.7 AGVMGPPGSR, Oxidation (M); 
Oxidation (P)
16
1562.79 -1.9 GETGPSGPVGPAGAVGPR 26
1580.73 -19.9 GPPGESGAAGPTGPIGSR, Ox­
idation (P)
79
1751.80 -16.2 GPPGAVGSPGVNGAPGEAGR, 
3 Oxidation (P)
50
1775.87 -3.52 RGPNGEAGSAGPPGPPGLR, 2 
Oxidation (P)
39
1833.89 3.97 RGPNGEAGSAGPPGPPGLR, 
Acetyl (N-tcrm); 3 Oxidation (P)
28
Continued on Next Page.
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Table 5.3 — Continued
P ro te in  n a m e / A c­ Mass Observed Mass Sequence MS/MS location
cessio n  num ber (Da) peptide error ion and
m /z (ppm) score function
C ollagen  alpha- 138479 836.43 -3.75 GAPGPQGPR 43
l ( I I I ) /  P 0 2 4 6 1
852.43 -0.76 GPPGPQGAR, Oxidation (P) 25
1094.58 -9.87 GPPGLAGAPGLR, 2 Oxidation
(P)
37
1111.59 -4.6 GRPGLPGAAGAR, 2 Oxidation
(P)
41
1154.56 -1.11 GLAGPPGMPGPR. Oxidation 
(M); 2 Oxidation (P)
33
1303.61 4.85 GSPGGPGAAGFPGAR, 3 Oxi­
dation (P)
48
1320.66 -7.12 GPPGPAGANGAPGLR, 2 Oxi­
dation (P)
18
1508.72 9.67 GESGPAGPAGAPGPAGSR, 
Oxidation (P)
20
1702.79 2.81 g e m g p a g i p g a p g l m g a r , 2
Oxidation (M); 2 Oxidation (P)
13
1833.89 -9.76 GPPGPQGLPGLAGTAGEPGR, 
3 Oxidation (P)
12
2104.07 -3.70 GSPGAQGPPGAPGPLGIAGIT  
GAR, 3 Oxidation (P)
25
C ollagen  alpha- 66117 1466.67 -9.59 GLNGPTGPPGPP GPR, 6 Oxi­ 21
1 ( X ) /  Q 03692 dation (P)
H ea t-sh o ck  p ro te in 22768 987.61 -1.22 RVPFSLLR 26 Cyto­
b e ta -1 /  P 04 7 9 2 plasm, 
nucleus, 
Involved 
in stress 
resis­
tance
1163.61 -7.54 LFDQAFGLPR 31
H isto n e  H 2 A .Z / 13545 944.53 -5.55 AGLQFPVGR 41 Nucleus,
P 0C 0 S 5 Gene
regula­
tion
Continued on Next Page.
Results and Discussion 195
Tabic 5.3 — Continued
P r o te in  n a m e / A c­ Mass Observed Mass Sequence MS/MS location
cessio n  num ber (Da) peptide error ion and
m /z (ppm) score function
H isto n e -ly s in e  N - 563831 1095.55 0.21 GGAHGGRGRGR, Acetyl (N- 14 Nucleus,
m eth y  ltra n sfera se / tcrm); Oxidation (HW) Acts as
0 1 4 6 8 6 a coacti­
vator for 
estrogen 
receptor, 
activates 
tran­
scription
1286.64 -6.24 NLTMSPLHKR, Acetyl (N- 
term); Oxidation (HW); Oxida­
tion (M); Oxidation (P)
23
K era tin , ty p e  II 51386 1406.68 -18.8 SIHFSSPVFTSR, Acetyl (N- 40 Cyto­
c y to sk e le ta l 7 / term) plasm,
P 0 8 7 2 9 struc­
tural
molecule
O bscurin-like pro­ 152786 1111.59 5.44 NGAVVTPGPQR, Oxidation (P) 33 muscle
te in  1 /  0 7 5 1 4 7 develop­
ment
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5.3 .3  IM S-T ag M A L D I-M S im aging o f biom arkers and  m etastasis-  
assoc ia ted  p rotein  m arkers in  hum an F F P E  b reast adenocar­
cinom a tissu e  section s
M etastasis is a complex molecular process which occurs often in cancers. It involves 
a multistep molecular mechanism in which tumour cells escape from the prim ary tumour 
site to other distant organs, hence creating new neoplasm environments [28]. M etastatic 
lymph nodes result also from sequenced steps which involve breaching of the basement 
membrane by tumour cells, infiltration into the extracellular matrix, invasion into the 
lymphatic vessels, transport to local lymph node, adherence and proliferation of tumour 
cells [28, 29]. Tumour growth and progression results also from defects in apoptotic 
pathways during cell cycles. Protein markers of tumour progression and metastasis 
formation are required in order to improve therapies and hence target appropriate genes 
and/or proteins. In this section, FFPE  early stage (ES) and m etastatic lymph node 
(MLN) breast tumour tissue sections were analysed using IMS-Tag MALDI-MS imaging 
in order to perform a comparison study and highlight possible protein markers th a t can 
be used as indicators of tumour progression and metastasis-associated proteins.
5.3.3.1 In  situ  identification of protein tumour markers w ithin human FFPE  
early stage breast cancer tissue sections using IMS-Tag M ALDI-M S  
imaging
Figures 5.12 displays a mass spectrum acquired directly from FFP E  early stage 
breast tumour tissue sections after antigen retrieval and on-tissue digestion using MALDI- 
IMS-MS. Numerous peptide signals were detected. Ion signals corresponding to tryptic 
autolysis peptides as well as collagen protein tryptic peptide signals were removed from 
the mass list prior to a PM F search. However no significant results for protein identifi­
cation were obtained when performing a PM F MASCOT search.
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B C 9 9 /1 4 1 2 8 C  M S  te s t  b e fo re  im a g e
MCD_090610_11 4 (0.085) AM2 (Ar.9000.0.0.00.0.70): ABS; Cm (1:7)
iiiiuV
Figure 5.12: M A L D I-IM S -M S  p e p tid e  profile  ac q u ired  d ire c tly  fro m  a  F F P E  
ea rly  s ta g e  b re a s t tu m o u r  tis su e  section .
Numerous signals are detected. Among them, several peptides arising from trypsin 
autolysis and collagen species were observed.
Table 5.4 shows a complete list of identified proteins from MALDI-MS/MS analy­
ses followed by a protein database search, which were grouped into biological processes 
using the PANTHER (Protein ANalysis THrough Evolutionary Relationships) classifi­
cation system. PANTHER is a freely available software which aims to correlate protein 
sequence evolution to molecular functions and biological processes [30, 31]. The use of 
PANTHER software has been reported to achieve more robust classification of proteins 
into molecular functions, biological processes and pathways [32]. Table 5.4 displays a 
classification of identified proteins in FFPE  early stage breast cancer tissue sections into 
biological process using PANTHER.
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Table 5.4: L ist o f  p ro te in s identified  after  in  s itu  d ig estio n  o f  F F P E  
b reast tu m o u r  tissu e  sec tio n s  u sin g  d irec t M A L D I-IM S -M S /M S .
Proteins were grouped into biological processes using the PANTHER classi­
fication system.
B io log ica l P ro te in  n a m e / A c­ Mass Observed Sequence MS/MS Molecular
P ro cess cessio n  num ber (Da) peptide
m /z
ion
score
function/
Pathways
A p o p to sis R e lA -a sso c ia ted  in­
h ib ito r /  Q 8 W U F 5
89036 1067.52 RSDAGSYRR 16 Select
regulatory
molecule
B lo o d H a em oglob in  al­ 15085 1087.6 MFLSFPTTK, Oxidation (M) 26
circu­ p h a /  P 69 9 0 5
la tio n
and gas
exch ange
1529.7 VGAHAGEYGAEALER 115 Other
trans­
fer/carrier
protein
H aem o g lo b in  b e t a / 15866.8 1274.7 LLVVYPWTQR 27
P 6 8 8 7 1
C ation N a + /K + -A T P a se 111779 1002.5 RDLDDLKK de Ion chan­
tra n sp o rt a lp h a  3 su b u n it  
v a r ia n t/ Q 53E S0
novo nel, Cation 
trans­
porter
C ytoske- A c tin , cy to p la sm ic 41710 976.43 AGFAGDDAPR 21 cell mobil­
leta l 1 /  P 6 0 7 0 9 ity, Actin
p ro te in
1198.69
2215.1
AVFPSIVGRPR
DLYANTVLSGGTTMYPGIADR
12
83
and actin
related
protein
C ell ad ­ C ollagen  alpha- 138827 836.43 GPAGPQGPR 55
hesion 1 (1 ) /  P 02 4 5 2
852.43
1105.57
1546.79
1585.76
1775.87
GPPGPQGAR, Oxidation (P) 
GVQGPPGPAGPR, Oxidation
(P)
GETGPAGPAGPVGPVGAR 
GANGAPGIAGAPGFPGAR, 3 
Oxidation (P)
GARGEPGPTGLPGPPGER, 
Acetyl (N-tcrm); 2 Oxidation (P)
31
24
75
34
11
C ollagen  alpha- 129209 868.45 VGAPGPAGAR, Oxidation (P) 14
2 (1 ) /  P 0 8 1 2 3
Continued on Next Page.. .
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Tabic 5.4 — Continued
B io log ica l P ro te in  n a m e / A c­ Mass Observed Sequence MS/MS Molecular
P ro cess cessio n  num ber (Da) peptide
m /z
ion
score
function/
Pathways
960.45 AGVMGPPGSR, Oxidation (M); 
Oxidation (P)
16
1562.79 GETGPSGPVGPAGAVGPR 26
1580.73 GPPGESGAAGPTGPIGSR, Ox­
idation (P)
79
1751.80 GPPGAVGSPGVNGAPGEAGR, 
3 Oxidation (P)
50
1775.87 RGPNGEAGSAGPPGPPGLR, 2 
Oxidation (P)
39
1833.89 RGPNGEAGSAGPPGPPGLR, 
Acetyl (N-term); 3 Oxidation (P)
28
C o lla g en  alpha- 138479 836.43 GAPGPQGPR 43
l ( I I I ) /  P 02 4 6 1
852.43
1094.58
1111.59 
1154.56 
1303.61 
1320.66 
1508.72 
1702.79 
1833.89 
2104.07
GPPGPQGAR, Oxidation (P) 
GPPGLAGAPGLR, 2 Oxidation
(P)
GRPGLPGAAGAR, 2 Oxidation
(P)
GLAGPPGMPGPR. Oxidation 
(M); 2 Oxidation (P) 
GSPGGPGAAGFPGAR, 3 Oxi­
dation (P)
GPPGPAGANGAPGLR, 2 Oxi­
dation (P)
GESGPAGPAGAPGPAGSR, 
Oxidation (P)
g e m g p a g i p g a p g l m g a r , 2
Oxidation (M); 2 Oxidation (P) 
GPPGPQGLPGLAGTAGEPGR, 
3 Oxidation (P)
GSPGAQGPPGAPGPLGIAGIT 
GAR, 3 Oxidation (P)
25
37
41
33
48
18
20
13
12
25
C o lla g en  alpha- 66117 1466.67 GLNGPTGPPGPPGPR. 6 Oxi­ 21 Extracellular
1 ( X ) /  Q 03692 dation (P) matrix
structural
protein
L um ican  [Precur­ 38405 1024.6 FNALQYLR 21 Receptor
so r ]) /  P 5 1 8 8 4 Extra­
cellular
matrix
Continued on Next Page.
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Table 5.4 -  Continued
B io log ica l P ro te in  n a m e / A c ­ Mass Observed Sequence MS/MS Molecular
P ro cess cessio n  num ber (Da) peptide
m /z
ion
score
function/
Pathways
C ell cy cle T um our p ro te in 76736 1127.6 RCPNHELSR, Oxidation (HW) 15, de Other
contro l 6 3 /  Q 9H 3D 4 novo transcrip­
tion factor
R e lA -a sso c ia ted  in­ 89036 1067.52 Select
h ib ito r / Q 8 W U F 5 regulatory
molecule
C ell T um our p ro te in 76736 1127.6
prolifera­ 6 3 /  Q 9H 3D 4
tio n  and
differen­
tia tio n
R e lA -a sso c ia ted  in­
h ib ito r /  Q 8 W U F 5
89036 1067.52
C h aperon e H ea t-sh o ck  p ro te in 22768 987.61 RVPFSLLR 26
P ro te in b e ta -1 /  P 04 7 9 2
fo ld ing
1163.61 LFDQAFGLPR 31 Chaperones,
p38
MAPK
pathway,
VEGF
signaling
pathway,
Angiogene-
sis
C h rom atin H isto n e  H 2 A .Z / 13545 944.53 AGLQFPVGR 41
packag­ P 0C 0 S 5
ing  and
rem od el­
ing
H isto n e  H 3 -lik e / 15204 1032.6 YRPGTVALR 20
Q 6N X T 2
H isto n e  H 4 / 11360 1325.74 DNIQGITKPAIR 39 Gene regu­
P 6 2 8 0 5 lation, his­
tone
Continued on Next Page.
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Table 5.4 -  Continued
B io log ica l
P ro cess
P ro te in  n a m e / A c ­
cessio n  num ber
Mass
(Da)
Observed
peptide
m /z
Sequence MS/MS
ion
score
Molecular
function/
Pathways
H isto n e -ly s in e  N -  
m eth y ltra n sfera se  /  
0 1 4 6 8 6
563831 1095.55
1286.64
GGAHGGRGRGR, Acetyl (N- 
term); Oxidation (HW)
NLTMSPLHKR, Acetyl (N- 
term); Oxidation (HW); Oxida­
tion (M); Oxidation (P)
14
23
Acts as 
a coacti­
vator for 
estrogen 
receptor, 
methyl- 
transferasc
D eh y d ro ­
g en ase
2 -o x o g lu ta ra te  
d eh yd rogen ase  
E l  co m p o n en t-  
lik e /Q 9 U L D 0
114409 952.5 FMTILRR, Oxidation (M) 21 Dehydro­
genase, 
Tricar­
boxylic 
acid path­
way
H yd ro lase N a + /K + -A T P a se  
a lph a  3 su b u n it  
v a r ia n t/ Q 53E S0
111779 1002.5 RDLDDLKK
M u scle
d ev e lo p ­
m ent
O bscurin-lik e pro­
te in  1 /  0 7 5 1 4 7
152786 1111.59 NGAVVTPGPQR, Oxidation (P) 33 Guanyl-
nucleotide
exchange
factor
P ro te in
b io sy n ­
th esis ,
o th er
m eta b o lisn
28S r ib osom al pro­
te in  S 1 8 b / Q 9Y 676
.
29377 1105.6 NHKGGVPPQR, Oxidation 
(HW)
20 Ribosomal
protein
T ransport A lb u m in / P 02 7 6 8
H a em oglob in  al­
p h a /  P 69 9 0 5  
H a em oglob in  b e t a /  
P 68 8 7 1
N a + /K + -A T P a se  
a lp h a  3 su b u n it  
v a r ia n t/ Q 53E S0
69321
15085
15866.8
111779
1311.73
1087.6
1274.7 
1002.5
HPDYSVVLLLR 57 Other
trans­
fer/carrier
protein
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In this study, the number of identified proteins remains low when compared to clas­
sical MS proteomic approaches such as 2D gel electrophoresis, LC-MS/MS and quan­
titative ESI-LC/M S/M S [32, 33]. However, based on the fact that a direct proteomic 
methodology is employed here, numerous peptides were attributed to proteins with no 
pre-extraction and purification.
Examination of the data  reported in table 5.4 revealed tha t several protein classes 
were identified directly from FFPE  ES breast cancer tissue sections, including proteins 
involved in metabolism, cell proliferation and stress response. Peptide signals arising 
from heat-shock protein b e ta l (HSPB1 or Hsp27) were also observed. Hsp27 has been 
reported to be up-regulated in early stage breast cancer [34, 35].
5.3.3.2 Study of the distribution of tumour markers within human FFPE  
early stage breast cancer tissue sections using IMS-Tag M ALDI-M S  
imaging
MALDI-IMS-MS images of the distribution of peptides within FFP E  early stage 
breast cancer tissue sections were also generated in order to study the localisation of 
identified proteins within the tissue sections after in situ digestion. Figure 5.13 displays 
the localisation of actin, histone H2A, haemoglobin alpha and beta chain and Hsp27 
within FFPE  ES breast cancer tissue sections. Examination of these images shows 
tha t the distribution of actin, histone H2A and Hsp27 within the tissue sections allows 
discrimination between regions. Hsp27 has been reported to be over-expressed in early 
stage breast cancers as well as correlated with cell proliferation, actin polymerisation 
and chaperone processes. Hence the distribution of Hsp27 within ES breast cancer 
tissue sections obtained using MALDI-IMS-MSI may indicate the localisation of tumour 
regions.
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6 .72
0 .76
a) m /z 976 Actin
d) m /z 1529 H BA 
g) m /z 944 H istone H2A h) m /z 1529 HBA
MCD_BCM!D662O_100608_0l0_m3x_div (t^EANtl
c) m/z 944 H istone H2A
f) m/z 1163 H sp27 ■■
M Rii1
Figure 5.13: M A L D I-IM S -M S  im ages o f th e  d is tr ib u t io n  o f p ro te in s  w ith in  
F F P E  e a rly  s ta g e  b re a s t tu m o u r  tis su e  sec tio n s  a f te r  in  s itu  d ig estio n .
The first two rows show images of the localisation of actin, histone H2A, haemoglobin 
alpha and beta chain and Hsp27 tryptic peptides within a FFPE early stage breast tu ­
mour tissue section. The third row displays the localisation of histone H2A, haemoglobin 
alpha and beta chain tryptic peptides within another FFPE  early stage breast tumour 
tissue section. The distribution of Hsp27 may show the localisation of tum our regions 
within the tissue sections.
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To verify this hypothesis, HE and immunohistochemistry staining were performed 
on consecutive breast tumour tissue sections. Figure 5.14 displays the obtained images. 
In both HE (figures 5.14a,b and c) and IHC (figures 5.14d, e and f) staining images, 
tumour regions were localised within the tissue sections. In figure 5.14a, b and c, tumour 
regions were found to be colocalised with the obtained spatial distribution of Hsp27 
tryptic peptide at m /z 1163 by MALDI-MSI (figure 5.13f). The results obtained using 
MALDI-IMS-MSI analyses were found to be in good agreement with those obtained 
with histological staining. Here, the use of MALDI-IMS-MSI allowed the targeting of 
proteins present in tumour cells, and hence the localisation of tumour regions within 
tissue sections. In the work reported here, classifying proteins into molecular functions 
or biological processes contributed to the generation of images of the distribution of 
proteins which were found to play a key role in tumour cell progression, and hence to 
the localisation of tumour regions using IMS-Tag MALDI-MSI.
Figure 5.14: H E  a n d  im m u n o h is to ch e m is try  (IH C ) s ta in in g  p ic tu re s  o f  F F P E  
e a rly  s ta g e  b re a s t can cer tis su e  sections.
(a) and (d) display digital scans of the tissue sections after HE and IHC Grp78 staining 
respectively, (b) and (c) show images of tumour cells within the tissue section after 
HE staining at magnifications of xlO and x40 respectively and were acquired from the 
region of the tissue section defined by the red and yellow circles in (a) respectively, (e) 
and (f) show images of tumour cells within the tissue section after IHC Grp78 staining 
at magnifications of xlO and x40 respectively and were acquired from the region of the 
tissue section defined by the black and blue circles in (d) respectively.
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Several studies have reported a significant correlation of Grp78 expression with tu­
mour stage and behaviour [13, 36]. Grp78 has been found to be associated with local 
tumour growth in early stage adenocarcinoma [36] and can be used as a prediction 
factor of responsiveness to chemotherapy in breast cancers [19]. In the work reported 
here, a spot of in-solution digested Grp78 recombinant protein was imaged alongside 
the tumour tissue sections. Figure 5.15 displays the distribution of peptide signals at 
m /z 1887 and 1934, which were identified as Grp78 tryptic peptides (section 5.3.1.2), 
within FFPE  ES breast tumour tissue sections. These peptides were found to be lo­
calised within the tumour areas of the tissue sections identified by PIE staining (figure 
5.14a). Additionally, the positive control of in-solution digested Grp78 recombinant 
protein spot was also highlighted in the MALDI-MS images. Hence the distribution of 
the peptide ions at m /z 1887 and 1934 may correspond to the localisation of Grp78 
within the tumour tissue section. However, MALDI-MS/MS analysis and /or Grp78 
immunohistochemical staining are required to validate the results.
Figure 5.15: M A L D I-IM S -M S  im ages o f th e  d is tr ib u t io n  o f th e  p e p tid e  signa ls  
a t  m /z  1887 a n d  1934 w ith in  F F P E  ea rly  s ta g e  b re a s t  ca n ce r t is su e  sec tio n s , 
a long  w ith  a  scan  o f th e  tis su e  sec tio n  a f te r  H E  s ta in ing .
(a) displays a digital scan of the tissue section after HE staining, (b) and (c) display 
the distribution of the peptide signals at m /z 1887 and 1934 respectively within a 
FFPE  early stage breast cancer tissue section. A spot of in-solution digested Grp78 
recombinant protein was imaged alongside the tissue section. The distribution of these 
peptides may correspond to the localisation of Grp78 within the tissue section.
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5.3 .3 .3  I n  s i tu  id en tif ica tio n  o f b re a s t  tu m o u r  m e ta s ta s is -a sso c ia te d  p ro ­
te in s  w ith in  F F P E  m e ta s ta t ic  ly m p h  n o d e  b re a s t  ca n ce r t is su e  sec­
tio n s
MALDI-mass spectra were acquired directly from FFPE  breast cancer m etasta­
tic lymph node tissue sections. The obtained mass spectra were subjected to a PM F 
search using MASCOT. The peptide mass tolerance was set at 80 ppm. Prior to the 
PM F search, ion signals corresponding to m atrix adducts, tryptic autolysis peptides 
and collagen-derived peptides were removed from the mass list. Only proteins with 
a significant MASCOT score, i.e. with a score greater than 56, were selected. Thus, 
interleukin-1 receptor type I and zinc finger protein 616 were identified with PM F MAS­
COT scores of 6 6  and 56 respectively. Figure 5.16 displays the obtained results. However 
the identification of zinc finger protein 616 by PM F was not confirmed since the obtained 
MASCOT score was not higher than 56. Direct MALDI-IMS-MS/MS analysis was also 
performed on FFPE  breast cancer m etastatic lymph node tissue sections. Numerous 
peptide signals were identified as arising from collagen species but also other proteins 
were identified, including Hsp27 as well as tum our necrosis factor receptor. Table 5.5 
displays a list of proteins identified in addition to those shown in table 5.4.
P ro te in  n a m e / A c­
cessio n  num ber
Mass
(Da)
Observed
peptide
m /z
Mass
error
(ppm)
Sequence MOW-
SE
Score
Sub­
location 
and Func­
tion
T um or n ecrosis  
factor recep to r  su ­
p erfam ily  m em b er  
1 0 A / 0 0 0 2 2 0
50029 1105.63 23 AGRAPGPRPAR 22 Membrane,
receptor,
apoptosis
In ter leu k in -1  re­
cep to r  ty p e  1 /  
P 14778
65361 32 pep­
tides 
matched 
using 
a PMF 
search
66 Membrane,
receptor,
immunity
response
Table 5.5: L ist o f a d d itio n a l t ry p t ic  p e p tid e s  id en tif ied  a f te r  in  s i tu  d ig e s tio n  
o f F F P E  b re a s t  ca n ce r m e ta s ta tic  ly m p h  n o d e  tis su e  sec tio n s  u s in g  d ire c t  
M A L D I-IM S -M S /M S .
All database searches for protein identification were performed using Swissprot human 
database.
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/"iMwi/'Mascot Search Results
User
Email
Search title
Database
residues)Taxonomy
Timestamp
Top Score
m a n e
marie-elaude.djidj a@ student.shu.ac.uk
SwissProt 56.6 (4055 06 sequences; 146166984
Homo sapiens (human) (20413 sequences)
9 Jan 2009 at 08:44:12 GMT
66 for IlilRl HUl-lAN, Interleukin-1 receptor type I
OS=Homo sapiens GN=ILlHl PE=1 SV=1
Probability Based Mows© Score
Protein score is -1 0 1 Log(P). wlieie P is Hie probability that the observed match is a 
random event.
Protein scores greater than 5<5 are significant (jr 0.05).
Score
1. IL1R1 HUMAN Mass: 65361 Score: 66 Expect: 0.0056 Que ries matched: 32
Interleukin-1 receptor type I OS=Homo sapiens GN=ILlRl PE=1 
SV=1
2. ZN616 HUMAN Mass: 90205 Score: 56 Expect: 0.04 9 Quer 
ies matched: 55
Zinc finger protein 616 OS=Homo sapiens GN=ZNF616 PE=2 SV=1
Figure 5.16: P e p tid e  m ass f in g e rp rin t M A S C O T  sea rch  re su lts  o b ta in e d  from  
M A L D I m ass s p e c tra  o f F F P E  b re a s t  ca n ce r m e ta s ta tic  ly m p h  n o d e  tis su e  
section .
Interleukin-1 receptor type I and zinc finger protein 616 were identified with the PM F 
MASCOT search. The identification of zinc finger protein 616 was not confirmed as the 
obtained MASCOT score was not higher than 56.
m M BP i l l i
i  i i r 50 60
P ro b a b ility  Based dowse
Results and Discussion 208
5.3.3.4 P r in c ip a l  co m p o n e n t an a ly s is-d isc rim in a n t ana lysis  o f F F P E  b re a s t  
can ce r m e ta s ta tic  ly m p h  n o d e  tis su e  sec tions
Using BioMap 3.7.5.5 software, a rapid screening of the results obtained from imag­
ing analysis allowed the visualisation of 3 distinct regions within the FFPE  breast tu ­
mour MLN tissue section. In order to confirm these observations, principal component 
analysis-discriminant analysis (PCA-DA) was performed. Figure 5.17a displays the dis­
tribution of the peptide ion signal at m /z 1325 as a MALDI-MS image which allows the 
visualisation of the 3 regions defined as 1, 2 and 3. Peptide profiles were then exported 
from MALDI-MSI data  for PCA-DA.
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Figure 5.17: P C A -D A  o f p e p tid e  profiles e x p o rte d  from  M A L D I-IM S -M S  im ­
ages o f F F P E  m e ta s ta tic  ly m p h  n o d e  b re a s t  can ce r tis su e  section .
(a) MALDI-IMS-MS image of the peptide ion signal at m /z 1325 showing 3 distinct 
regions defined as 1, 2 and 3. (b) The scores plots show discrimination between regions 
within the tissue section, (c) The loadings plots highlighted characteristic masses in­
cluding peptide signals at 944, 987 and 1198 corresponding to histone H2A, Hsp27 and 
actin respectively, which were found to be predominantly present in the tum our region.
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The method employed for PCA-DA was the same as described in chapter 4 (section 
4.3.4.1). Figure 5.17b displays the scores plots obtained, where 3 groups within the 
tissue section were distinguished: the groups were defined by the red, blue and green 
spots. The red spots corresponded to spectra obtained from the right central region of 
the tissue section (region 1 ), the green spots resulted from profiles from the outer area 
of the tissue section (region 3) and the blue spots represented spectra obtained from 
the margin (region 2 ).
In the loadings plots (figure 5.17c), several peptide signals were found to be char­
acteristic masses of each distinct region. Peptide ions at m /z 944, 987 and 1198, cor­
responding to histone H2A, Hsp27 and actin respectively, were found to be associated 
with the central area of the tissue section (defined by the red spots in figure 5.17a). The 
results obtained from MALDI-MS images of FFPE  early stage breast cancer tissue sec­
tions demonstrated tha t histone H2A and Hsp27 were mainly found in tum our regions 
(section 5.3.3.2). Here, the results obtained with PCA-DA allowed the localisation of 
tumour regions within MLN breast cancer tissue sections.
Regions corresponding to a margin (blue spots in figure 5.17a) and surrounding area 
(green spots in figure 5.17a) within the tissue section were also distinguished by PCA- 
DA. It can also be noticed tha t peptide profiles resulting from the surrounding area 
were found to be data  rich with collagen tryptic peptides. The peptide signals a t m /z 
1562 and 1833 were identified as collagen alpha-2(I) and collagen alpha-1 (III) tryptic 
peptides respectively. The signal at m /z 1467, which was not identified, however was 
mainly found to be localised in the margin. PCA-DA allowed discrimination between 
regions within the tissue section, and also the identification of characteristic masses for 
each distinct regions.
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5.3.3.5 Study of the distribution of tumour markers within FFPE breast
cancer m etastatic lymph node tissue sections
To confirm the results obtained with PCA-DA, MALDI-IMS-MS images of the dis­
tribution of peptide localisation within FFPE  MLN breast tumour tissue sections were 
also generated. Figure 5.18 displays the localisation of peptides from several proteins 
within the tissue section. Examination of the obtained images allowed the identification 
of 3 regions present in the tissue section. The right central area of the tissue section 
was found to be data  rich in several peptides arising from proteins which were found 
to be associated with tumour regions, such as histone H2 A, actin, Hsp27 and Grp78 
(figures 5.18b, c and f-i). These results were found to be in good agreement with those 
obtained with PCA-DA. This indicated the presence of tumour cells within this area of 
the MLN tissue section. In contrast, some peptides were found to be mainly localised 
in the margin and surrounding area, including signals at m /z 1467 and 1481 (figures 
5.18k and 1).
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j)  m /z 1105  TN FR
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Figure 5.18: M A L D I-IM S -M S  a n d  d ig ita l im ages o f th e  d is tr ib u t io n  o f  p e p ­
tid e s  a f te r  in  s itu  d ig es tio n  o f F F P E  b re a s t  can ce r m e ta s ta t ic  ly m p h  n o d e  
tis su e  sections.
(a) Digital scan of the tissue section obtained prior to MALDI-IMS-MSI analysis.
(b-rn) Distribution of peptides within the tissue section. Peptides were identified as 
arising from (b) histone H2A, (c) actin, (d-e) haemoglobin alpha and beta chain respec­
tively, (f-g) Hsp27, (h-i) Grp78, (j) tumour necrosis factor receptor, (k-m) Distribution 
of peptide signals at m /z 1467, 1481 and 2233 respectively, which were not identified.
5 .3 .3 . 6  D iscussion
Breast cancer is the second most common cancer in the world and one of the major 
causes of female mortality [33]. Advances in breast cancer research have led to the detec­
tion and identification of proliferation factors, oncogenes and tumour suppressor genes 
which are involved in tumour progression [33]. Currently, patients suffering from breast 
cancer are usually tested for the expression of oestrogen and progesterone receptors, as 
well as human epidermal growth factor receptor 2 (Her2) protein. This has been found 
to help in decision making regarding diagnostics and prognostics as well as treatm ent. 
However breast cancer often presents resistance to chemotherapy [35, 37], which can 
be explained by defects or changes in regulation of proteins and/or genes involved in 
apotosis or tha t affect the level of intracellular drug targets [37, 38]. Hence, improving 
biomarker discovery for tumour progression and metastasis may enhance drug develop­
ment.
Results and Discussion 212
In this section, the use of MALDI-IMS-MSI was described for targeting tumour 
protein markers as well as metastasis-associated proteins in FFPE  ES and MLN breast 
cancer tissue sections. Using the specificity and selectivity of the methodology described 
here, several proteins were identified directly from tumour tissue sections after in situ 
digestion and further classified using the PANTHER classification system, into molec­
ular functions and biological processes. The distribution of peptides within FFPE  ES 
breast cancer tissue sections allowed the localisation of tumour regions and hence the 
targeting of proteins which may be associated with tumour growth, metabolism and cell 
proliferation. Among them  Hsp27 was found to be mainly located in tum our regions 
of the tissue sections. This was found to be in good agreement with previous studies 
which reported an over-expression of Hsp27 in breast cancer cells and to be associated 
with tumour growth as well as resistance to chemotherapy [35, 37].
The identified proteins found to be localised in tumour regions of ES breast cancer 
tissue sections were also present in tumour cells in breast cancer MLN tissue sections. 
Proteins related to apoptosis and inflammatory response, including tum our necrosis 
factor receptor and interleukin 1  receptor were also identified. Some peptide signals 
were also found to be only detected in FFPE  breast cancer MLN tissue sections. This 
demonstrated the presence of metastasis-associated proteins. However limitations were 
encountered when performing direct protein identification. Extensive de novo sequenc­
ing approaches are therefore required in order to identify existing protein modifications 
and hence achieve more protein identification directly from the tissue sections. In the 
work reported here, tumour protein markers were localised within FFPE  early stage 
and m etastatic lymph node breast cancer tissue sections using IMS-Tag MALDI-MSI.
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5.4 C oncluding Rem arks
In this chapter, the use of MALDI-MSI technology as a biomarker discovery tool 
is described via both bottom -up and top-down proteomic approaches. Here, adeno­
carcinoma tissue sections were investigated using MALDI-MS imaging methodology in 
order to identify and localise tumour biomarkers directly within the tissue sections. 
Successful identification of heat shock proteins, including Grp78 and Hsp27, directly 
within adenocarcinoma tissue sections was achieved. Even more interestingly, the study 
of their distribution across the tissue sections revealed tha t these proteins were mainly 
located and highly intense in tumour regions. These results were found to be in agree­
ment with studies reported previously, where hsps were found to be highly expressed 
in tumour cells or tumour tissue sections [35, 37]. Furthermore Grp78 and Hsp27 are 
known as tumour biomarkers since they are correlated with tum our growth, progres­
sion and resistance to chemotherapy. In the work reported here, some proteins found 
to be located in tumour regions within early stage breast cancer tissue sections were 
also found to be present in tumour cells in m etastatic lymph nodes using MALDI-MSI. 
This demonstrated the ability of the technique to identify tumour markers as well as 
potential metastasis-associated proteins with no requirement for pre-defined targets.
The use of in situ digestion and ion mobility separation with MALDI-MSI has been 
found to be beneficial for protein identification directly from tissue sections. However 
direct identification of proteins within tissue section by MALDI-IMS-MS/MS remains 
challenging. This may be due to existing post-translational modifications. In the work 
reported here, the identification of proline oxidation as a protein modification which oc­
curs during the sample preparation facilitated the MASCOT search as well as de novo 
sequencing for protein identification. However, method improvement is still required in 
order to overcome remaining limitations associated with direct protein identification. 
Alternative methodologies have been reported. Methods including in situ  chemical 
derivatisation [39] and/or the use of other enzymes such as Lys-N may enhance identi­
fication of proteins directly from tissue sections [40]. Additionally, high resolution mass 
spectrometry imaging technologies such as FT-ICR MS imaging can improve mass mea­
surement accuracy for on-tissue MS/MS analysis for protein identification [6 , 41].
Concluding Remarks 214
In the work reported here, IMS-Tag MALDI-MSI analyses of FFPE  adenocarcinoma 
tissue sections allowed the localisation of tum our regions within tissue sections. Even 
more interestingly, the distribution and identification of tumour biomarkers th a t are 
indicators of tumour growth, proliferation and metastasis-associated were obtained. 
This was found to be beneficial as it could help in biomarker discovery and also in 
tumour classification models. However to design tumour classification systems, a large 
number of samples are required as well as the combination of high-throughput analysis 
with statistical tools.
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6.1 Introduction
Cancer classification is usually based on the morphological and histopathological ap­
pearances of the tumour. Commonly, cancers are graded on the tumour node metastasis 
(TNM) approach with the variables being tumour size, presence or absence of tumour 
cells in dependent lymph nodes and the presence or absence of distant m etastatic tumour 
deposits [1, 2]. However, tumours with the same histopathological and morphological 
features can pursue very different clinical courses: the response to chemotherapy may be 
attenuated or a theoretically curative resection can be complicated by early recurrence
[3]. In order to improve the ability of clinicians to make more accurate patient-tailored 
prognoses novel tumour classification models are required. Such classifications will most 
likely be based on molecular information, i.e. genomic and proteomic data  th a t provide 
insights into tumour progression, aggressiveness and resistance to therapy. In order to 
assess biological and clinical differences between tum our samples, a high-throughput 
analysis of heterogeneity within tumour tissue samples is required.
The introduction of tissue micro array (TMA) technologies has facilitated high- 
throughput analysis of a large number of archived samples for clinical applications as 
well as biomarker validation. It allows simultaneous analysis of a large number of speci­
mens in a single experiment [4, 5]. TMAs consist of paraffin blocks of up to a thousand 
individual biopsy cores arranged in arrays and allowing multiple analyses. Several stud­
ies have described the use of TMA sections for high-throughput clinical and molecular 
analysis of tumour samples, leading to biomarker validation [6 , 7]. The ability to iden­
tify and study the distribution of biomarkers directly from a large number of formalin 
fixed paraffin embedded (FFPE) tumour samples with known outcome is of im portant 
clinical interest as it could lead to a novel tumour classification system [4-7].
M atrix assisted laser desorption/ionisation- mass spectrometry imaging (MALDI- 
MSI) is rapidly becoming a powerful technology for studying the distribution and in 
situ identification of several classes of compounds including proteins, lipids, drugs and 
other small molecules directly within biological tissue sections. It hence provides and 
creates new fundamental and translational research opportunities in various fields in­
cluding cancer biomarker discovery [8-10]. Recently the use of MALDI-MSI has been
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described for the direct analysis of in situ digested proteins within a formalin fixed 
paraffin embedded lung cancer TMA showing the reproducibility of the method as well 
as the discrimination between cancer tissue types [11]. Of further interest is the use 
of statistical analysis, including principal component analysis (PCA) and hierarchical 
clustering analysis, in correlation with MALDI-MSI which has been reported in several 
studies [12-14]. The selection and highlighting of characteristic ion masses whose rela­
tive abundance in the tissue closely define and represent a region of interest of the tissue 
section or a sample type was clearly demonstrated.
The aim of this work is to establish a novel approach to molecular tum our classifica­
tion based on MALDI-MSI of pancreatic TMA. Using the specificity and selectivity of 
the technique in combination with principal component analysis-discriminant analysis 
(PCA-DA) class differentiation between tumour samples was obtained. Several identi­
fied peptides were found to be characteristic proteins of tumour classes and the results 
were found to be statistically significant. The methodology used here describes a novel 
proof-of-concept and also explains the benefits of such an approach.
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6.2 M a te ria ls  a n d  M eth o d s
6 .2 .1  M a te r ia ls
Modified sequence grade trypsin was purchased from Promega (Southampton, UK). 
All other materials, including alpha-cyano-4-hydroxycinnamic acid (ct-CHCA), aniline 
(ANI), ethanol (EtOH), methanol (MeOH), xylene, octyl-a/ /3-glucoside (OcGlc), tri- 
fluoroacetic acid (TFA), haematoxylin, eosin, hydrogen peroxide (H2 O2 ), tri-sodium 
citrate and ammonium bicarbonate, were purchased from Sigma-Aldrich (Dorset, UK).
6 .2 .2  T is s u e  s a m p le s
Following fully informed patient consent and full ethical committee approval anonymi- 
sed 5 /in i ex vivo human FFPE pancreatic tumour tissue sections were obtained (Study 
Number SSREC/04/Q2305/67 and subsequent amendments). AccuMax7 M FFPE  pan­
creatic cancer TMA were purchased from Stretton Scientific (Stretton, UK). TMA sam­
ples contain either 60 adenocarcinoma needle cores from 30 patients and 8 non-neoplastic 
needle cores or 60 adenocarcinoma needle cores from 30 patients (2 spots from each can­
cer case) and 30 non-neoplastic needle cores (corresponding normal tissues). Figure 6.1 
displays the layout of the TMA samples.
a)AccuMax™PancreaticcancerTMA A207V b)AccuMax™PancreatlccancerTMA A307 
2 spo ts from each cancercase  (60 spots) 2 spots from each cancercase  (60 spots)
8 non-neoplastlc spots (8 spots) 30 non-neoplastic spots (30 spots)
Figure 6.1: F F P E  p a n c re a tic  can ce r tis su e  m icro  a rra y  layou ts.
(a) Schematic layout of pancreatic cancer TMA containing 68 needle cores, (b) 
Schematic layout of pancreatic cancer TMA containing 90 needle cores after m atrix 
deposition.
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6.2.3 Tissue preparation
The methodology used for tissue preparation was the same as that described in 
chapter 5 (section 5.2.3). Briefly, the paraffin film was removed from FFPE  tissue 
sections using xylene. Following peroxidase blocking in hydrogen peroxide solution made 
a t 3% in MeOH, antigen retrieval (AR) was performed in tri-sodium citrate buffer for 
13 minutes in a microwave oven over 2 cycles of 5 minutes and one cycle of 3 minutes. 
Here, the duration of AR was reduced to 13 minutes in order to minimise loss of the 
needle cores during the microwave heating. The tissue sections were cooled to room 
tem perature, rinsed with water and then allowed to dry at room tem perature before 
trypsin and m atrix deposition.
6.2.4 In situ  digestion and matrix deposition
The methodology employed for in situ digestion was the same as tha t described in 
chapter 5 (section 5.2.3.1). Briefly, the trypsin solution was made at 20 /ig/m L in 50 mM 
ammonium bicarbonate buffer (pH =  8.1) containing 0.1 % octyl glucoside (OcGlc) and 
deposited onto the tissue sections using a SunCollect™  automatic sprayer (SunChrom, 
Friedrichsdorf, Germany). After trypsin deposition, the tissue section was incubated for 
2  hours at 37°C (5% CO 2 ) in a humid environment.
cr-CHCA mixed with aniline (a-CHCA/ANI) was used as the matrix. The m atrix 
solution was prepared at 5 m g/mL in 50% ACN and 0.2% TFA and was sprayed onto 
the tissue sections using a SunCollect™  automatic sprayer.
6.2.5 Direct MALDI-MS profiling and imaging
MALDI-MS profiles were acquired in the reflector and positive ion mode using an 
U ltraflex™ II M ALDI-TOF/TOF instrument (Bruker Daltoniks, Bremen, Germany) 
equipped with a Sm artbeam ™  (Bruker Daltoniks, Bremen, Germany) laser. Prior 
to data  acquisition, the instrument was calibrated using a standard mixture of pep­
tides (Bruker Daltoniks, Bremen, Germany) ranging between m /z 900 and 3500. Full 
scan mass spectra were recorded from m /z 600 to 5000. FlexAnalysis™  2.0 and 
Flexlm aging™  2.0 software (Bruker Daltoniks, Bremen, Germany) were used for da ta  
processing.
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MALDI-IMS-MS profiling and imaging data were acquired in V-mode and positive 
ion mode using a MALDI SYNAPT™ HDM S system (Waters Corporation, Manch­
ester, UK) operating with a 200 Hz Nd:YAG laser. The instrument calibration was 
performed using a standard mixture of polyethylene glycol (Sigma-Aldrich, Gilling­
ham, UK) ranging between m /z 100 to 3000 prior to MALDI-IMS-MSI analysis. Prior 
to MALDI-IMS-MSI experiments, digital scans of tissue sections were obtained using a 
CanoScan 4400F flatbed scanner (Canon, Reigate, UK) and then imported into MALDI 
Imaging Pattern  C reato r™  (Waters Corporation, Milford, MA) software. All data were 
acquired with ion mobility separation in the mass range from 800 Da to 3000 Da. Pep­
tide images were acquired at a spatial resolution of 2 0 0  //m with 600 laser shots per 
position. Using D riftscope™  (Waters Corporation, Milford, MA) software, mobility 
data of individual peptide signals were selected and extracted using M ALDIExtracb™  
(Waters Corporation, Milford, MA) software. The extracted data  were converted into 
imaging files using MALDI Imaging C onvertor™  (Waters Corporation, Milford, MA) 
software and ion images were generated with BioMap 3.7.5.5 software (Novartis, Basel, 
Switzerland).
6.2.6 Direct MALDI-IMS-MS/MS and MALDI-MS/MS data acqui­
sition
On-tissue MALDI-IMS-MS/MS and MALDI-MS/MS analyses were performed using 
a MALDI SYNAPT™ HDM S (Waters Corporation, Manchester, UK) using the same 
methodology as th a t described in chapter 5 (section 5.2.4).
MASCOT (Matrix Science, London, UK) query searches were performed against 
the UniProt database (release 56.0). W ithin the MASCOT search engine, the parent 
and fragment ion tolerances were set at 30 ppm and 0.1 Da respectively. The criteria 
also included up to two missed cleavages and the variable modifications allowed were 
protein N terminus acetylation, histidine/tryptophan oxidation, methionine oxidation 
and proline oxidation. De novo sequencing was performed manually and also using the 
PepSeq™  (Waters Corporation, Milford, MA) de novo interactive MS/MS sequencing 
tool. The parent and fragment ion tolerances were set at 0.1 Da and the threshold was 
set at 1%. Protein Blast searches against the Swissprot database were also performed 
to confirm tryptic sequences.
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6.2.7 MALDI- IMS-MS/MS imaging
Digital scans of the tissue sections were also obtained using a CanoScan 4400F 
flatbed scanner (Canon, Reigate, UK) prior to MALDI-IMS-MS/MS imaging. Imaging 
patterns were created using MALDI Imaging Pattern  C reato r™  (Waters Corporation, 
Milford, MA) software depending on the desired number of peptide ion signals to be 
monitored. Image acquisition was performed using the MALDI SYNAPTt ^H D M S 
system (Waters Corporation, Manchester, UK) with ion mobility separation at a spatial 
resolution of 300 /mi, as two MALDI-IMS-MS/MS images were acquired from one tissue 
section. Ion images were generated with BioMap 3.7.5.5 software.
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6.3 R esu lts and D iscussion
6.3.1 Evaluation of the method specificity
TMA technology allows several samples to be analysed simultaneously, thus min­
imising time, costs and the amount of samples required for the analysis. The specificity 
of the MALDI-MSI technique was demonstrated here by profiling adenocarcinoma and 
non-neoplastic tissue cores. Figure 6.2 displays the peptide profiles obtained after in 
situ digestion of a pancreatic cancer TMA, where different peptide profile patterns 
were observed when comparing adenocarcinoma and non-neoplastic cores. Peptide pro­
files were obtained using an U ltraflex™ II M ALDI-TOF/TOF instrument (Bruker Dal­
toniks, Bremen, Germany).
The method employed here was found to be very sensitive as peptide signals were 
detected above m /z 4000. Here, tissue needle cores defined as adenocarcinoma 1 , ade­
nocarcinoma 2 and non-neoplastic corresponded to the tissue core spots A l, A5 and II 
respectively as described in the TMA layout (figure 6.2a). These samples were diag­
nosed as stage IIA, moderately and poorly differentiated. When comparing MALDI-MS 
peptide profiles, differences in the peptide signals detected as well as peptide signal in­
tensities were noticed. This demonstrated the potential of the technique to differentiate 
tumour samples. Different peptide profiles were also observed when comparing tumour 
samples and non-neoplastic tissue cores. This shows the specificity of the methodology 
employed.
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Figure 6.2: T M A  layou t a n d  M A L D I-M S  p e p tid e  profiles o b ta in e d  a f te r  on- 
tis su e  d ig es tio n  o f F F P E  p a n c re a tic  ca n ce r T M A  sam ples.
(a) FFPE  pancreatic cancer TMA layout. Peptide profiles were acquired using an 
U ltraflex™ II M ALDI-TOF/TOF instrument (Bruker Daltoniks). (b) MALDI-MS 
spectra of peptides observed after in situ digestion of TMA samples: peptide pro­
files resulting from adenocarcinoma arid non-neoplastic cores are shown, (c) Expanded 
regions of the spectra. Differences in peptide signal intensities can be observed: the 
peptide signal at m /z 2072 was only detected in adenocarcinoma peptide profiles.
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6 .3 .2  D ir e c t  M A L D I -I M S -M S  a n d  M S /M S  a n a ly s is  o f  t i s s u e  m ic r o  
a r r a y  s e c t io n s
The layout of the pancreatic cancer TMA sections used here is displayed in figure 
6.3a. It comprised 90 needle core biopsies of 1 mm diameter each from tumour tissues 
spotted in duplicate and diagnosed as adenocarcinoma moderately, poorly or well differ­
entiated with their corresponding normal tissues. Figure 6.3b shows the TMA sections 
after matrix coverage prior to MALDI mass spectrometry imaging analysis. MALDI 
mass spectra were generated from each tissue section. Figure 6.3c displays an example 
of a mass spectrum, obtained from a tissue core after antigen retrieval treatm ent and 
in situ digestion, in the mass range m /z 800 to 3000.
a)
b)
Figure 6.3: T M A  la y o u t  a n d  M A L D I  m a s s  s p e c t r u m  o b ta in e d  f r o m  o n e  t is s u e  
c o re  a f t e r  in situ  d ig e s t io n  o f  F F P E  p a n c r e a t ic  t is s u e  m ic r o  a r r a y  s e c t io n s .
(a) Schematic TMA layout and (b) digital scan of the TMA after in-situ tryptic digestion 
and matrix coverage, (c) MALDI mass spectrum obtained from one tissue core after in 
situ digestion.
More than 500 individual peptide signals per spectrum were detected. From this 
mass list, peptide ions were selected for MS/MS analysis directly within the tissue sec­
tions. 320 peptide m /z values were randomly selected from the obtained mass spectra 
using Excel (Microsoft 2003). This aimed to obtain a mass list of high and low inten­
sity peptide signals for MALDI-MS/MS analyses. MALDI- MS/MS analyses were then 
acquired from these 320 peptide ions. To do so, the tissue micro-array glass slide was 
redefined as a MALDI spot target plate for an automatic MS/MS run as described in 
chapter 5 (section 5.2.4). Using automatic MALDI-MS/MS data acquisition directly
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from the TMA, it is not possible currently to use the IMS. However, the MASCOT 
database searches allowed the identification of numerous proteins. Manual acquisitions 
of MALDI-IMS-MS/MS spectra were also performed in order to achieve more protein 
identification. Figure 6.4a displays the D riftscope™  plot of the MS/MS fragmentation 
of the peptide ion at m /z 1477. This diagram shows the separation of ions based on 
their mobility where their corresponding driftime is plotted against their m /z values. 
Here, it can be noticed in figure 6.4b that two species were simultaneously detected at 
m /z 1477. Using their mobility, it was possible to separate the MS/MS spectrum of the 
fragmentation of the peptide from the unknown compound. The peptide was identified 
as a tryptic peptide arising from type I collagen alpha-2 chain (figure 6.4b). The other 
compound was not identified. Table 6.1 displays a list of tryptic peptide signals with 
their corresponding MASCOT identifications.
19509
D rift Tim e (B in s )
Figure 6.4: D r if ts c o p e ™  p lo t a n d  M A L D I-IM S -M S /M S  s p e c tru m  o f th e  ion 
signal a t  m /z  1477 ac q u ired  d ire c tly  from  F F P E  p a n c re a tic  T M A  tissu e  
sections.
(a) D riftscope™  plot of the MS/MS fragmentation of the ion signal at m /z 1477 where 
two isobaric compounds were simultaneously detected, (b) The MS/MS spectrum  of 
the peptide ion at m /z 1477 was separated from the interfering unknown compound 
using the ion mobility separation: the peptide was identified as type I collagen.
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Table 6.1: L ist o f  tr y p tic  p ep tid es  id en tified  a fter  in  s itu  d ig estio n  o f  
p an creatic  cancer T M A  sectio n s u sin g  d irect M A L D I-IM S -M S /M S .
All database searches for protein identification were performed using the 
UniProt human database.
P ro te in  n a m e / A c­ Mass Observed Mass Sequence MS/MS
cessio n  num ber (Da) peptide
m /z
error
(ppm)
ion
Score
A ctin , aortic 41982 1198.72 12.9 AVFPSIVGRPR 40
sm o o th  m u sc le /
P 6 2 7 3 6
1790.90 2.96 SYELPDGQVITIGNER 75
A ctin , cy to p la sm ic 41710 1954.06 0.78 VAPEEHPVLLTEAPLNPK 108
1 /  P 6 0 7 0 9
2215.08 4.22 DLYANTVLSGGTTMYPGIADR 61
A lb u m in / P 02768 69321 1149.63 15.4 LVNEVTEFAK 37
1311.73 7.05 HPDYSVVLLLR 57
B rea st cancer ty p e 207592 852.4 -19.81 NHQGPKR, oxidation (HW) 33
1 su scep tib ility
p r o te in /  P 3 8 3 9 8
C ollagen  alpha- 138799 886.44 0.87 GSEGPQGVR 30
1 (1 ) /  P 02 4 5 2
898.51 -4.91 GVVGLPGQR, oxidation (P) 18
1088.56 17.2 GFPGADGVAGPK, oxidation (P) 18
1105.56 -14.13 GVQGPPGPAGPR, oxidation (P) 35
1297.62 8.77 GESGPSGPAGPTGAR 39
1302.63 -13.69 GPSGPQGPGGPPGPK, oxidation (P) 42
1459.68 -6.41 GSAGPPGATGFPGAAGR, 2 oxidation (P) 50
1465.69 -2.99 GEPGPTGLPGPPGER, 3 oxidation (P) 60
1546.78 -13.88 GETGPAGPAGPVGPVGAR 74
1561.78 -12.57 DGLNGLPGPIGPPGPR, 3 oxidation (P) 42
1655.78 -8.25 GSPGEAGRPGEAGLPGAK, 3 Oxidation
(P)
19
1690.78 0.74 DGEAGAQGPPGPAGPAGER 45
1706.75 -11.59 DGEAGAQGPPGPAGPAGER, oxidation
(P)
100
1742.77 18.2 GEPGSPGENGAPGQMGPR, oxidation 
(M); 2 oxidation (P)
31
1812.88 -2.40 VGPPGPSGNAGPPGPPGPAGK, 3 oxida­
tion (P)
22
1816.85 -9.90 GPPGPMGPPGLAGPPGESGR, 2 oxida­
tion (P)
51
1832.85 -2.95 PPGPMGPPGLAGPPGESGR, Oxidation 
(M); 2 Oxidation (P)
68
Continued on Next Page.
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Table 6.1 -  Continued
P r o te in  n a m e / A c­ Mass Observed Mass Sequence MS/MS
cessio n  num ber (Da) peptide
m /z
error
(ppm)
ion
Score
1848.85 -2.88 GPPGPMGPPGLAGPPGESGR, Oxidation 
(M); 3 Oxidation (P)
34
2003.95 -11.65 GEPGPVGVQGPPGPAGEEGKR, 2 oxida­
tion (P)
55
2198.99 12.10 GDAGAPGAPGSQGAPGLQGMPGER, 4 
oxidation (P)
67
2454.23 -1.06 GPPGSAGAPGKDGLNGLPGPIGPPGPR, 
4 oxidation (P)
20
2703.23 -4.11 GAPGDRGEPGPPGPAGFAGPPGADGQ  
PGAK, 4 oxidation (P)
16
2705.29 -9.56 GFSGLQGPPGPPGSPGEQGPSGASGPA  
GPR, 3 oxidation (P)
58
2869.39 -4.86 GLTGPIGPPGPAGAPGDKGESGPSGPAG  
PTGAR, 2 oxidation (P)
72
C ollagen  alpha- 129333 1184.49 -0.33 DGNPGNDGPPGR, 2 Oxidation (P) 44
2 (1 ) /  P 08 1 2 3
1217.62 -0.45 NPARTCRDLR, oxidation (P) 19
1235.63 -11.37 TGHPGTVGPAGIR, oxidation (P) 36
1267.67 -0.27 GIPGP V G A AG ATG AR, oxidation (P) 9
1477.73 -14.66 GLHGEFGLPGPAGPR, oxidation (P) 65
1562.78 -9.65 GETGPSGPVGPAGAVGPR 36
1619.77 -7.25 GPNGEAGSAGPPGPPGLR, 2 oxidation
(P)
58
1664.72 -29.36 AGEDGHPGKPGRPGER, 3 oxidation (P) 11
1766.78 -24.95 GPNGDAGRPGEPGLMGPR, 2 oxidation
(P)
13
1775.86 -10.73 RGPNGEAGSAGPPGPPGLR, 2 oxidation
(P)
53
1829.90 -0.52 TGPPGPSGISGPPGPPGPAGK, 3 oxida­
tion (P)
11
1845.91 5.05 TGPPGPSGISGPPGPPGPAGK. 4 oxida­
tion (P)
16
2567.22 -16.74 GENGVVGPTGPVGAAGPAGPNGPPGP  
AGSR, oxidation (P)
28
2832.33 -6.84 GEQGPAGPPGFQGLPGPSGPAGEVGK  
PGER, 3 oxidation (P)
13
2865.36 -20.55 GPKGENGVVGPTGPVGAAGPAGPNGPP 
GPAGSR., 2 oxidation (P)
20
C ollagen  alpha- 138470 1138.57 -0.23 GLAGPPGMPGPR, oxidation (M); oxida­ 16
l ( I I I ) /  P 02461 tion (P)
1508.68 -15.99 GESGPAGPAGAPGPAGSR, oxidation (P) 41
Continued on Next Page.
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Table 6.1 -  Continued
P r o te in  n a m e / A c ­
cessio n  num ber
Mass
(Da)
Observed
peptide
m /z
Mass
error
(ppm)
Sequence MS/MS
ion
Score
1530.72
2539.13
2641.26
2950.44
-8.94
-4.58
0.05
-7.73
DGTSGHPGPIGPPGPR, 2 Oxidation (P) 
GETGPPGPAGFPGAPGQNGEPGGKGER, 
4 Oxidation (P)
GEGGPPGVAGPPGGSGPAGPPGPQGVK  
GER, 4 Oxidation (P) 
GPTGPIGPPGPAGQPGDKGEGGAP 
GLPGIAGPR, 4 Oxidation (P)
52
25
19
54
B a sic  fibroblast 
gro w th  factor re­
cep to r  1 /  P 11362
91809 1832.95 -12.19 TVKFKCPSSGTPNPTLR 15
78 k D a  g lu cose-  
reg u la ted  p rote in  
(G r p 7 8 ) / P 11021
72288 1887.95
1934.00
12.9
6.23
VTHAVVTVPAYFNDAQR
DNHLLGTFDLTGIPPAPR
10
76
H a em oglob in  al­
p h a /  P 69905
15258 1087.57
1529.74
17.3
2.57
MFLSFPTTK, oxidation (M) 
VGAHAGEYGAEALER
26
115
H a em oglob in  b e t a /  
P 68 8 7 1
15988 1274.73 2.22 LLVVYPWTQR 27
H isto n e  H 2 A .Z /  
P 0C 0S 5
13545 944.53 -5.55 AGLQFPVGR 26
H isto n e  H 2 B /  
P 3 3 7 7 8
13942 1775.84 20.6 AMGIMNSFVNDIFER, 2 oxidation (M) 36
H isto n e  H 3 -lik e /  
Q 6 N X T 2
15204 1032.59 4.15 YRPGTVALR 19
H isto n e  H 4 /  
P 62 8 0 5
11360 1325.74
1466.80
7.59
-3.72
DNIQGITKPAIR
TVTAM DW YALKR
39
29
P a n crea tic  a lph a- 
a m y la se / P 04 7 4 6
57670 1427.70 2.60 ALVFVDNHDNQR 59
P a n crea tic  tr ia cy l-  
g ly cero l lip ase  pre­
c u r so r / P 16 2 3 3
51124 1746.90 19.58 FIWYNNVINPTLPR 58
P e r io s t in /  Q 15063 93255 1400.78 6.62 AAAITSDILEALGR 75
P ro to ca d h er in -1  /  
Q 08174
114676 1141.71 -22.74 QPQLIVMGNLDR, acetyl (N-term); xida- 
tion (M)
20
S e r in e /t  hreonine- 
p ro te in  k in a se /  
Q 9Y 3S1
242525 1327.72 6.13 GLTLPCLPWRR, oxidation 23
Continued on Next P age...
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Table 6.1 — Continued
P ro te in  n a m e / A c­
cessio n  num ber
Mass
(Da)
Observed
peptide
m /z
Mass
error
(ppm)
Sequence MS/MS
ion
Score
T um or necrosis  
factor  recep to r  su ­
perfam ily  m em b er  
10A /  0 0 0 2 2 0
50029 1105.63 2.98 AGRAPGPRPAR 19
Zinc finger p rote in  
2 1 9 /  Q 9 P 2 Y 4
76830 1303.65 6.08 AGPGGEAGPGGALHR 23
6.3.3 Principal component analysis-discriminant analysis (PCA-DA) 
of tissue micro-array sections
Principal component analysis (PCA) is a statistical method commonly used for re­
ducing the dimensionality of a multivariate data set whilst retaining most of the original 
information. Discriminant analysis (DA) is often used to define a classification from an 
observation of pre-defined groups. PCA-DA is a two stage supervised statistical tech­
nique, the number of variables in the data  set is first reduced by the use of PCA before 
a second discriminant analysis is performed. PCA-DA takes into account user supplied 
information about external variables (group information) when reducing the dimension­
ality of the datasets in the first stage. Therefore, it is better suited than  PCA for 
clustering analysis [15]. Here, PCA-DA was used as a statistical analytical method 
with the aim of generating a classification model based on sample clusters defined by 
PCA. Peptide profiles obtained from MALDI-IMS-MS imaging of TMA sections were 
evaluated by principal component analysis-discriminant analysis (PCA-DA). For this 
analysis, the selected peptide profiles were de-isotoped with MASCOT D istiller™  soft­
ware and the resulting peak lists were used for PCA-DA. Each peak list consisted of 
300 individual peptide signals. An exclusion peak list containing m atrix adducts as 
well as trypsin peptide peaks was used. PCA-DA consisted of assessing if a model of 
classification could be generated and then validating these results using another set of 
data.
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6.3.3.1 P C A -D A  of a  tra in in g  se t o f d a ta  for th e  g e n e ra tio n  o f tu m o u r  
c lassifica tion  m odels
Peptide profiles obtained from adenocarcinoma cores were separated into two data 
sets: the first data set was used as a training data set in order to generate a model of 
classification and the second was used as a test data  set for validating the classification 
model [24]. Then PCA-DA was conducted on peptide profiles from the training data set 
in order to assess possible differences between adenocarcinoma cores. For this purpose, 
40 spectra obtained from the adenocarcinoma cores were loaded into Marker View2 M
1.2 software for PCA-DA. The results of PCA-DA is visualised as a projection of scores 
and loadings plots. The scores plots represent the variance of the original variables, 
i.e. the obtained sample groups. The loadings plots describe the variable behaviour 
and differences between the observed groups. Figures 6.5a and b display the obtained 
scores and loading plots respectively. The scores plots show that spectra were grouped 
in 3 classes. For result interpretation purposes, the group defined by the blue spots 
was named group 1; group 2 and group 3 were defined by the red and green spots 
respectively.
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Figure 6.5: P C A -D A  o f p e p tid e  profiles e x p o rte d  from  M A L D I-IM S -M S  im ­
ages o f F F P E  p a n c re a tic  tu m o u r  T M A  sections.
(a) Tumour samples were separated into three groups by PCA-DA, which are indicated 
by the blue, red and green spots, (b) The loading scores indicate characteristic ion 
masses which are specific to a given group.
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Examination of the data  showed that spectra obtained from duplicate biopsies of the 
same tumour were contained in the same group. This demonstrates th a t the method 
is potentially reproducible. In the scores plot (figure 6.5a), it can be noticed tha t D1 
scores separates group 1 from group 2 and group 3. Group 2 and group 3 are also 
separated as they display negative and positive values of D2 respectively. According to 
the pathological classification provided with the TMA samples, group 2 and group 3 
present the same tumour grade and lymph node stage. Here using MALDI-MSI followed 
by PCA-DA, separations between the tumour samples, which were not highlighted using 
the conventional tumour metastasis node (TMN) classification, were obtained based on 
direct proteomic analysis. Examination of the loading plots (figure 6.5b) revealed tha t 
several peptide signals were found to be characteristic of a given group.
In order to assess if the peptide signals highlighted in the loading scores were sta­
tistically significant so as to enable the classification of tumour samples, a t-test was 
performed using M arkerView™  1.2 software. Each tumour group was compared to the 
other two in terms of obtained peptide profiles. The t-test was found to be in good 
agreement with the results obtained with PCA-DA as it highlighted the same peptide 
m /z values which were found to be characteristic of a tumour group when performing 
PCA-DA. Figure 6 . 6  displays the mean of the peptide signal intensities and standard 
deviation of the peptide signal intensities in each group. Several peptide signals were 
found to be characteristic of each given group.
Group 1 (n =  15) was compared to group 2 (n =  10) and group 3 (n =  10). The pep­
tide signal at m /z 1105, identified as a peptide T8-9 arising from tumour necrosis factor 
receptor, was found to be highly intense in group 1  when compared to group 2  and group 
3. Peptide signals at m /z 1325 and 1327, arising from histone H4 and serine/threonine 
protein kinase respectively, were also found to be significantly characteristic of group 
1. When comparing group 2 (n =  10) to groups 1 and 3, and group 3 (n =  10) to 
group 1  and group 2 , it can be noticed th a t several peptide signals were found to  be 
of high intensity in a given group, hence allowing the discrimination between classes. 
The results obtained from the t-test were found to be in good agreement with those 
obtained from PCA-DA (figure 6.5). Here the PCA-DA based on high-throughput pep­
tide profiles obtained with MALDI-IMS-MSI allowed significant discrimination between 
tumour samples.
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Figure 6.6: Comparison of the mean of peptide signal intensities between tum our classes using a t - te s t .
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6 .3 .3.2 V a lid a tio n  o f th e  tu m o u r  c lassifica tion  m odel u sing  a  te s t  d a ta  se t
PCA-DA of the first set of data  allowed the generation of a classification model 
in which peptide profiles obtained from tumour tissue cores were distinguished. The 
second step of the statistical analysis was assessing if the model generated correctly 
described and classified tumour tissue sections using another data set obtained from 
the TMA. For this purpose, PCA-DA was performed on 35 other spectra. Figure 6.7a 
displays the obtained scores where tumour groups were noticed.
•V '  •  '  !«-• t .  y ■ *• '7 # •Z’j
* ^  91551
89048 1
|  J67f!
'1406 75 * 4
Figure 6.7: V a lid a tio n  o f th e  P C A -D A  re su lts  u s in g  a n o th e r  se t o f d a ta .
Discrimination between tumour samples was obtained when examining (a) the resulting 
scores plots and (b) loading plots.
In the loading plots (figure 6.7b), several peptides were found to be class identi­
fiers. More interesting is the highlight of the same peptide signals, which were found 
to be class identifiers from the training set, as characteristic masses for distinguishing 
tumour groups in the test set. It can be noticed for instance that the peptide signal 
at m /z 2915, which corresponds to a tryptic peptide of histone H2A, was found to be 
highly intense in a tumour group obtained with the test data set. This demonstrates 
that the methodology used here is potentially robust. These results were found to be 
in agreement with those obtained from the PCA-DA of the training da ta  set. The 
methodology described here allowed the validation of proof-of-principle as it shows tha t 
tumour classes were generated based on molecular information i.e. protein distribu­
tion and in situ identification within pancreatic cancer TMA using MALDI-IMS-MSI
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combined with PCA-DA.
Additionally a discrimination between non-neoplastic and tumour cores were ob­
tained. This highlights the specificity of the methodology. A total of 54 spectra were 
used for PCA-DA. Figure 6.8a displays the scores plots where group separation can 
be noticed. Peptide profiles obtained from normal tissue sections are separated from 
those obtained from tumour tissue cores. Examination of the data obtained from the 
loading plots (Figure 6.8b) highlights several peptide signals, including peptides at m /z 
944, 1198, 1400 and 1477, which were identified as tryptic peptides arasinf from histone 
H2A, actin, periostin and type 1 collagen alpha-2 chain respectively, which were found 
to be highly intense in tumour samples.
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Figure 6.8: P C A -D A  o f p e p tid e  profiles e x p o rte d  from  M A L D I-IM S -M S  im ­
ages o f tu m o u r  a n d  n o n -n eo p la s tic  tis su e  cores o f F F P E  p a n c re a tic  T M A  
sections.
(a) The obtained scores plots display tha t non-neoplastic tumour samples are distin­
guished from tumour samples as well as discrimination between tumour samples, (b) 
The loadings plot highlights peptide ions that are specific to the obtained groups.
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6 .3 .4  M A L D I -I M S -M S  im a g in g  o f  t i s s u e  m ic r o -a r r a y  s e c t io n s  a n d  F F P E  
p a n c r e a t ic  tu m o u r  t i s s u e  s e c t io n s
Using MALDI-IMS-MSI, peptide distributions within the tissue microarray sections 
were also generated. Figure 6.9 shows the distribution of some observed peptide signals 
within the TMA sections. Images were normalised against the m atrix ion signal at m /z 
867. These peptides were identified as actin, periostin, haemoglobin alpha-chain and 
histone H2A respectively. The results obtained from imaging analysis were in good 
agreement with those obtained from PCA-DA.
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Figure 6.9: M A L D I-IM S -M S  im ages o f th e  lo ca lisa tio n  o f p e p tid e s  w ith in  
F F P E  p a n c re a tic  T M A  sec tio n s  a f te r  in  s itu  d igestion .
The distributions of (a) actin, (b) periostin, (c) haemoglobin alpha chain and (d) histone 
H2A are displayed.
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c) m/z 1477 collagen I
FFPE pancreatic tumour tissue sections were subsequently analysed using MALDI- 
IMS-MSI. The data generated from statistical analysis of the pancreatic tumour tissue 
microarray allowed the selection of characteristic ion signals that were used for high­
lighting tumour regions. Figures 6.10a, b and c display the distribution of ion signals 
at m /z 944, 1032 and 1477, identified as histone H2A, histone H3 and type I collagen 
respectively. These were found to be located in the tumour regions. Figures 6.10d, e 
and f show the HE staining images of the tissue section were tumour regions are high­
lighted. The HE staining pictures were found to be in good agreement with the obtained 
MALDI-IMS-MS images.
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Figure 6.10: Im ag es o f th e  d is tr ib u t io n  o f p e p tid e s  w ith in  a  F F P E  p a n c re a tic  
tu m o u r  tis su e  section .
(a-c) MALDI-IMS-MS images of the distribution of histone H2A, histone H3 and type 
I collagen tryptic peptides respectively. Images were normalised against the m atrix 
adduct at m /z 877. (d) HE staining of a FFPE  human pancreatic cancer with the 
localisation of tumour regions, (e) and (f) are microscopic images acquired from tumour 
regions 1 and 2 of figure 6.10d at magnification xlO showing tumour cells.
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Tumour necrosis factor receptor was also detected and identified from FFPE  pan­
creatic cancer tissue sections. The upper panel of figure 6.11 (figure 6.11a) displays 
the resulting MALDI-IMS-MS/MS spectrum of the ion signal at m /z 1105 identified 
directly from FFPE  pancreatic tissue sections as a tryptic peptide arising from tumour 
necrosis factor receptor. The lower panels of figure 6.11 (figure 6.11b, c, d and e) dis­
play MALDI-IMS-MS/MS images of the distribution of tumour necrosis factor receptor 
tryptic peptide at m /z 1105 as well as some y and b product ions including ys (m/z 
821), b 7  (m /z 607) and bs (m /z 453).
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Figure 6.11: M A L D I-IM S -M S /M S  s p e c tru m  a n d  im ages o f th e  d is tr ib u t io n  
o f tu m o u r  necrosis fac to r  re c e p to r  w ith in  a  F F P E  p a n c re a tic  tu m o u r  tis su e  
section .
(a) MALDI-IMS-MS/MS spectrum of the peptide signal at m /z 1105 which was identi­
fied as arising from tumour necrosis factor receptor, (b-e) MALDI-IMS-MS/MS images 
of the distribution of product ions of the tumour necrosis factor receptor tryptic peptide 
signal at m /z 1005.
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6.4 Concluding Rem arks
Pancreatic cancer is the 10th most common cancer in the UK but the 6 th  most com­
mon cause of cancer death. Many patients present late with inoperable disease. Current 
limited therapeutic options include surgical resection and chemotherapy; however this 
cancer is still associated with a very poor prognosis [16]. The most recent national 
figures for the United Kingdom show a 1 year survival of 13% and a 5 year survival 
of 2-3% overall. Where possible, surgical resection offers the best chance of extended 
survival with a median survival of 11-20 months (5 year survival 7-25%) compared to 
6-11 months for patients with Stage III (non resectable locally advanced) disease and 
2 - 6  months for patients with m etastatic disease.
There are no globally recognised classification systems for pancreatic tumours. The 
most clinically relevant current classification technique relies on radiological staging into 
potentially resectable, locally advanced or non-resectable and m etastatic disease. Novel 
tumour classification systems are required in order to improve clinical diagnosis and 
treatm ent.
In the work reported here, a novel methodology for pancreatic tumour classification 
models is described using MALDI-IMS-MSI and PCA-DA analysis of tissue micro-array 
sections. Using this strategy, high-throughput analysis of TMA sections by MALDI- 
IMS-MSI allowed the visualisation of numerous peptides within the tissue sections after 
in situ enzymatic digestion. The differences obtained in peptide profiles reflect the com­
plexity and heterogeneity of the molecular nature of the disease. In the work reported 
here, distinct peptide profile patterns obtained by MALDI-IMS-MSI have contributed to 
generating classes of pancreatic tumour using PCA-DA. Discriminations between pep­
tide profiles and images obtained from adenocarcinoma cores were observed. In some 
cases, tumour samples presenting the same pathologic classification (tumour grade, 
lymph node stage) were found to be significantly different after performing PCA-DA. 
Using other sets of data, the methodology was validated as tumour classes which exhib­
ited the same peptide tumour class identifiers as the training data set were generated. 
This demonstrates the robustness of the method. A proof-of-concept was hence estab­
lished, since MALDI-MSI combined with PCA-DA of TMA sections allowed the design 
of a novel molecular tumour classification model based on in situ proteomic information.
Concluding Remarks 243
Several peptides were found to be characteristic of an obtained tumour class. D ata such 
as those could be used to build a proteomic platform or database of peptides and/or 
proteins tha t can help to distinguish between samples with known or unknown clinical 
outcomes. Indeed the methodology reported here allowed tumour classification, and also 
spatial localisation and in situ identification of several peptide candidates from TMA 
sections in a single experiment and therefore fewer samples were required compared 
to other classical proteomic approaches. The in situ identification of several proteins 
directly from the tissue sections was also achieved.
The use of ion mobility separation combined with MALDI-MSI has been found to 
be beneficial for the study of proteome patterns and their identification directly within 
TMA cores as it allowed the generation of the exact distribution of peptides within tis­
sue sections by minimising peak interferences and hence facilitated the database search 
for protein identification. Several peptide signals were identified as type I collagen which 
was found with a high signal intensity within tumour tissue cores. These results confirm 
previous studies which described an up-regulation of type I collagen in pancreatic can­
cer cells which promotes the proliferation of cancer cells [17]. Tumour necrosis factor 
receptor (TNFR) was also identified in the pancreatic TMA. It has been reported th a t 
tumour necrosis factor was found to be over-expressed in patients with pancreatic can­
cer and tha t it is involved in metabolic changes associated with cancer [18]. However, 
further analyses are required in order to explain these findings and to correlate them  
with clinical information.
It can be noticed th a t although about 300 MS/MS spectra were acquired for protein 
identification, only about 1 0 0  signals have been identified to date; numerous peptides 
remained unidentified following MS/MS analyses and protein database searches. This 
can be explained by existing post-translational modifications as well as protein variants. 
Method improvements including de novo sequencing are required in order to identify 
these modifications and identify further proteins.
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FFPE  pancreatic cancer tissue sections were also investigated with MALDI-IMS- 
MSI. Using the characteristic peptides of the tum our region highlighted by the statis­
tical analysis, the results were in good agreement with those obtained with histological 
staining in terms of located tumour regions.
The outline strategy described here allowed the rapid screening of the distribution 
of peptides and their identification after in situ digestion of FFPE  pancreatic tumour 
tissue micro-array sections using MALDI-ion mobility separation- mass spectrometry 
profiling and imaging. The results obtained from the statistical analysis of the di­
rect peptide imaging of TMA sections demonstrated tha t a novel tumour classification 
model based on direct proteome information is feasible. However a large number of 
samples with more detailed clinical information including survival, time to recurrence 
and chemoresponsiveness are required. Here one of the limitations of the study has 
been tha t only limited clinical information is obtained with a commercial TMA. Even 
so, this enabled the establishment of a methodology for molecular tumour classification 
using MALDI-MSI and PCA-DA.
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7.1 Introduction
Molecular imaging is one of the techniques of choice to investigate the complexity of 
the spatial localisation of proteins contained in biological tissue sections. MALDI-mass 
spectrometry is becoming a translational research tool with the potential to be used in 
clinical studies as it allows the study of the distribution of several compounds including 
peptides and proteins directly within tissue sections and hence provides molecular in­
sights into the complexities of biological processes. However, in order for the technique 
to be fully established as a routine tool and to be used at the optimum of its perfor­
mance, several limitations associated with the currently available instrum entation need 
to be overcome and resolved [1, 2 ]. Among these limitations are those which are asso­
ciated with the spatial resolution of the image, the sensitivity and the data acquisition 
time.
Improvements in mass spectrometry instrumentation have resulted in enhanced mass 
accuracy and resolution as well as sensitivity and data  acquisition time. Hence MS 
technologies are often used for high throughput analysis in several fields, including pro- 
teomics [3]. In the case of MALDI-MS, these improvements include the design of new 
laser technologies as well as electronics and optics devices [4-7]. The laser type is a key 
feature to take into account for MALDI-MSI experiments as it influences the amount 
of ions generated in the source, the image resolution and also the data acquisition time 
[2 , 6 ]. Common standard nitrogen (N2 ) lasers are being replaced by solid-state lasers 
for MALDI-MS profiling and imaging experiments. Traditional N2  lasers provide a high 
energy power, however they operate at a shot-to-shot repetition rate comprised of 1 - 
30 Hz [4]. Since several laser shots, typically between 100 and 1000, are required to 
generate spectra per position during a MALDI-MS image acquisition, this can result in 
data  acquisition times of several hours, up to 60 hours in some cases, depending on the 
tissue section area to be analysed [2] and the spatial resolution required. Orthogonal 
MALDI-TOFMS (o-MALDI-TOFMS) instrument geometries have the ability to oper­
ate at 10 kHz which allows the detection of a continuous ion beam from the source, 
hence considerably enhancing the sensitivity. However this capacity is limited when 
using standard N2  lasers which have a repetition rate of 1-30 Hz.
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The introduction of solid-state lasers, which have a higher repetition rate (between 
1  and 10 kHz) than standard N2  lasers, has been shown to improve high throughput MS 
and MALDI-MS imaging data  acquisition by enhancing the ion yield and hence the sig­
nal intensity, while maintaining data  quality in terms of mass accuracy and sensitivity
[4]. The use of Nd:YAG (neodymium-doped yttrium  aluminium garnet; NdiYsAlsO]^) 
lasers has been reported as an improvement in MALDI-MSI instrum entation [8 - 1 0 ]. 
Nd:YAG lasers have a long lifetime, good reproducibility and high repetition rate com­
pared to N2  lasers. Sm artbeam ™  (Bruker Daltoniks, Bremen, Germany) laser tech­
nology has been reported and allows modulation of the Nd:YAG laser beam over the 
tissue surface [8 ]. This results in a more focused laser beam with a laser pulse which 
has been found to be compatible with a wide range of matrices and increases ionisation 
of several compounds. 1  kHz repetition rate Nd:YAG lasers have also been described 
to be used in a dynamic pixel mode which involves a figure of eight movement of the 
focused laser beam within each spot, thus allowing the desorption of several analytes
[11]. Using high repetition rate solid state lasers can result in improved image sen­
sitivity and resolution as well as allowing fast data  acquisition. Recently, the use of 
continuous laser ablation rastering across the tissue section has been shown to reduce 
considerably MALDI-MS imaging data acquisition time, while preserving an acceptable 
image resolution and sensitivity [1 2 ].
The aims of this chapter are to evaluate a 20 kHz repetition rate  solid-state laser 
for performing continuous laser raster MALDI-MS imaging and multiple reaction mon­
itoring MALDI-MS imaging (MRM-MALDI-MSI) of peptides after in situ digestion of 
tumour tissue sections. The MRM-MALDI-MSI analysis of peptides directly within in 
situ digested tissue sections, described in this work, has demonstrated a novel proof- 
of-principle which combines the dynamic pixel scanning mode capability offered by the 
instrument with MRM analysis and may allow specific images of monitored peptide 
fragments. This may improve the sensitivity of the MALDI-MSI methodology and as 
well as provide an approach to relative quantification of peptide signals within directly 
within tissue sections. The current limitations and advantages of the methodologies 
employed are discussed.
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7.2 M aterials and M ethods
7.2 .1  M aterials
Modified sequence grade trypsin was purchased from Promega (Southampton, UK). 
All other materials, including alpha-cyano-4-hydroxycinnamic acid (cr-CHCA), aniline 
(ANI), ethanol (EtOH), methanol (MeOH), chloroform (CHCI3), xylene, octyl-ex./(3- 
glucoside (OcGlc), trifluoroacetic acid (TFA), haematoxylin, eosin, hydrogen peroxide 
(H2 O2 ), tri-sodium citrate and ammonium bicarbonate were purchased from Sigma- 
Aldrich (Dorset, UK).
7 .2 .2  T issu e sam ples
7.2.2.1 Rat brain tissue samples
Rat brain samples were obtained from the Sheffield Hallam University laboratory 
(Biomedical Research Centre, Sheffield Hallam University, Sheffield, UK) directly after 
animal sacrifice. Samples were immediately snap-frozen in liquid nitrogen and stored at 
-80°C to minimize protein degradation through enzymatic proteolysis and to preserve 
the sample morphology.
7.2.2.2 Human formalin fixed paraffin embedded (FFPE) pancreatic tu ­
mour samples
Following fully informed patient consent and full ethical committee approval anonymi- 
sed 5 //m ex vivo human FFPE  pancreatic tum our tissue sections were obtained (Study 
Number SSREC/04/Q2305/67 and subsequent amendments). Tissue samples were fixed 
in 10% buffered formalin for 24 hours, dehydrated in 70% EtOH and paraffin embedded. 
5 //m sections were cut using a cryostat (Leica Microsystems, UK) and mounted onto 
histological Polysine™  glass slides (Menzel-Glaser, Germany). FFP E  tissue sections 
were stored at room tem perature until further analysis.
7 .2 .3  T issu e preparation
Frozen ra t brain tissue samples were cut using a cryostat (Leica Microsystems, 
UK) operating at -20°C. 10 //m sections were cut and thaw-mounted onto histologi­
cal Polysine™  glass slides (Menzel-Glaser, Germany). Washing procedures were per­
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formed to increase the MS data  quality: the rinsing steps consisted of immersing the 
section for 1  min in cold ethanol solutions (stored at -20°C) at 70 and 90% followed by 
a 30 second wash in chloroform (CHCI3 ). Sections were then allowed to dry at room 
tem perature before digestion and m atrix deposition.
Prior to on-tissue digestion and matrix deposition, FFPE  pancreatic tum our tissue 
sections were prepared as described in chapters 5 and 6  (sections 5.2.3 and 6.2.3).
7 .2 .4  T rypsin  and m atrix  d ep osition
Trypsin solution was made at 20 fig/m l in 50 mM ammonium bicarbonate buffer 
(pH =  8.1) containing 0.1 % octyl glucoside (OcGlc). The methods used for in situ 
digestion of both frozen ra t brain and FFPE  pancreatic tumour tissue sections were 
the same as described in chapter 5 (section 5.2.3.1) using a SunCollect™  autom atic 
sprayer (SunChrom, Friedrichsdorf, Germany).
a-CHCA mixed with aniline (a-CHCA/ANI), prepared at 5 m g/m l in 50% ACN:0.2% 
TFA, was used as the m atrix for peptide analysis. The m atrix deposition onto the 
tissue sections was performed using a SunCollect7^  automatic sprayer (SunChrom, 
Friedrichsdorf, Germany).
7.2 .5  D irect M A L D I-M SI analysis
MALDI-MSI experiments were performed using a modified Q-Star®  Pulsar i quadru- 
pole time-of-flight mass spectrometer (Applied Biosystems/MDS Sciex, Concord, On­
tario, Canada) fitted with an oMALDI-™ 2 (Applied Biosystems/MDS Sciex, Concord, 
Ontario, Canada) orthogonal MALDI source. The original laser was replaced with a 20 
kHz repetition rate solid state yttrium  vanadate (Nd:YV0 4 ) laser (Elforlight Ltd, Dav- 
entry, UK). The Nd:YV0 4  laser was used at a power of 2.9 fiJ and a repetition rate of 5 
kHz. Areas of the tissue sections to be imaged were defined using oMALDIrM  Server 5.1 
software (Applied Biosystems/MDS Sciex, Concord, Ontario, Canada). Prior to da ta  
acquisition, instrument calibration was performed using a standard mixture of peptides 
(Applied Biosystems/MDS Sciex, Concord, Ontario, Canada) ranging from m /z  900 to 
1800. D ata acquisition was performed in the mass range m /z 800 to 2000. Images were 
obtained with a spatial resolution of 150/mi X 150/mi using Raster im age™  acquisi­
tion with a slow speed setting. Ion images were processed using oMALDI-™ Server 5.1
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software (Applied Biosystems/MDS Sciex, Concord, Ontario, Canada).
7.2 .6  M R M -M A L D I-M S im aging d ata  acqu isition
In order to perform MRM experiments, the m /z value of the compound of interest, 
here the peptide, must be known as well as its fragment ions and hence their MS/MS 
fragmentation patterns [13]. MS/MS analyses were performed on some peptides in order 
to define the collision-induced dissociation (CID) parameters which should be used for 
the MRM analysis. In the MS/MS method used here, the collision energy and the colli­
sion gas were set at 90 and 20 respectively. MS/MS peptide sequencing was performed 
with a quadrupole operating at a low resolution. MRM-MALDI-MSI data  acquisition 
was achieved using the same CID parameters as for the MS/MS analyses, enhancing the 
signal response in the desired mass range for MRM scanning. MRM-MALDI-MS im­
ages were acquired at 400 /zm spatial resolution in a spot-to-spot acquisition mode with 
dynamic pixel. In the work reported here, based on direct MALDI-MS/MS analyses 
performed on human FFPE  pancreatic tumour tissue sections (described in chapters 5 
and 6 ), 8  peptide mass signals, identified as arising from several proteins including actin, 
glucose-regulated protein 78 kDa (Grp78), haemoglobin alpha and beta, histone H2A, 
pancreatic alpha-amylase, periostin and tumour necrosis factor receptor, were selected 
for MRM screening.
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7.3 R esu lts and D iscussion
7.3 .1  M A L D I-M S raster im aging w ith  a 20 kH z rep etitio n  ra te  laser
Conventional MALDI-MSI experiments performed in microprobe mode involve a 
spot-to-spot laser ablation across the tissue section, so th a t mass spectra are recorded 
from an individual position during a certain accumulation time followed by a switch off 
of the laser while the plate stage is moved to the adjacent position. This results in a 
spot-to-spot data  acquisition, where the distance between laser spot centres defines the 
image resolution. High resolution MALDI-MS images have been produced using this 
method, however the observed data  acquisition time was very long, up to 55 hours in 
some cases [2]. Here, MALDI-MS images of peptide localisation were obtained within 
a frozen ra t brain tissue section after in situ digestion using a continuous laser raster 
imaging mode. Figure 7.1 shows the distribution of peptide signals within the tissue 
section. Images were normalised against the m atrix peak at m /z 1066.
For the acquisition of the images shown in figure 7.1, the continuous laser rastering 
imaging mode was performed at a fast speed setting. This was found to considerably 
decrease the sensitivity and also produced dead pixels in the resulting images. However, 
the advantage of using a high repetition rate laser is demonstrated here as the images 
produced of peptide localisation within the tissue section allowed the discrimination 
of regions associated with the ra t brain morphology. Even if a poor resolution was 
observed, it can be noticed tha t the peptide signal at m /z 1274 (figure 7.1f), which has 
been identified as arising from haemoglobin beta, was found to be localised at the edge 
of the tissue section where blood was observed after animal sacrifice.
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Figure 7.1: Im ages o f p e p tid e  d is tr ib u t io n  w ith in  a  frozen  r a t  b ra in  tis su e  
sec tio n  o b ta in e d  w ith  M A L D I-M S  ra s te r  im ag ing  a f te r  in  s itu  d igestion .
A 20 kHz repetition rate laser was used for continuous laser raster imaging. The dis­
tribution of several peptide signals, including (a) m /z 851, (b) m /z 1572, (c) histone 
H2A, (d) histone H3, (e) myelin and (f) haemoglobin beta, within the tissue section was 
obtained.
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FFPE  pancreatic tumour tissue sections were also imaged using a continuous laser 
raster imaging mode. Figure 7.2 displays the obtained MALDI-MS raster images of 
peptide distribution within an in situ digested FFPE  pancreatic tumour tissue sec­
tion. The localisations of the actin, histone H2A, tumour necrosis factor receptor and 
haemoglobin beta and alpha within the tissue section were shown.
Here, continuous laser raster imaging was performed at a slow speed setting, so that 
dead pixels were not observed in the obtained images. Using a slow speed laser raster 
was also found to improve the signal sensitivity when compared to the images obtained 
at a fast speed laser setting. It can also be noticed tha t the resulting peptide images 
were comparable to those obtained using a MALDI SYNAPTrM HDMS system (Waters 
Corporation, Manchester, UK) in terms of observed signal distribution (chapters 5 and 
6 ). However, the data acquisition time for the MALDI-MS raster images was approx­
imately lh30 compared to 8  hours when performing spot-to-spot imaging, acquired at 
spatial resolution of 200 {im using a MALDI SYNAPT™ HDM S system (Waters Cor­
poration, Manchester, UK) fitted with a 200 Hz ND:YAG laser. Imaging and profiling 
data  resulting from MALDI-MSI analysis of in situ digested FFPE  tissue sections often 
present poor S/N  ratio as well as poor signal sensitivity. Here, the obtained S/N  ratio 
and signal sensitivity allowed the generation of acceptable images of the localisation 
of peptide within in situ digested FFPE  tissue sections using continuous laser raster 
imaging data  acquisition.
Using a 20 kHz repetition rate laser for continuous laser raster MALDI-MSI allowed 
fast screening of the tissue sections for peptide analysis after in situ digestion and 
the generation of their distributions within the tissue section, while maintaining an 
acceptable data quality in terms of S/N  ratio and sensitivity. Such an approach can 
be used prior to acquisition of high resolution images using conventional (i.e. spot-to- 
spot) MALDI-MSI data acquisition. It can also be used in order to highlight regions 
of interest within the tissue sections and perform further more specific, sensitive and 
quantitative MALDI-MS imaging such as multiple reaction monitoring analyses.
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Figure 7.2: D ig ita l scan  o f a  F F P E  p a n c re a tic  tu m o u r  tis su e  se c tio n  a f te r  
H E  s ta in in g  a n d  im ages o f p e p tid e  d is tr ib u t io n  w ith in  th is  tis su e  se c tio n  
o b ta in e d  w ith  M A L D I-M S  ra s te r  im ag ing  a f te r  in  s itu  d ig estio n .
(a) Digital scan of a FFPE pancreatic tumour tissue section after HE staining . A 20 kHz 
repetition rate laser was used for continuous laser raster imaging. The distribution of 
several peptide signals, including (b) actin, (c) histone H2A, (d) tumour necrosis factor 
receptor, (e) haemoglobin beta and (f) haemoglobin alpha, within the tissue section was 
obtained.
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7.3 .2  M R M  M A L D I-M S im aging screening o f p ep tid es  d irectly  w ith in  
in  s itu  d igested  F F P E  p ancreatic tu m our tissu e  section s
7.3.2.1 Evaluation of M ALD I-M S/M S analysis directly within in situ  di­
gested FFPE pancreatic tumour tissue sections using a 20 kHz rep­
etition rate laser
One of the requirements for MRM analysis is tha t the m /z values of the compounds 
of interest and significant product ions are known. The high repetition rate laser was 
evaluated for on-tissue MS/MS analysis. The peptide signal a t m /z 944, which was iden­
tified as arising from histone H2 A using a MALDI SYNAPT™ HDM S system (Waters 
Corporation, Manchester, UK), was sequenced using tandem  MS with a 1 0 kHz repe­
tition rate solid-state laser. Figures 7.3 and 7.4 display the obtained MS/MS spectra 
using each instrument respectively.
Good sequence coverage was observed. When comparing the spectrum in figure
7.3 to the MS/MS spectrum of the peptide a t m /z 944 (figure 7.4) obtained using a 
MALDI SY N A PT™  HDMS system (Waters Corporation, Manchester, UK), identical 
fragmentation patterns were observed.
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Figure 7.3: M A LD I-M S/M S spectrum of the peptide signal at m/z 944 obtained directly after in situ digestion of a F F P E  
pancreatic tissue section using a Q-Star® Pulsar i QTOF MS instrum en t fitted with a 20 kHz repetition rate laser.
A good fragmentation pattern was observed: a, b and y ions are displayed.
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Using MS/MS data  obtained with a MALDI SYNAPT™ HDM S system (Waters 
Corporation, Manchester, UK), as described in previous chapters including chapters 5 
and 6 , eight peptide precursor ions, with their corresponding most intense product ions 
present in the MS/MS spectrum, were selected for MRM-MALDI-MSI analysis. Table
7.1 displays a list of the selected peptide signals and their corresponding product ions: 
a total of 26 transitions were plotted.
P ro te in  n a m e / A ccess io n  
num ber
Peptide
m /z
Fragment ions
H isto n e  H 2 A .Z / P 0 C 0 S 5 944.53 370. 21 b4 
411. 25 y4* 
428.28 y4 
575.33 y5
T um or n ecrosis factor  recep ­ 1105.64 436.23 b5*
t o r /  0 0 0 2 2 0
493.25 bc* 
650.37 d8
A ctin , a o rtic  sm o o th  m u sc le / 1198.72 272.17 y2
P62736
468.27 y4 
615.35 b6
H a em oglob in  b e t a /  P 68 8 7 1 1274.73 227.18 b2 
326.85 b3 
670.34 y 5*
P e r io s t in / Q 15063 1400.78 327.21 b4 
416.26 y4 
771.50 y 7
78 k D a  g lu co se -reg u la ted  
p ro te in  (G r p 7 8 ) / P 1 1 0 2 1
1934.01 367.14 b3
520.29 b4 
537.32 y 5 
921.57 y 9
H a em oglob in  a lp h a / P 6 9 9 0 5 1529.74 365.2 b4 
436.23 b5 
622.30 b7
P a n crea tic  a lp h a -a m y la se / 
P 0 4 7 4 6
1427.70 783.35 y 6
417.23 y3 
284.20 b3
Table 7.1: List of peptide masses used for M RM -M ALDI-M SI analysis of 
FFPE pancreatic tumour tissue sections.
Peptide signals are listed in the order of monitored reactions. Note: y* or b* represent 
y or b ions with a loss of H2 O
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7.3.2.2 M R M -M A L D I-M S  Im ag in g  o f p e p tid e s  w ith in  in  s itu  d ig es ted  F F P E  
p a n c re a tic  tu m o u r  tis su e  sec tio n s  using  a  20 kH z r e p e t i t io n  r a te  
laser
MRM is a sensitive and specific MS scanning approach. To perform MRM, precursor 
ions and their corresponding product ions, collectively called transitions, are selected 
and each MS scan monitors a specific transition [13]. Such an approach can be very 
beneficial for the investigation of peptide distribution within the tissue section using 
MALDI-MSI as it may lead to specific and sensitive data  acquisition, since it reflects an 
amino acid sequence of a given peptide. In the work reported here, the use of a 20 kHz 
repetition rate laser may improve data quality and acquisition time for such analysis.
In a first approach, MRM-MALDI-MSI analyses of selected peptides were acquired 
at 250 fim  spatial resolution using a 20 kHz repetition rate NdiYVCH laser. Figure 7.5 
displays the localisation of histone H2A and haemoglobin beta within a FFPE  pancreatic 
tissue section.
b ) H is to n e  H 2 A  m /z  9 4 4  4 2 8 c) H a e m o g lo b in  b e ta  m /z  1 2 7 4  2 2 7
Figure 7.5: Im ages o f p e p tid e  d is tr ib u t io n  w ith in  a  F F P E  p a n c re a tic  tis su e  
sec tio n  o b ta in e d  w ith  M R M -M A L D I-M S  im ag ing  w ith o u t u sin g  d y n a m ic  
p ixel o p tio n  a f te r  in  s itu  d igestion .
A 20 kHz repetition rate laser was used for MRM-MALDI-MS imaging data  acquisition, 
(a) Digital scan of a FFPE  pancreatic tissue section obtained after HE staining. The 
distribution of peptide transitions, including (b) histone H2A (m /z 944 —» 428) and (c) 
haemoglobin beta (m /z 1274 —* 227) was obtained. Images were acquired at 250 fim 
spatial resolution. A poor signal sensitivity was noticed as the dynamic pixel operating 
mode was not used.
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The transitions of histone H2A peptide signal at m /z 944 to 428 and haemoglobin 
beta peptide ion at m /z 1274 to 227 are shown. A considerable loss of sensitivity was 
noticed for the transition of haemoglobin beta tryptic peptide ion at m /z  1274 to 22. 
Here, when acquiring images at 250 /im spatial resolution, it was not possible to have 
the high repetition rate laser operating in the dynamic pixel mode. This resulted in 
a complete ablation of each pixel across the tissue section for only the first transition 
monitored.
Using a 20 kHz repetition rate laser in the dynamic pixel mode may improve the 
detection and sensitivity of each selected transition. However, it is currently impossible 
to use the dynamic pixel mode with the modified Q-Star®  Pulsar i QTOF instrument 
(Applied Biosystems/MDS Sciex, Concord, Ontario, Canada) fitted with a 20 kHz rep­
etition rate Nd:YVOs laser when acquiring an image at a spatial resolution higher than  
400 /mi. This current limitation is related to the software settings. However, in order 
to assess if such an analytical method can be used for fast, specific and sensitive in 
situ identification and localisation of peptide within on-tissue digested tissue sections, 
MRM-MALDI-MSI was performed at 400 /im. Figure 7.6 displays the obtained images.
The images were obtained at a low spatial resolution, however an improved sensi­
tivity was observed since the localisation of several peptide transitions are displayed in 
figure 7.6. This showed tha t the use of a high repetition rate laser in dynamic pixel 
mode allowed an improved detection and sensitivity of targeted peptides within in situ 
digested tumour tissue sections. This demonstrates a novel proof-of-principle and th a t 
such a methodology is feasible. However, further software and method improvement are 
required for the method to be used at its optimum.
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Figure 7.6: Im a g e s  o f  p e p t id e  d i s t r i b u t i o n  w i t h i n  a  F F P E  p a n c r e a t ic  t is s u e  
s e c t io n  o b ta in e d  w i t h  M R M - M A L D I - M S  im a g in g  u s in g  t h e  d y n a m ic  p ix e l  
o p t io n  a f t e r  in situ  d ig e s t io n .
A 20 kHz repetition rate laser was used for MRM-MALDI-MS imaging data  acquisition, 
(a) Digital scan of a FFPE pancreatic tissue section obtained after HE staining. The 
distribution of peptide transitions, including (b) histone H2A (m /z 944 —> 428), (c, d) 
tumour necrosis factor receptor (m /z 1105 —> 436, 493), (e) pancreatic alpha amylase 
(m /z 1427 —> 417), (f) actin (m /z 1198 —> 468), (g) haemoglobin beta (m /z 1274 —> 
227) and (h) haemoglobin alpha (m /z 1529 —■> 622) was obtained. Images were acquired 
at 400 /im  spatial resolution. An improved signal sensitivity was noticed as the dynamic 
pixel operating mode was used here.
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7.4 C oncluding R em arks
MALDI-MS imaging is now demonstrating its potential for studying peptide distri­
bution within tissue sections and allowing in situ protein identification while providing 
spatial distribution information within the tissue sections. Developments in instrumen­
tation and methodology are currently being made in order to improve MALDI-MS image 
spatial resolution, thereby achieving cellular resolution while maintaining high sensitiv­
ity and specificity. MALDI-MS image resolution is currently limited by several factors, 
including the laser irradiation spot size and the m atrix coverage method. Studies have 
reported the achievement of high resolution images using various methodologies includ­
ing oversampling [14], reduction of the laser irradiation spot [6 ] as well as improvements 
in m atrix coverage methods [15, 16]. However, in some cases, high resolution MALDI- 
MS images were obtained at the expense of loss in signal sensitivity and/or long data  
acquisition time. Therefore, the laser repetition rate is a key factor to take into account 
as it may improve signal sensitivity and/or reduce data acquisition time.
In the work reported here, using a 20 kHz repetition rate laser for continuous laser 
raster imaging enabled fast data  acquisition but also acceptable signal detection and 
sensitivity. By defining an optimum speed for the laser raster across the tissue sec­
tions, images of the distribution of peptides within in situ digested tissue sections were 
generated and enabled tumour regions within a FFPE  pancreatic tissue section to be 
highlighted. Improved MALDI-MS image spatial resolution has been reported using 
continuous laser raster MALDI-MS imaging data  acquisition [1 2 ]. However, in the work 
reported here, improvement of image resolution was not observed, but the obtained 
signal sensitivity allowed detection and discrimination between tissue regions. This 
methodology can be used to perform rapid tissue section screening prior to the acquisi­
tion of high resolution images using a spot-to-spot laser ablation.
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Additionally, a proof-of-concept was described by means of MRM-MALDI-MSI anal­
ysis of peptides after in situ digestion of FFPE  tumour tissue sections. Such an ap­
proach has not been reported before. MRM is one of the most sensitive MS analysis 
methodologies as it allows fast, sensitive and specific detection as well as quantification 
of compounds present in a given sample [13]. Here, MRM has been used in combination 
with MALDI-MSI using a 20 kHz repetition rate Nd:YV0 4  laser. This demonstrated 
tha t a more specific approach to targeting and studying the distribution of a given 
protein or tum our marker within the tissue section can be achieved, since pre-selected 
transitions from a peptide, hence from a specific amino acid sequence, are monitored 
and imaged directly from the tissue section after in situ digestion. The use of a high 
repetition rate laser has been found to improve signal sensitivity.
In summary, in this chapter, specific and targeted methodologies were described us­
ing MALDI-MSI technologies, showing other potentials of the technique as a biomarker 
discovery tool.
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Changes in protein expression and profile patterns are observed in several diseases 
including cancers and are used to discriminate between healthy and cancerous tissues as 
well as between classes of cancers. Improvements in mass spectrometry instrum entation 
have led to it being widely used for high-throughput analysis in order to characterise 
potential biomarkers tha t can help in cancer research.
MALDI-MSI techniques represent an enormous development and improvement in 
MS imaging technologies. In fact, MALDI-MSI is becoming a novel translational ap­
proach for cancer biomarker discovery since it allows the study of the distribution and 
the identification of proteins directly within tumour tissue sections with no requirement 
for pre-defined targets. The aim of this thesis was to develop efficient methodologies, 
which addressed sample preparation, instrumentation and data acquisition issues, in or­
der to apply MALDI-MSI to protein biomarker targeting and discovery directly within 
tumour tissue sections.
The use of MALDI-MSI for direct analysis of proteins within tum our tissue sections 
was achieved by optimising tissue section washing protocols, the composition of ma­
trix solutions and m atrix deposition. However, other solvents should be investigated 
for tissue section washing prior to direct MALDI-MSI analysis in order to improve the 
detection of low abundance proteins. The developments reported here resulted in im­
provement in sensitivity for the detection of several protein signals, and hence allowed 
discrimination between regions within the tissue sections. D ata pre-processing methods 
were also developed using freely available software, with the aim of reducing instrumen­
tal and experimental errors prior to statistical analysis.
Using MALDI-MSI for direct protein analysis within tumour tissue sections resulted 
in the localisation and detection of protein signals which were found to  be character­
istic in differentiating between tissue regions. In chapter 3, on-tissue digestion was 
reported for protein identification directly from both frozen and FFP E  tissue sections 
and protein identifications were correlated with their observed distribution within the 
tissue sections. The addition of a non-ionic detergent, here octyl glucoside, to  the 
trypsin solution was shown to greatly improve the solubilisation of low abundance and
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membrane-associated proteins for tryptic digestion. The use of ion mobility separation 
combined with MALDI-MSI was found to be beneficial in minimising peak interfer­
ences, hence improving the specificity for direct protein identification through peptide 
sequencing by tandem MS/MS.
MALDI-IMS-MSI was found to be a rapid and efficient approach to study the distri­
bution and identification of tumour hypoxia-associated proteins within AQ4N-treated 
tumour xenografts in correlation with the in situ localisation of the drug and its metabo­
lites. The use of such an approach allowed the discrimination between non-treated and 
AQ4N-treated tumour xenografts and also between the type of drug treatm ent. Further 
work is recommended in order to improve the detection and in situ validation of protein 
markers such as angiogenic factors and glucose transporters. A quantitative study of 
the expression of such proteins in correlation with AQ4N treatm ent is highly desirable 
since it may help in assessing the efficiency of the drug.
The concept of IMS-Tag MALDI-MSI, developed in this thesis, allowed the localisa­
tion and in situ identification of tumour biomarkers using both bottom-up and top-down 
proteomic approaches directly within FFPE  adenocarcinoma tissue sections. The iden­
tification of protein modifications, including proline oxidation, resulting from the sample 
preparation process has been found to be beneficial for protein identification. Further 
work will be required, including the use of other proteases and extensive de novo se­
quencing, in order to identify more proteins.
In chapter 6, the use of MALDI-MSI has been demonstrated for high-throughput 
analysis using tissue micro array technologies. This allowed the design of a novel tu ­
mour classification model based on molecular information obtained with MALDI-IMS- 
MSI and statistical analysis. This shows the huge potential of the technique as it may 
offer the possibility of building a protein database for tumour classifications and also 
the possibility tha t those could be used to select the appropriate required treatm ents. 
This can also generate biomarker candidates tha t can be further validated using other 
methods such as IHC, western blot, etc. Further desirable work could be to study a 
large data  set of TMA that includes several patients with detailed clinical information.
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Additionally method improvements may be performed in order to achieve the identifica­
tion and semi-quantification of more peptides and biomarkers from TMA sections. This 
may lead to a better understanding of cancer progression and aggressiveness when cor­
relating the MALDI-MSI data  with clinical information from the patients. The coupling 
of PCA-DA statistical analysis with artificial network analysis in order to link peptides 
and/or proteins with tumour class and even appropriate treatm ent may also be explored.
One of the challenges of the MALDI-MSI technique is its efficient use for in situ quan­
tification. Chapter 7 of this thesis describes and discusses the use of MRM-MALDI-MSI 
as a methodology for a more specific in situ localisation and identification of proteins 
within tumour tissue sections after on-tissue digestion. However, further developments 
in the current instrumentation, including laser technologies and software, are still re­
quired.
Several methods, as well as new concepts, have been developed and improved in this 
thesis in order to use MALDI-MSI at its optimum capacity as a biomarker discovery 
tool. Further work will require the use of other types of reagent, the combination of 
various mass analysers and the development of statistical analysis software in order 
to standardise MALDI-MSI protocols as well as achieve improved biomarker discovery 
directly within tissue sections.
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